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The maintenance of genetic information is a fundamental function of every organism. 
The DNA in every human cell endures thousands of lesions per day, and eukaryotes have 
developed a sophisticated response to tackle this damage. Double strand breaks (DSBs) are the 
most toxic type of DNA damage, potentially leading to chromosomal rearrangements and 
tumorigenesis.  Homologous recombination (HR) is a repair pathway that uses a homologous 
template to faithfully repair the DSBs. Central to HR is a recombinase protein RAD51, which 
forms a nucleoprotein filament with the broken ends, and allows efficient homology search. 
RAD51 is a promising therapeutic target in oncology.  
BRCA2 is a crucial mediator of RAD51 function and interacts with RAD51 through a 
set of 8 BRC repeats. A BRC repeat consists of two modules, an FxxA and an LFDE module, 
each containing hot-spot residues that mediate binding. In this work, I set out to utilise these 
for the pharmacological targeting of human RAD51. First, using biophysical methods, I 
investigated a novel, high-affinity chimeric repeat BRC8-2 composed of FxxA and LFDE 
modules from different natural repeats. I determined the X-ray crystallographic structure of its 
complex, which allowed me to uncover the determinants of high affinity binding. 
 I applied these findings to the design of novel macrocyclic peptide inhibitors of 
RAD51. A method for cysteine stapling of recombinantly produced peptides was optimised to 
yield the correct product of high purity. The optimised stapling methodology provides a 
promising general approach for recombinant production and evaluation of cysteine-stapled 
peptides.  Peptides were rationally designed in a structure-guided manner, and a variety of 
stapling architectures were evaluated for binding. The resulting purified molecules exhibit high 
potency and are stable in serum. Further crystallographic studies shed light on how the stapling 
moiety affects the peptide binding mode. The derived peptides serve as novel modalities for 
targeting Rad51 protein-protein interactions and can inform subsequent development of 
therapeutic drugs.  
In addition to the human proteins, I investigated the BRC:RAD51 interactions in 
orthologs from Leishmania infantum, the causative agent of leishmaniasis. Using 
crystallography and biophysical methods, I uncovered novel features of BRC repeat binding. 
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1 Introduction 
Genomic integrity is critical for the survival of all forms of life, and successful repair 
of DNA lesions is an essential function of the cell. Excessive DNA damage and a compromised 
ability to repair are both a cause and a symptom of numerous pathological states. Crucially, 
genomic instability is a hallmark of cancer.1 It has been estimated that a single human cell 
experiences tens of thousands of DNA lesions per day, of which double-strand breaks (DSBs) 
are the most severe type of genotoxic damage that can result in irreversible genomic 
rearrangements, aneuploidy and cell death.2 The aetiology of DSBs is multi-faceted, and they 
can arise both as a result of exogenous and endogenous factors. Ionising radiation (IR) and 
genotoxic chemicals are examples of external agents that can cause DSBs either by directly 
breaking the DNA, or by generating reactive oxygen species that then react with the nucleic 
acid. DSBs can arise from stalled replication forks that are generated during normal DNA 
replication or when the replisome encounters a DNA lesion or modification.3 DSBs also happen 
as a result of normal programmed cellular function, and in such instances are introduced by 
endogenous nucleases, for example, in meiotic recombination, where they are essential for the 
formation of chiasmata between homologous chromosomes, leading to expanded genetic 
diversity, or during V(D)J recombination that generates combinatorial immunoglobulin 
repertoires for the adaptive immunity.4,5  
1.1 Double strand break repair 
Eukaryotes have evolved a sensitive and highly organised response to DNA damage, 
which senses genotoxic events and elicits an appropriate repair cascade.2 In eukaryotes, DSB 
repair can happen via a number of pathways, namely, homologous recombination (HR), non-
homologous end joining (NHEJ)6, microhomology-mediated end joining (MMEJ)7 and single 
strand annealing (SSA)8. The relative preference of each repair pathway varies depending on 
the species, cell type, nature and source of the DSB, and is cell-cycle dependent, because the 
availability of a template sister chromatid is limited to S and G2 phases of cell cycle. Cyclin-
dependent kinases thus have a critical role in pathway selection.9 Moreover, the precise nature 
of the DSB influences the choice of pathway. For example, DSBs originating from stalled 
replication forks are one-ended and cannot be repaired by NHEJ and MMEJ, and are thus 
processed through HR, whereas in the case of IR-induced DSBs, there is competition between 
the pathways.10,11 
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1.2 DSB repair by homologous recombination 
HR is the most faithful DSB repair pathway, as it employs a DNA template that is 
homologous to the broken locus in order to resynthesise the DNA at the double-strand break, 
and thus restores the original nucleotide sequence.12 This is in contrast to NHEJ, MMEJ and 
SSA, which can introduce small but potentially detrimental changes to the genome. A mitotic 
sister chromatid is the preferred DNA donor template for HR, but repair can also proceed using 
the corresponding homologous chromosome or other homologous loci in the genome, which 
can lead to the loss of heterozygosity.13,14 Due to the requirement for a sister chromatid, HR 
happens predominantly during S and G2 phases of cell cycle.15  
Homologous recombination has been traditionally divided into three stages: pre-
synapsis, synapsis and post-synapsis. Pre-synapsis is the preparative stage, during which the 
double strand break is recognised and processed, rendering it capable of searching for 
homologous sequences that will be used as repair template. During synapsis, the processed 
DSB ends sample genomic dsDNA for matching sequences, and, once a region of sufficient 
homology is found, form a long-lasting complex via strand exchange. During post-synapsis, 
the broken DNA end is re-synthesised and intact duplex products are restored. 
1.3 Pre-synapsis 
An end of a double strand break is first recognised by the MRN complex, consisting of 
the three proteins Mre11, Rad50 and Nbs1.16 The MRN complex is the primary sensor of 
broken DNA ends in homologous recombination, and initiates the downstream biochemical 
cascade by recruiting other repair proteins to the break site, as well as exhibiting its own 
biochemical activity (Figure 1). 
Mre11 is the central member of the MRN complex that interacts with the other two 
protein components and with DNA, and together with Rad50 forms a hetero-tetrameric MR 
core complex, which is conserved across all domains of life. In addition to recognising the 
DNA break ends, Mre11, through its N-terminal domain, exhibits both endonuclease and 3’-5’ 
dsDNA exonuclease activities. This dual nuclease function allows Mre11 to process the DSB 
into short 3' ssDNA overhangs, first by nicking a DNA strand distally from the break end, and 
then by cleaving the strand in 3’-5’direction.17 ATP binding to Rad50 initially induces a closed 
conformation on Mre11, which inhibits its exonuclease activity, leaving it function as an 
nicking endonuclease only. Subsequent hydrolysis of ATP by the Rad50 ATP-binding cassette 
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changes the conformation of the complex and renders exonuclease motifs accessible to permit 
short range resection.18  
The resulting overhangs of up to 300 bp are then bulk-resected in the 5’-3’ direction 
either by the exonuclease ExoI, or alternatively by the BTR-DNA2 complex, both recruited by 
MRN, producing single-stranded overhangs ranging from several hundred to tens of thousands 
of bases in length (Figure 1).19,20,21 In BTR-DNA2-mediated resection, the RecQ-like BLM 
helicase, a member of the BTR complex, unwinds the 5’ strand of a short-range resected end 
in an ATP-dependent manner, and feeds it to DNA2 for nucleolytic degradation.22 ExoI, on the 
other hand, can process the DSB end in the absence of BLM helicase-mediated unwinding. 
However, both MRN and BLM stimulate ExoI activity by increasing its affinity for DNA.19 
For more detail on end resection, the reader is referred to a review by Symington.23   
DNA end resection is the key step for committing the break for repair by HR, as 
resection by the MRN-CtIP complex causes the dissociation of Ku70-Ku80 from the break end, 
thereby inhibiting NHEJ.24  It is therefore at this step that there exist many levels of regulation 
to favour one pathway or the other. Through Nbs1, the MRN complex recruits CtIP, on which 
many of these regulatory signals act. Upon T847 phosphorylation by CDKs during the S/G2 
phases of the cell cycle, CtIP associates with MRN and stimulates the endonuclease activity of 
Mre11, leading to DSB end resection and thus favours DNA repair by HR.25,26  
Nbs1 is involved in the nuclear translocation of the MRN complex, as it is the only 
component with a nuclear localisation signal.27 Nbs1 also activates ATM kinase, a master 
regulator of HR, and recruits it to the DSB, which triggers the downstream activation of many 
repair factors to the break site.28 ATM kinase has a profound role in inducing checkpoint 
signalling in response to DNA damage. For example, it phosphorylates and inhibits the MDM2 
E3 ligase, leading to the accumulation of p53 tumour suppressor protein, and causes cell cycle 
arrest, therefore allowing sufficient time for the DNA damage repair.29  
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Figure 1. Pre-synapsis. During the pre-synaptic stage of homologous recombination, a double-strand break end 
is processed to yield a RAD51-coated 3’ ssDNA overhang. Many of the protein involved in this complex pathway 
have been omitted from the figure for simplicity. 
The resulting ssDNA overhang is immediately coated with replication protein A (RPA), 
a ubiquitous stabilising factor that prevents the ssDNA from acquiring inhibitory secondary 
structure, prevents it from annealing with other homologous ssDNA, and promotes long-range 
strand resection by ExoI or BTR-DNA2 (Figure 1).20,30 Moreover, it protects the ssDNA from 
nucleolytic cleavage.31 Eventually RPA is displaced from the ssDNA by RAD51, which is the 
principal recombinase catalysing the strand exchange reaction and the primary focus of this 
dissertation. In vitro, RPA has been shown have both inhibitory and stimulatory effects on 
RAD51 loading. If RPA is added after RAD51 nucleation has been allowed to happen, RPA 
stimulates further growth of RAD51 nucleofilaments by eliminating inhibitory secondary 
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abundant and has higher affinity for ssDNA than RAD51, and therefore is rapidly bound to 
nascent ssDNA prior RAD51 loading.33 Such RPA binding inhibits nucleation by competing 
for the same ssDNA and sterically precluding RAD51 binding, implying that additional 
mediators are necessary for the exchange of the two proteins.34  
In budding yeast, RAD51 loading and displacement of RPA is mediated by RAD52. 
Rad52 interacts with RPA, DNA and RAD51, and has been proposed to seed RAD51 
nucleation events on RPA-coated DNA.34 Once a nucleation event happens, RAD51 
nucleofilament extension proceeds readily due to the cooperative interactions between RAD51 
protomers. S. cerevisiae Rad52 is essential for homologous recombination and loss-of-function 
mutants display dramatic hypersensitivity to DNA-damaging agents.35 Interestingly, in 
mammals, loss of RAD52 is tolerated and does not exhibit a strong phenotype, indicating the 
existence of another gene with similar function.36 Indeed, nucleation of RAD51 on ssDNA and 
the concomitant displacement of RPA in mammals is dependent on stimulation by BRCA2, a 
crucial mediator that is not found in S. cerevisiae.37 In BRCA2-deficient human cells, RAD52 
is able to compensate for loss of BRCA2 activity, but synthetic lethality arises when both gene 
products are depleted.38 The two proteins therefore have overlapping function as stimulators of 
RAD51 loading. This explains why some eukaryotes that have a BRCA2 ortholog, such as C. 
elegans and D. melanogaster, do not have a RAD52 homolog at all.39 BRCA2 and its function 
are discussed in detail later in this work.  
In addition to the mediator proteins RAD52 and BRCA2, seven RAD51 paralogs that 
share limited homology to RAD51 have been identified in vertebrates: RAD51B, RAD51C, 
RAD51D, XRCC2, XRCC3 and SWSAP1, along with the meiotic recombinase DMC1. 
RAD51 paralogs have arisen as a result of gene duplication events and mutagenesis or knock-
out of each of them sensitises cells to DNA damage or confers embryonic lethality to the 
organism.40,41,42 RAD51 paralogs act as RAD51 mediators downstream of BRCA2-stimulated 
nucleofilament formation.43 For example, RAD51B and RAD51C form a heterodimeric 
complex that lacks recombinase activity but is capable in vitro of integrating into the RAD51 
nucleofilament, exerting a stabilising effect on it and conferring enhanced strand exchange 
activity, while preventing RAD51 disassembly by anti-recombinogenic helicases (Figure 1).44 
1.4 Synapsis and post-synapsis 
RAD51 binding to ssDNA results in a pre-synaptic nucleofilament (NF): an oligomeric, 
filamentous assembly that is capable of searching for a double-stranded homologous 
template.45,46 During homology search, the pre-synaptic nucleofilament probes the genomic 
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DNA for matching sequences by forming dynamic, transient interaction with the duplex that 
are stabilised when a sufficient number of base-paired contacts arise.47  
Once a template match is found, strand exchange proceeds, and the presynaptic NF 
displaces the strand that is (+) to the ssDNA overhang and anneals to the complementary (-) 
template strand, forming a short-lived synaptic complex intermediate which contains all three 
strands within the nucleofilament. The structural details of the synaptic complex are poorly 
understood. Eventually, the (+) template strand becomes completely displaced, leaving a 
heteroduplex post-synaptic nucleofilament. The resulting total structure, containing the newly 
formed heteroduplex and the displaced strand is called a displacement loop (D-loop, Figure 
2).  
The annealed 3’ overhang within the D-loop serves as a primer for DNA synthesis by 
DNA polymerases, which use the homologous DNA as template, further unwinding the 
template duplex and extending the D-loop in a displacement synthesis step.48 For this to 
happen, the motor protein Rad54 removes terminal RAD51 protomers from the invading 3’ 
strand in an ATP-dependent manner to allow polymerase binding to the priming region.49,50 
Following D-loop formation, homologous recombination can proceed two main pathways: 
double strand break repair (DSBR), synthesis-dependent strand-annealing (SDSA) (Figure 2). 
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Figure 2. Synapsis and post-synapsis. A generalised schematic depicting the pre-synaptic stage involving 
homology search and strand invasion (blue background, second end not shown), followed by the two main post-
synaptic pathways of HR-mediated DSB repair, DSBR and SDSA. Some of the critical proteins involved in the 
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1.4.1 DSBR 
The critical step that differentiates between the post-synaptic pathways is the treatment 
of the second DSB end, so far excluded from the discussion. In DSBR, the second end of the 
DSB is similarly processed to yield a 3′ overhang, which is then coated with RPA. Then, in a 
step called “second end capture”, it is annealed by Rad52 to the displaced template strand 
within the extended D-loop, which now has an extensive displaced ssDNA strand  (Figure 2).51 
Annealing of RPA-coated ssDNA is another function of Rad52 besides its pre-synaptic 
mediator activity.51 This results in a second heteroduplex product that can serve as a priming 
region for a DNA synthesis in the opposite direction.51 The elongation of the two strands is 
eventually halted and the newly synthesised 3′ extensions at both ends are ligated to the 
corresponding 5′ of the opposite ends, resulting in the formation of a double Holliday junction 
(dHJ).  
  Holliday junctions are DNA secondary structure elements that contain two homo-
duplex and two hetero-duplex dsDNA arms, joined together at a single eight-stranded 
intersection. To restore intact linear chromosomes after nascent end synthesis, the dHJs are 
either dissolved or resolved (Figure 2).52 Dissolution entails the convergent migration of the 
two HJs towards each other and their eventual collapse into a hemicatenane structure, catalysed 
by the BLM helicase activity within the BTR complex (also called “dissolvasome”, STR in 
yeast), followed by the unlinking of the interwound strands by topoisomerase IIIα, also part of 
the BTR complex.53,54 Dissolution results exclusively in non-crossover recombination 
products, with the DSB ends re-connected and intact template restored. Non-crossover products 
produced by dissolution are preferred to crossover in mitotic HR in order to avoid loss-of-
heterozygosity (LOH), which can arise when a homologous chromosome, rather than a sister 
chromatid, is used as template for repair.52 BTR-mediated dissolution is therefore the 
predominant pathway for dHJ processing and occurs at the early stages of cell cycle.52 
Resolution, on the other hand, acts as a back-up pathway later in mitosis, to ensure that 
no residual links between chromatids exist before chromatid segregation.52 Resolution is 
catalysed by nucleolytic resolvase enzymes, such as mammalian GEN1 or the SLX-MUS 
complex, that nick the dHJs at symmetric positions across the junction, allowing the non-
covalent separation of two nicked homo-duplexes.52 Because resolvases can cut at two different 
orientations at each of the holiday junctions, a range of crossover and non-crossover products 
are possible, which can be lead to detrimental loss of heterozygosity when a homologous 
chromosome, rather than a sister chromatid, is used as template.55  
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1.4.2  SDSA 
During SDSA, the first captured end is synthesised in the absence of second end 
capture, and double holiday junctions are not formed (Figure 2). The second end is also 
resected but remains passive. Instead, the extended invading strand is eventually displaced by 
the branch migration activity of the BLM helicase within the BTR complex and can re-anneal 
to the second end.56 The resulting ssDNA gaps are filled, and the nicks ligated, forming 
exclusively non-crossover products. SDSA is the dominant HR pathway for repairing mitotic 
DSBs in mammalian cells, but also occurs in meiotic cells.57 Because a dHJ is not formed 
during SDSA, the pathway results in exclusively non-crossover products .  
1.5 The RAD51 recombinase  
The eukaryotic Rad51 gene was first identified and mapped in a screen for 
Saccharomyces cerevisiae mutants that are sensitive to X-ray radiation.58 Its involvement in 
the maintenance of genomic integrity stemming from its recombinase activity, as well as its 
functional and structural homology to bacterial RecA, have since been extensively 
characterised.59 Today, RAD51 is recognised as a ubiquitous mediator of homologous 
recombination that is central for this mode of DNA repair. It is essential for cellular survival in 
higher eukaryotes, for example, RAD51-null chicken DT40 cells accumulate chromosomal 
breaks and eventually die.60 Embryonic lethality arises as a result of defective Rad51 in 
mammals.61 The RAD51/RecA family of proteins stems from a common evolutionary origin 
and is highly conserved: eukaryotic RAD51 orthologs have >60% sequence identity, which 
increases to >97% when only mammalian sequences are examined.62 Gene duplication events 
in eukaryotes have resulted in RAD51 paralogs with divergent or specialised function, such as 
the meiosis-specific recombinase DMC1 or the RAD55-RAD57 paralogs, which are mediators 
of RAD51 function.63,64 
1.5.1 Biochemical characteristics of RAD51 
 The first extensive biochemical characterisation of purified human RAD51 (HsRAD51) 
in vitro was reported by Baumann et al. not long after the identification of the human 
ortholog.65 The study showed that human RAD51 binds both ssDNA and dsDNA in vitro with 
comparable affinities, and has a slightly higher affinity for the single-stranded substrate than 
the duplex. The stoichiometry of DNA binding corresponds to 3 nucleotides per RAD51 
protomer, and is conserved across species.65 The ATPase activity of HsRAD51 is orders of 
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magnitude lower than that of RecA, and it is modulated by DNA binding. 65 Steady-state ATP 
turnover by RAD51 increases from 0.03 molecules per minute in the absence of DNA, to 0.05 
and 0.16 ATP/min when dsDNA and ssDNA is added, respectively.65 RAD51 catalyses the 
strand exchange between a ssDNA molecule and a homologous dsDNA template, leading to 
the formation of joint molecules, a process that is ATP/Mg2+-dependent, but also happens in 
the presence of other nucleotides, such as GTP, UTP, dATP or the non-hydrolysable ATPyS, 
as shown in the same study.65 However, given the higher abundance of ATP in the cell, it is 
unlikely that the other nucleotides contribute significantly to NTPase activity. 
 RAD51 polymerisation on DNA occurs in two phases: a rate-limiting nucleation phase 
and a faster growth phase. As a result of RAD51 forming oligomeric species in solution, initial 
nuclei are formed by the binding of short RAD51 oligomers, with a minimum length 2-3 
protomers, sufficient as a stable nucleating species.66 Gradual coverage of DNA happens 
through the formation of many such nucleation sites, followed by their extension through short-
range growth and eventual joining.66 
The mechanism of homology search had long eluded detailed examination due to the 
dynamic features of the process being obscured by bulk ensemble measurements. Single 
molecule optical trap experiments with RecA, the bacterial homolog of RAD51, revealed that 
efficient homology search involves hopping of the pre-synaptic NF between spatially 
proximate but sequence-distant segments of the randomly coiled dsDNA, in a process termed 
‘intersegmental contact sampling’.67 It is likely that during these non-specific dsDNA binding 
events, the pre-synaptic nucleofilament samples the duplex sequence via base-flipping, where 
the duplex Watson-Crick hydrogen-bonding interactions are transiently disrupted and matched 
with the pre-synaptic NF.47 
 ATP hydrolysis is not required for strand exchange to happen, and hydrolysis-
incompetent HsRAD51 K133R mutant can rescue DNA repair function in RAD51-null chicken 
DT40 cells.68 Moreover, the same mutant can form pre-synaptic NF and catalyse strand 
exchange more efficiently in vitro than the wild-type protein.69 Similarly, Ca2+ ions, which 
inhibit ATPase activity, have been shown to enhance the strand-exchange activity of RAD51.70 
It has therefore been suggested that ATP hydrolysis functions in the dynamic disassembly and 
turnover of RAD51 from the nucleofilament, rather than the strand-exchange reaction itself.71 
RAD51/RecA family recombinases have to dissociate from the post-synaptic dsDNA 
nucleofilament product to allow the execution of subsequent steps of recombination, such as 
DNA synthesis and Holliday junction resolution. In vitro, bacterial RecA rapidly dissociates 
from dsDNA as a result of ATP hydrolysis, whereas eukaryotic RAD51-dsDNA 
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nucleofilaments stay associated after ATP has been converted to ADP.66 Additional protein co-
factors are required for post-synaptic disassembly.  
1.5.2 Rad51 structure 
The human RAD51 gene product is a 37 kDa protein that consists of two globular 
domains, a C-terminal ATPase domain and a smaller N-terminal domain, which are linked by 
a flexible linker called the oligomerisation epitope (OE) (Figure 3A). The ATPase domain has 
a classic Rossmann fold common to many nucleotide-binding proteins, such as helicases or 
ATP synthases, 72,73 containing an extended core β-sheet that is surrounded by α-helices at both 
faces, resulting in a three-layered sandwich tertiary architecture. The central β-sheet consists 
of mixed parallel (β3,β2,β4,β5,β1,β6) and anti-parallel (β7,β8,β9) strands. Two flexible DNA-
binding loops, L1 and L2, protrude from one side of the ATPase domain and interact with DNA 
upon formation of a nucleofilament. The L2 loop is significantly larger and is only partially 
resolved in structural models due to conformational flexibility (see Section 1.5.4, Figure 6C).  
Near the DNA binding loops on the ATPase domain, a nucleotide-binding site is formed 
by Walker A (also called P-loop) and Walker B motifs that interacts with the nucleotide di- 
and tri- phosphates in a metal-ion dependent fashion and make up the catalytic centre for ATP 
hydrolysis (Figure 3B). The interaction with nucleotides is further stabilised by additional 
contacts between the nucleobase and the ATPase domain outside of the Walker A motif, which 
determines the specificity for ATP as catalytic co-factor.74  
The N-terminal domain of human RAD51 is smaller than the ATPase and composed 
entirely of α-helices. It interacts with both ssDNA and dsDNA, however, its exact functional 
role has not been conclusively elucidated.75 
 




Figure 3. Tertiary structure of a RAD51 protomer. (A) A ribbon representation of a RAD51 monomer showing 
the different domains: N-terminal domain (NTD, blue), oligomerisation epitope (OE, green), ATPase domain 
(grey). Nucleotide (AMP-PNP) depicted in light green bound to the ATP site. L1, L2 – DNA binding loops. 
Electron density lacking for L2. Monomer extracted from a cryo-EM structure of the active ssDNA-bound 
nucleofilament (PDB ID: 5H1B).76 (B) RAD51 ATP-binding site with the nucleotide cofactor bound. 
Triphosphate is seen binding the P-loop (also called Walker A motif) and an Mg2+ ion cofactor. Additional 
interaction through the adenine base (right) determine specificity for ATP (PDB: 4A6X).74  (C) Comparison of 
domain organisation in different RAD51 orthologs.  
A comprehensive discussion of RAD51 structure and function inevitably involves 
looking at different orthologs of the protein. Human RAD51 (HsRAD51) has ostensibly been 
the focus of most research, however, many published experiments have been conducted with 
orthologs from other species. Most notable examples are: Saccharomyces cerevisiae Rad51 
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(ScRad51), Escherichia coli RecA (EcRecA), Pyrococcus furiosus and Methanococcus voltae 
RadA (PfRadA, MvRadA). While their functional and structural properties remain broadly 
similar, there are differences worth noting. First, the domain organisation in bacterial RecA 
proteins is different from eukaryotes and archaea (Figure 3C), reflecting the phylogenetic 
distance between the different domains of life. The N-terminal domain as seen in eukaryotes 
and archaea is absent in bacteria, while the oligomerisation epitope is similarly found N-
terminal to the ATPase domain. Instead, a C-terminal domain of similar size to eukaryotic 
NTD, but different evolutionary origin and different fold, is present in bacteria and is believed 
to have arisen by convergent evolution to exert a similar function. Secondly, putative 
disordered extensions of varying length are observed in different homologs at the protein 
termini. For example, ScRad51 has a long, disordered N-terminal extension of unknown 
function. For a note on Rad51 nomenclature, see *. 
1.5.3 Rad51 oligomerisation 
It has been demonstrated by structural and biophysical methods that various RAD51 
orthologs and paralogs form soluble oligomers in the absence of DNA both in vitro and in vivo. 
The shape and assembly size of free RAD51 oligomers differs between species: for example, 
bacterial EcRecA forms closed, helicase-like hexameric rings77 while archaeal RadA from 
Pyrococcus furiosus forms closed heptameric ring dimers78 (Figure 4A, left) as evidenced by 
crystallography, electron microscopy and DLS. Human and other eukaryotic RAD51 orthologs, 
on the other hand, can form linear oligomers of varying assembly size. For example, yeast 
Rad51 crystallises as a linear filament (Figure 4A, right).79 It has been shown that increasing 
concentration of purified HsRAD51 shifts the distribution of oligomeric species towards higher 
molecular weight in vitro. 
 
* A note on nomenclature. In this work, depending on the context, “RAD51” in uppercase 
refers to the human protein and is used interchangeably with HsRAD51, or to the protein family 
as a whole. If other non-human species are used, an appropriate prefix, such as “Sc”, is applied 
to a lowercase “Rad51”. Archaeal and bacterial Rad51 homologs are exclusively called 
“RadA” and “RecA”, respectively. Surrogate systems based on thermostable archaeal RadA 
are described later in the text. These contain a RadA root and a prefix that denotes which protein 
the system mimics, e.g. HumRadA22 is a PfRadA protein that mimics human RAD51. 
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Figure 4. Rad51 oligomerisation happens through a conserved mechanisms and gives rise to different oligomeric species 
such as (A) heptameric rings formed by Pyrococcus furiosus RadA (left, PDB: 1PZN) or helical filaments in Saccharomyces 
cerevisiae Rad51 (right, PDB: 1SZP). (B) Rad51 oligomerisation is mediated by the FxxA motif located on the 
oligomerisation epitope. The FxxA motif binds through a combination of hydrophobic contacts via the Phe and Ala side-
chains, and backbone-backbone hydrogen bonds (PDB: 1PZN).  
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The oligomerisation mechanism is highly conserved in the RAD51/RecA family in both 
ring and filament structures, and is likely to have arisen early in the evolution of its common 
ancestor. The bulk of the interface between adjacent RAD51 protomers is mediated by the 
oligomerisation epitope (OE), located between the NTD and the ATPase domains (Figure 4B). 
The OE contains a conserved FxxA motif, whose hydrophobic Phe and Ala side chains bind 
cognate pockets on the ATPase domain of a second RAD51 protomer. Importantly, the FxxA 
phenyl is buried within a deep hydrophobic cavity and this hot-spot residue is responsible for 
a large fraction of the free energy of binding.80,81 Hydrogen-bonds are formed by FxxA motif 
backbone amides with the upper-most β-strand of the ATPase, resulting in an anti-parallel β-
sheet augmentation. This interface is also maintained in the DNA-bound nucleofilament state 
(discussed below). The oligomerisation epitope is flexible, which allows a significant degree 
of conformational freedom between adjacent RAD51 subunits: while the FxxA contacts are 
relatively static, the orientation of ATPase and N-terminal domains can vary significantly. This 
flexibility of the OE explains the variety of oligomerisation morphologies observed in different 
orthologs and different assembly states. The closed ring arrangements seen in structures of 
PfRadA (Figure 4A, left) and EcRecA require the ATPase domains to remain co-planar, with 
a pure rotational symmetry axis crossing the ring centroid. Movement between consecutive 
ATPase domains results in a rise along this axis and transforms the oligomer into helical 
structure with a screw symmetry, like observed for the ScRad51 filament crystal structure 
(Figure 4A, right). 
The transition from a ring conformation, having no pitch, to a filament with a non-zero 
pitch, involves the rotation of the globular ATPase domains relative to each other. For this to 
happen, backbone movement occurs in a flexible part of the OE immediately following the 
FxxA motif and preceding the ATPase domain, which corresponds to residues Glu98-Thr103 
in HsRAD51. This relatively small-scale local conformational transition enables large-scale 
movement at the DNA-binding region on the opposite side of the ATPase domain, as illustrated 
in Figure 5. 
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Figure 5. Movement between adjacent protomer ATP domain determines the assembly morphology. 
Conformational change at a region of flexibility in the oligomerisation epitope is required for the ATPase domains 
to rotate relative to each other. Image on the left shows a dimer extracted from a PfRadA heptameric ring (PDB: 
1PZN) while the dimer on the right is from a high-pitch ScRad51 filament X-ray structure (PDB: 1SZP). One 
ATPase domain is held in identical position in both images (light grey), while the other is allowed to move (dark 
grey). 
1.5.4 RAD51 nucleofilament: structure and function 
 
To exert its catalytic function, RAD51 first has to form an active, ATP-bound pre-
synaptic nucleoprotein filament (NF) with the invading ssDNA strand. Human RAD51 can 
also bind DNA in the absence of nucleotide cofactor or if bound to ADP, however, these 
nucleoprotein filament states are unable to catalyse strand exchange. While ATP-bound state 
is essential for an efficient homology search82, ATP hydrolysis is not necessary for this 
process68,69 and hydrolysis-inhibited Ca2+-bound state has enhanced strand-exchange activity, 
whereas the conversion ATP to ADP decreases it.70 
Structures of RAD51 NFs have been determined at various resolutions using cryo-
electron microscopy for the human protein and its orthologs. Early low-resolution studies with 
EcRecA established that the prokaryotic NF has a helical morphology, where RecA oligomers 
wind around the ssDNA or dsDNA, forming a right-handed helix with the DNA strand lying 
close to the filament axis 83,84. A similar morphology was later also observed for human RAD51 
(Figure 6A). NFs are flexible with significant local polymorphism, contain ~6 protomers per 
turn and three bases or base-pairs per protomer, and maintain DNA in an under-wound, 
extended conformation compared to classical Watson-Crick B-DNA structure.  
EM studies also revealed that the identity of the bound nucleotide co-factor 
significantly modulates a number of helical parameters in the NF. Importantly, the helical pitch, 
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that is, the height of a full turn of a helix along a helical axis, is significantly higher in the active 
ATP-bound RecA (~95 Å) versus the inactive apo/ADP-bound states (65-85 Å).85 
Two relatively recent publications by Xu et al.76 and Short et al.86 report remarkably 
similar near-atomic resolution structures of the active pre-synaptic human RAD51 NF in the 
presence of a non-hydrolysable ATP mimetic AMP-PNP (Figure 6B). In these, the active 
filament has an average helical pitch of 103 Å and an inter-protomer displacement of 57°, 
closely resembling the structures of active yeast Rad51 and bacterial RecA filaments.  6.3 
protomers or 19 nucleotides are positioned per turn of the right-handed NF helix, in line with 
previously reported RAD51:ssDNA binding stoichiometry of 1:3. The ssDNA in the pre-
synaptic NF is extended by approximately a half compared to the length of duplex B-DNA.  
In these structures, nucleobases are arranged as tightly stacked triplets resulting in a B-
DNA-like stacking that favours Watson-Crick base pairing with the homologous template 
during strand invasion (Figure 6B,C). Each RAD51 protomer forms distinct contacts with 
three sets of adjacent nucleotide triplets in a regular, repetitive manner. The bulk of the RAD51-
DNA interface is formed between the ssDNA phosphate backbone and the DNA-binding loops, 
thus orienting the nucleobases towards the helical axis (Figure 6C). Hydrogen bonding and 
charge-charge interactions make up majority of this interface. Val273 side chain from loop L2 
of each RAD51 protomer inserts between every base triplet to enforce the tight stacking in an 
otherwise extended sugar-phosphate backbone conformation. 
Three distinct interfaces contribute to the protein-protein interaction between adjacent 
RAD51 protomers in the active NF (Figure 6D). The largest interface is mediated by the FxxA 
motif from the oligomerisation epitope in a similar fashion to free RAD51 oligomers. A second, 
much smaller interface results from the stacking of Tyr54 aromatic side-chain, located on the 
NTD of one protomer, with the Phe195 on the ATPase domain of an adjacent protomer situated 
in the 5′ direction of the bound ssDNA. A third interface in the active NF is formed by a 
nucleotide binding site that is occupied by the AMP-PNP molecule and a metal ion co-factor, 
which are then covered by a different set of residues from the ATPase domain of the adjacent 
protomer, resulting in a tightly sandwiched nucleotide binding mode. 
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Figure 6. Pre-synaptic RAD51-ssDNA nucleofilament structure. (A) Electron micrograph of RAD51-ssDNA 
nucleofilament (reported by Davies and Pellegrini87) (B-C) High-resolution cryo-EM structure of the RAD51-
ssDNA nucleofilament76 (PDB: 5H1B). (B) A three-protomer segment of pre-synaptic NF. Three nucleotides in 
ssDNA bind per single protomer with nucleobases stacked in triplets and pointing outward for efficient base-
pairing. Non-hydrolysable ATP mimetic AMP-PNP molecules (light green) are sandwiched between adjacent 
protomer ATPase domains (grey), stabilising the extended filament conformation. (C) RAD51-ssDNA interaction 
is mediated by the two DNA-binding loops L1 (Arg229-Ala240) and L2 (Val269-Asn290) protruding from the 
ATPase domain. (D) Three distinct interfaces form between adjacent RAD51 protomers in the active 
nucleofilament.  
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1.5.5 Allosteric regulation of RAD51 function 
 Several allosteric pathways have been proposed to control the different steps of 
RAD51-catalysed strand exchange. ATP hydrolysis rates increase when RAD51 binds 
DNA65,88 and such up-regulation of ATPase activity likely stems from conformational change 
induced within the RAD51 filament by DNA binding and transmitted to the ATPase active site. 
A report by Chen and colleagues89 proposed that this DNA-sensing pathway is transmitted 
through a cis-trans switching of a peptide bond between ScRad51 Asp280-Ser281 dyad 
(Asp222-Ser223 in HsRAD51) located at the junction between the DNA-binding loop L1 and 
the catalytic Walker B residues (Figure 7). The peptide bond linking the two residues is 
observed in the energetically unfavourable cis conformation in all DNA-free structures of 
RAD51/RecA family members. In DNA-bound nucleofilament structures, on the other hand, 
the peptide bond switches to a trans conformation. The authors propose that this brings the 
ScRad51 catalytic Glu221 side-chain closer to the reaction centre and increases catalytic rates 
as a result of DNA binding. However, no further studies have confirmed the validity of the 
proposed mechanism of activation. An earlier study on Pyrococcus furiosus RadA by Shin and 
colleagues examined the effect of recombinase-disabling L1 loop mutations on ATP hydrolysis 
rates, and found only marginal effects on ATPase activity, indicating that other mechanisms 
than L1-Walker B translation could be responsible for DNA sensing.78 
 A second allosteric pathway regulates the dependence of the filament state on the 
identity of the bound nucleotide.  Because ATP and ADP differ by the presence of a γ-
phosphate, it is likely that this moiety is central to inducing the inter-protomer rotation 
necessary to achieve the active ATP-bound filament state. Several allosteric mechanisms have 
been proposed for how γ-phosphate sensing is transmitted to large-scale conformational change 
based on structural and mutagenesis data. In the reported active RAD51/RecA filament 
structures, non-hydrolysable ATP analogues bind between the two “half-sites” of two adjacent 
ATPase domains, where one half-site is composed of the phosphate binding P-loop and the 
surrounding nucleoside-binding residues. The other half-site is provided by a different set of 
residues from an adjacent protomer. Specifically, the nucleotide molecule is covered by a β-
hairpin structure spanning residues Tyr315-Glu322 in HsRAD51, also called the “ATP cap”, 
(Figure 7). Pro321 from the ATP cap stacks tightly against the adenine base, while the 
preceding Cys319 backbone carbonyl further stabilises the interaction with the base by 
hydrogen-bonding with the exocyclic adenine NH2. A Glu322 residue that follows Pro321 does 
not directly interact with the nucleotide, but instead forms a salt bridge with a P-loop Arg130 
from the other ATPase domain, contributing an additional inter-protomer link.  
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Figure 7. Two-way allosteric coupling of ATP hydrolysis and DNA binding. Residues considered to be important 
for allosteric signalling are highlighted in purple, AMP-PNP nucleotide is shown in green carbons, adjacent 
protomers are represent by light grey and dark grey ribbons.  Residues Asp222-Ser223 have been proposed to act 
as a conformational sensors linking DNA binding to increased ATP hydrolysis rates through cis-trans peptide 
bond switching. Asp316 and Phe129 are putative γ-phosphate sensors that stabilise the high-pitch active NF.  
It is likely that the ATP-cap contacts contribute to the stabilisation of the extended, 
active filament state, however, on their own, are insufficient to induce it, since identical 
contacts would be possible with an ADP cofactor. It is thus reasonable to suggest that there 
exists a γ-phosphate sensor that distinguishes between the cofactors. Asp316, located within 
the ATP cap β-hairpin, has been proposed to harbour such function by Amunugama and 
colleagues (Figure 7).90 Its side chain is positioned adjacent to the g and β-phosphates of the 
ATP-PNP molecules in NF structures and can interact with the gamma phosphate though a 
cation-mediated salt bridge, as evidenced by X-ray crystallography.90 The Asp316 residue is 
conserved in eukaryotic and archaeal RAD51 orthologs, whereas in bacterial RecA and 
eukaryotic RAD51 paralogs it is replaced by a lysine that can directly bind the phosphate and 
does not require the intermediate cation.90 The human RAD51 D316K mutant, which reverts 
this position to the bacterial lysine, has a markedly enhanced strand exchange activity and a 
decreased ATPase activity compared to the wild type protein, and exhibits a significantly 
higher NF stability as determined by SPR.90 The authors propose an allosteric mechanism 
wherein this residue senses the ATP γ-phosphate, stabilising an ATP-capped conformation, 
with the concurrent inter-protomer rotation resulting in an increased filament pitch compared 
to ADP-bound or nucleotide-free filament. In a separate paper from the same group, the authors 
propose that the conserved lysine in RAD51 paralogs RAD51B-RAD51C confers increased 
stability to the nucleofilament.44 
A conserved phenylalanine residue corresponding to Phe129 in human RAD51 (Phe140 
in PfRadA, Phe187 in ScRad51) has also been proposed to act in γ-phosphate sensing (Figure 
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7). It is located in the middle of the P-loop and the phenyl side chain forms a flexible cap over 
the P-loop phosphate site. In the apo form, lacking a nucleotide co-factor, and in ADP-bound 
states, all published atomic resolution structures reveal the side chain to be in a “closed” or 
“up” conformation, with the phenyl covering the γ-phosphate binding site. When bound to 
nucleotides with a γ-phosphate, i.e. ATP and AMP-PNP, the side chain has to undergo a 
rotamer flip to an “open” or “down” conformation that accommodates the additional phosphate 
(Figure 7). In the active filament structure, the open Phe129 interacts with Ala293, His294 and 
Arg299 from the adjacent protomer, possibly stabilising the inter-protomer orientation. The 
closed state of Phe129 would not be compatible with the active conformation of the NPF, as 
the phenyl side-chain would sterically clash with the Ala293 backbone carbonyl from the 
adjacent half-site. This would prevent the positioning near the catalytic site of His294, which 
has been shown by mutagenesis to be involved in the control of ATP hydrolysis. 
Thus, it appears that a fine-tuned network of allosteric regulators exists within the 
RAD51 NF that maintain a sufficient level of ATP hydrolysis necessary for post-synaptic 
disassembly and recycling of RAD51 molecules, while ensuring that futile consumption of 
ATP is otherwise prevented, for example, in DNA-unbound RAD51. Hydrolysis-disabled 
mutants can catalyse strand invasion, but do not efficiently dissociate from the post-synaptic 
heteroduplex. It is likely that the hydrolytic dissociation of the γ-phosphate induces the 
conformational sensors of ATP, such as Asp316 and Phe129, to cease the stabilisation the 
extended inter-protomer orientation, and the filament reverts back to a lower-pitch, inactive 
state. 
1.6 Regulation of RAD51 by BRCA2 
In addition to the intrinsic allosteric pathways within the RAD51 nucleofilament, many 
regulatory proteins are involved in maintaining correct spatiotemporal control of RAD51 
function.91 BRCA2 is the most significant RAD51 protein mediator both mechanistically and 
from a clinical perspective, and will be discussed in the following section. Interestingly, there 
is no BRCA2 homolog in yeast, an important model organism in the study of DNA damage 
repair, and its functional homolog ScRad52 exerts similar mediator effects on ScRad51. 
BRCA2 (breast cancer 2) is a human tumour suppressor gene that first gained 
significance as mutations were identified that are associated with a large increase in breast and 
ovarian cancer incidence. Women who inherit mutations in the BRCA2 gene have an 85% 
chance of developing breast cancer.92 Homozygous BRCA2-/- homolog mutants are embryonic 
lethal in mice.93 Its orthologs are found across the eukaryote domain and differ widely in size 
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and number of constituent functional domains, suggesting significant evolutionary flexibility 
in structure and function. Cells from a wide range of species that have been rendered deficient 
in BRCA2 are sensitised to DNA damaging agents and have impaired ability to repair 
DSBs.94,95,96  
The 3418 amino acid protein product of BRCA2 is a regulator of homologous 
recombination and acts on molecules in this pathway, most crucial is its role as a mediator of 
RAD51, on which it exerts a number of functions.97 In the absence of DNA damage, BRCA2 
sequesters RAD51 in a monomeric form to prevent its oligomerisation and formation of 
RAD51 nucleofilament with off-target DNA substrates.98 Once the DSB repair pathway is 
activated, BRCA2 orchestrates the assembly and disassembly of oligomeric RAD51 on DNA. 
Consistent with this, BRCA2 is required for the formation of nuclear RAD51 foci following 
exposure to ionising radiation.99 
Purification and biochemical characterisation of full-length BRCA2 by Jensen et al.100 
elucidated many of the mechanistic steps this protein carries out to ensure efficient and tightly 
controlled homologous recombination and is to date the most comprehensive analysis of its in 
vitro function. BRCA2 contains several DNA binding domains – three oligonucleotide-binding 
(OB) folds and a helical domain, which interact with ssDNA, and a tower domain that binds 
dsDNA. The in vitro study showed that BRCA2 exhibits a strong preference for binding ssDNA 
and tailed ss/dsDNA substrate over dsDNA duplex, consistent with its role of targeting of 
recombination machinery to resected DSBs.100 In vitro strand exchange is inhibited when an 
excess of RAD51 binds the dsDNA template in addition to the ssDNA substrate. Thus, the full-
length BRCA2 protein was shown to stimulate RAD51-mediated strand exchange by 
enhancing active NF formation on ssDNA and decreasing inhibitory RAD51 binding to 
dsDNA.100 Pre-incubation of ssDNA with RPA impairs in vitro strand exchange, because 
RAD51 cannot displace the high affinity ssDNA-RPA interaction. The authors showed that 
catalytic amounts of BRCA2 restore RAD51 binding to ssDNA by rendering it capable of RPA 
displacement, in the absence of a direct interaction between BRCA2 and RPA.100 The same 
study reported that BRCA2 can stimulate strand exchange using both 3′ and 5′ tailed 
ssDNA/dsDNA substrates, as opposed to E. coli and U. maydis homologs, which act 
specifically on 3’ overhangs.100 Moreover, BRCA2 was found to inhibit ssDNA-dependent 
RAD51 ATPase activity.100 
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1.6.1 BRC repeats 
Two distinct regions for binding RAD51 have been identified in BRCA2 (Figure 8). In 
the central part of the protein, encoded by the exon 11, are located a series of eight conserved 
~30-40 residue long sequence fragments termed BRC repeats.101 BRC repeats are variably 
spaced within the human protein – the distance between BRC1 and BRC2 is 210 residues, 
while that between BRC3 and BRC4 is 96.  Corresponding repeats of same number in related 
organisms, e.g. BRC4 in mammals such as dog and mouse, are highly conserved, whereas 
sequence conservation between repeats of different number in the same ortholog is lower.102 
This suggests that the eight BRC repeats in mammals emerged as a result of sequence 
duplication before the radiation of the mammalian class.102  The number of BRC repeats varies 
dramatically as one explores BRCA2 homologs of more distant eukaryotes. For example, the 
fungus Ustilago maydis has only a single BRC repeat in its BRCA2 ortholog, whereas the 
protozoan Trypanosoma brucei has 15 BRC repeats.103,104  Step-wise removal of T. brucei BRC 
repeats has been shown by Trenaman et al. to perfectly correlate with the number of Rad51 
nuclear foci observed after induced DNA damage.105 It is therefore likely that BRC repeat 
number correlates with Rad51-mediator activity. 
Isolated individual BRC repeats or short BRCA2 fragments containing one or more 
repeats have been shown to exert many of the effects on RAD51 that are ascribed for the full-
length protein. A polypeptide construct encompassing a BRC3-BRC4 fragment fused to the 
BRCA2 DNA binding domain (DBD) was shown to be sufficient to stimulate RAD51-ssDNA 
nucleofilament formation and strand exchange, despite being only a fraction of the size of the 
full-length protein.106 
 
Figure 8. A schematic representation of the BRCA2 protein product with RAD51 and DNA-interacting domains 
highlighted (top). Alignment of the 8 human BRC repeats with conserved FxxA and LFDE motifs highlighted 
(bottom).   
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The exact mechanisms by which the BRC repeats modulate RAD51 function either as 
isolated peptides or in the context of the full-length BRCA2 protein are elusive. There appears 
to be functional differentiation between repeat groups 1-4 and 5-8, as shown in a study by 
Carreira and Kowalczykowski.107 The study reports that individual BRC repeats 1-4 bind free 
RAD51 with higher affinity than repeats 5-8, stabilise the active form of RAD51-ssDNA 
nucleofilament by inhibiting its ATPase activity, and decrease RAD51 binding to dsDNA. On 
the other hand, repeats in second group, comprising BRC5-8, bind free Rad51 with low affinity 
but RAD51-ssDNA nucleofilament with high affinity, and do not affect ATPase activity or 
dsDNA binding. The authors propose that two groups BRC1-4 and BRC5-8 have evolved 
different functions to promote the efficient nucleation and growth of RAD51 ssDNA 
nucleofilament, respectively.  
Remarkably, other studies have shown that, on the contrary, isolated BRC repeats 
prevent the assembly of RAD51 on ssDNA, rather than stabilise the filament, and are therefore 
inhibitors of homologous recombination when taken out of context of the full-length  BRCA2 
protein.87 In fact, when overexpressed in cells, isolated BRC4 has been shown to disrupt 
RAD51 foci formation and sequester RAD51 in the nucleus.108 BRC4 peptide also disrupts free 
RAD51 oligomers in vitro.97 These effects are consistent with the structural observation that 
the BRC repeat binding would overlap with RAD51 oligomerisation epitope (Section 1.6.2, 
Figure 9A,D). To date, structural explanations of how these conflicting observations can be 
reconciled are lacking. These discrepancies may be addressed to some extent by the fact that 
some of the published in vitro experiments use GST-fused repeats, which are expected to form 
dimeric species in solution, and are therefore not strictly isolated repeats, whereas other studies 
use free linear peptides.  
1.6.2 Structural basis of the RAD51-BRC repeat interaction 
The first and so far only structural model of a BRC repeat in complex with RAD51 was 
determined by Pellegrini and colleagues using X-ray crystallography.80 To obtain a 
crystallisable complex, the HsRAD51 C-terminal ATPase domain, lacking the OE and the N-
terminal domain, was recombinantly fused to BRC4, the highest-affinity BRC repeat, separated 
by a flexible linker, and the construct produced in a bacterial expression system. The resulting 
model elucidates the overall fold of the repeat when bound to the ATPase domain and suggests 
a number of critical structural features, or “hot-spots”, that drive the interaction (Figure 9A). 
The most outstanding feature of the binding mode is the interface formed by the repeat residues 
1524-FHTA-1527, interacting with the FxxA binding site on the RAD51 protomer (Figure 
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9B). These residues bind in an almost identical manner as the FxxA motif from the 
oligomerisation epitope (Figure 9A,B). Phe1524 constitutes the most extensive hydrophobic 
contact of the whole interface, while Ala1527 binds a much smaller nearby pocket. These FxxA 
motif residues are conserved in six out of eight human BRC repeats (Figure 8) and have been 
shown to be critical for binding RAD51.109,81    
Besides the FxxA motif tetrad, the rest of the repeat binds differently compared to the 
OE (Figure 9A). The N-terminal residues Leu1521-Gly1523 do not make significant contacts 
with the ATPase domain and form a short, solvent-exposed α-helix, the significance of which 
is unclear. 1528-SGK-1530 residues that lie immediately C-terminal to the FxxA motif form a 
β-turn, stabilised by hydrogen bonds between backbone amides and side-chain hydroxyl groups 
of Thr1526 and Ser1528 (Figure 9B). This turn causes the repeat to bend back in the opposite 
direction, folding into a β-hairpin whose peptide backbone hydrogen bonds with the ATPase 
central β-sheet and extends it in an inter-molecular fashion. A conserved cationic residue 
corresponding to Lys1530 in BRC4 forms a salt bridge with RAD51 Asp187 (Figure 9B). 
At its C-terminal half, spanning residues Lys1536 to Glu1548, the peptide folds into an 
α-helix that produces additional contacts with the ATPase domain through a combination of 
hydrophobic and polar interactions (Figure 9C). Residues Ile1534, Leu1539, Val1542, 
Leu1545 and Phe1546 form a continuous hydrophobic interface with RAD51 by projecting 
their side chains into the ATPase domain surface from a shared helical face. Of the five 
residues, Leu1545 and Phe1546 are significantly buried within cavities formed by RAD51. 
Further to the C-terminus, Glu1548 forms a salt-bridge with a nearby Arg250 and can 
potentially also interact with an adjacent Arg247. The combination of two hydrophobic 
residues at fixed positions within the repeats, represented by Leu1545 and Phe1546 in BRC4, 
with an acidic residue, represented by Glu1548, is a highly conserved feature found across all 
mammalian BRC repeats. Because BRC4 is the most studied and highest-affinity repeat, this 
feature has been termed the “LFDE” motif and has been shown to be critical for high-affinity 
binding in biochemical and cellular experiments,81 and thus represents an additional interaction 
hot-spot.  
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Figure 9. X-ray crystallographic structure of BRC4 repeat (blue) in complex with RAD51 ATPase domain (grey) 
(PDB: 1n0w). (A) Cartoon depiction of the BRC4 peptide superimposed with an oligomerisation epitope from 
PfRadA (PDB: 1pzn). Near-identical backbone trace is seen at the FxxA site but not beyond. (B) Binding of the 
BRC4 repeat at the FxxA site of RAD51. Hot-spot residue Phe1524/Ala1527, and β-turn stabilising residue 
Thr1526/Ser1528 side-chains are rendered as sticks. (C) Binding of the BRC4 repeat at the LFDE site of RAD51. 
Hydrophobic interface-mediating residue side-chains and acidic Asp1548 are depicted as sticks. Salt bridge-
mediating RAD51 arginines are shown behind a semi-transparent surface. (D) Superposition of the BRC4 repast 
structure with a cryo-EM model of a pre-synaptic nucleoprotein filament.  
The BRC repeats have been reported to span a wide range of affinities for RAD51, with 
BRC4 being the tightest binder.107,110 As evidenced by the BRC4 crystal structure, there is 
direct competition between the binding of BRC repeats and the RAD51 OE (Figure 9A,D). 
The OE has been shown to bind RAD51 with 800 nM affinity, which is more than a magnitude 
lower than BRC4.111 It is therefore remarkable that BRCA2 serves a RAD51 mediator function 
and stimulates its assembly on ssDNA, whereas isolated BRC peptides disrupt it.  
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1.6.3 TR2 region 
The C-terminal TR2 region (sometimes called CTRB) of BRCA2, encoded by exon 27, 
also binds RAD51 and is important for HR.112 The binding preferences of TR2 were reported 
in two simultaneous publications by Davies and Pellegrini87 and Esashi et al.113 TR2 binds 
RAD51 oligomers both in the absence of DNA and in the context of a Rad51-ssDNA 
nucleofilament. It protects the RAD51-ssDNA nucleofilament from depolymerisation by the 
isolated BRC4 repeat in an ATP hydrolysis-independent manner and inhibits the formation of 
1:1 RAD51-BRC4 complexes. Such effect is not observed on the depolymerisation of free 
RAD51 oligomers or RAD51-dsDNA nucleofilament. Phosphorylation of TR2 on Ser3291 by 
cyclin-dependent kinases (CDKs) disrupts this interaction in a cell cycle-dependent fashion. 
This post-translational modification ablates RAD51 binding at the TR2 and serves a molecular 
switch for turning off homologous recombination during the G2-M transition.114 
1.7 Shuffling of BRC repeats reveals modular contributions to 
binding 
Integration of previously published structural and affinity data indicates that binding of 
the conserved BRC repeat FxxA and LFDE motifs is contingent on the folding of two distinct 
secondary structure elements, a β-hairpin and an α-helix, respectively, that split the bound 
repeat into two structural modules (Figure 9A). For convenience, these modules are termed 
“FxxA” and “LFDE”, reflecting the hotspot motifs that they contain. Previously, Rajendra et 
al.81 demonstrated that an FxxA module from BRC4 and an LFDE module from BRC5 can be 
recombined into a new repeat, termed BRC4-5, in manner that preserves binding to RAD51, 
as evidenced by ELISA and streptavidin bead co-precipitation.   
The modular nature of BRC repeats prompted a collaborative project led by the group 
of Prof Florian Hollfelder (Department of Biochemistry, University of Cambridge), and our 
group, with the aim of investigating BRC repeat modularity. The findings uncovered in the 
project directly informed the aims of the work presented in this thesis. A pre-print describing 
this initial work has been published,115 and also includes data from Chapter 2 Characterisation 
of a chimeric BRC8-2 repeat. 
Understanding modular contribution to binding would provide insight into BRC repeat 
function. For example, it may be possible that the two repeat groups 1-4 and 5-8, that have 
been shown to manifest distinct biochemical effects on RAD51 nucleofilament,81,116 arise as a 
result of modular differentiation. Quantitative binding measurements of individual modules are 
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challenging given their low intrinsic affinities.81,117 Instead, FxxA and LFDE modules from 
each of the 8 parental human repeats were shuffled in every possible combination at a crossover 
point immediately C-terminal to the β-hairpin element, corresponding to the peptide bond 
between residues Lys1530 and Lys1531 in BRC4 (Figure 10B), leading to a total of 56 novel 
sequences that are not found in nature (Figure 10C). 
 
 
Figure 10. Shuffling of the FxxA and LFDE modules from 8 parental BRC repeats leads to binders with improved 
affinity. (A) Alignment of the 8 parental BRC repeats that were shuffled. (B) BRC4:RAD51 complex showing 
the cross-over point at which the FxxA/LFDE modules were delineated for shuffling (C) Depiction of the tested 
repeats, both shuffled and parental. (D) Diagram showing the fluorescence polarisation assay reaction used for 
affinity determination. (E) Affinity matrix of the shuffled and parental repeats expressed as KD. (F) Calculated 
ΔΔGparental values for individual shuffled repeats and their per-module averages shown at the bottom of each 
column (FxxA) or on the left of each row (LFDE).  
The resulting peptides and the eight parental repeats were cloned into a bacterial 
expression plasmid as fusions to a GB1 protein tag to aid expression and solubility. All repeat 
fusions were successfully expressed and purified in sufficient quantities for binding assays. 
Their affinities for a monomeric RAD51 ATPase domain surrogate protein, HumRadA22, were 
successfully determined using a microfluidic assay setup, described previously by Gielen et 
al.,118 that couples nanolitre droplet formation with a fluorescence polarisation (FP) 
competition assay, allowing rapid collection of a very large number of data points across 
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concentration gradients of the competitor GB1-BRC fusion. The FP assay used fluorescein-
tagged BRC4 peptide as a fluorescent probe that is progressively displaced by the competitor 
(Figure 10D). 
The parental repeat affinities determined in these experiments were in line with 
previously published KD values and broadly maintained a similar relative ranking 
(4>1>3>2>8>7>5>6) of repeats to what has been reported.107,110 Importantly, repeats 1, 2, 3 
and 4 displayed higher affinity (median KD = 245 nM) than repeats 5, 6, 7 and 8 (median KD = 
1636 nM), confirming the previously reported differentiation between the two groups. 
Systematic analysis of the chimeric repeat affinities revealed a number of trends that 
would not be discernible in the context of parental repeats (Figure 10E). All of the chimeras 
containing FxxABRC5 are relatively weak binders, with KD values above 2 μM, consistent with 
observations by Rajendra et al.,81 and likely resulting from a disruptive Ala to Ser substitution 
at the FxxA motif. Remarkably, the 56 new chimeras span an even wider range of affinities 
than the 8 parental repeats, from 6 nM to 11 μM, and a number of combinations bind more 
tightly than BRC4. Intriguingly, several of the shuffled repeats containing FxxABRC8, which 
originates in the “weak” 5-8 group of parental repeats, were amongst the tightest-binding 
sequences overall. BRC8-2 was the highest-affinity repeat in the whole matrix, with a KD of 6 
nM, exceeding both of its parental repeats BRC8 and BRC2 more than 40-fold.  
To enable analysis of module-specific contributions, affinities were first derived in 
terms of Gibbs free energy (ΔG°, Eq. 1) and then, for each chimeric repeat, the effect of 
shuffling was expressed as the average of the two differences of ΔG° between the chimeric 
repeat and its parents (ΔΔGparental, Eq. 2). 
 





A negative value for ΔΔGparental means that the net effect of recombining the two constituent 
modules is beneficial for binding, whereas a positive value indicates that on average the 
chimeric repeat is worse than its parents. One can then calculate the mean ΔΔGparental values 
for a given module across the series, that is, an average of all values in a column for an FxxA 
module or in a row for an LFDE module of the recombination matrix (Figure 10F). For 
example, ΔΔGFxxA-BRC5 equals 0.91 kCal/mol, indicating that the FxxA module from BRC5 is 
most detrimental to binding when recombined with other LFDE modules. ΔΔGFxxA-BRC8, on the 
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other hand, equals -0.96, meaning that FxxABRC8 is the most favourable FxxA module for 
binding. Surprisingly, the LFDE module from the same parental BRC8 is generally detrimental 
to binding (ΔΔGLFDE-BRC8 = 1.05 kCal/mol), which clearly demonstrates that parental repeat 
affinities are not indicative of both modules’ contributions to binding. For LFDE modules, 
LFDEBRC2 has the highest contribution to affinity with an ΔΔGLFDE-BRC2 of -1.15. Together the 
top-contributing modules, FxxABRC8 and LFDEBRC2, recombine to form the highest-affinity 
chimeric repeat, BRC8-2. The KD of this repeat is 6 nM, representing a more than 6 times 
tighter binding than BRC4. 
This analysis shows that both LFDE and FxxA modules make meaningful contributions 
to the interaction and greatly expands our understanding of module-specific effects that are 
obscured in the context of the parental repeats. However, the structural basis of these 
contributions still remains poorly understood. Besides the importance of the two conserved 
tetrad motifs, it is hard to predict what other structural factors are at play based on the sequence 
data and the BRC4 complex structure. The high affinity BRC8-2 repeat binds more strongly 
than any of the other repeats. This property makes it interesting for the development of 
pharmacological probes targeting RAD51. Understanding the structural features that drive the 
high-affinity interaction can inform the design of pharmacological probes, and the BRC 8-2 
sequence itself may provide an attractive template for the development of binders. 
1.8  RAD51 in protozoan parasites  
Protozoans are an informal phylogenetic category that describes a highly diverse group 
of unicellular eukaryotes characterised by having independent motility and heterotrophic 
feeding.119 A number of protozoans are important human parasites and cause severe disease, 
particularly in tropical and subtropical geographic regions.120 Most notable examples are 
Plasmodium, Trypanosoma, Leishmania and Toxoplasma species. Despite being evolutionarily 
distant from metazoans such as humans, many protozoan parasites have Rad51 and BRCA2 
homolog genes identified. Moreover, in a number of species, the two proteins have been 
functionally characterised and shown to contribute to specific aspects of the parasite life cycle 
and pathogenicity. A number of these roles are discussed below. 
Trypanosoma brucei, the causative agent of African sleeping sickness, is capable of 
host immune evasion through a process termed variable surface glycoprotein (VSG) switching, 
where the expression of alternate coat glycoproteins on the parasites’ surface is achieved by 
recombination of silent VSG genes into an actively expressed locus. McCulloch and Barry 
have shown that the recombination mechanism that underlies VSG switching is mediated by 
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Rad51.121 Interestingly, the T. brucei BRCA2 homolog has 15 BRC repeats of which 14 are 
identical in sequence, suggesting a relatively recent expansion in repeat number. A study by 
Hartley and McCulloch demonstrated that reducing the number of these repeat copies results 
in impaired VSG switching rates.104 
In T. cruzi, Rad51 has a protective effect on host-induced oxidative stress and promotes 
parasitaemia.122 Moreover, Rad51 is important for the process of genetic exchange in the T. 
cruzi parasite,123 which lacks sexual mechanisms of recombining genetic information and 
therefore relies on the formation of fused cell hybrids. 
Leishmania species and other kinetoplastids are unique among eukaryotic organisms in 
that they do not regulate gene expression at transcriptional level, that is, through promoters and 
transcription factors, and all genes are transcribed as long polycistrons of 10-100 genes with 
similar expression levels. One of the ways in which Leishmania responds to changing 
environment is by altering the copy number of specific genes. This can manifest as aneuploidy 
or amplification of smaller DNA segments. Genes can be multiplied within the chromosome 
or as extra-chromosomal amplicons. Laffitte et al. have shown that such amplicons underlie 
several antibiotic resistance mechanisms in Leishmania species.124 Formation of these extra-
chromosomal elements is facilitated by homologous recombination and therefore Rad51 is 
important for the resistance mechanisms.  
The specific roles of Rad51 in protozoan parasites make it an attractive potential 
therapeutic target. Selective targeting of parasitic Rad51 orthologs may provide novel 
therapeutic avenues for treatment of neglected diseases. Understanding of the structural 
determinants of the Rad51:BRCA2 axis can guide the development of such interventions. 
BRCA2 orthologs in protozoan parasites vary significantly in size and domain composition, 
and contain variable numbers of BRC repeats, ranging from two in L. infantum to fifteen in T. 
brucei. To date, no structural studies of protozoan Rad51 and BRCA2 have been reported in 
the public domain, and only qualitative investigations of these interactions have been 
published. 
1.9 RAD51 as a therapeutic target  
Radiation therapy (RTx) is a key method in cancer treatment. It has been estimated that 
around 50% of oncology patients receive some form of radiation as part of their treatment.125 
RTx acts primarily by causing DNA damage in rapidly dividing cancer cells.125 Moreover, RTx 
can prime the immune system to destroy metastatic secondary tumours via a variety of 
processes, such as increased presentation of tumour antigens.126 Despite its wide application, 
Pantelejevs, T.  Introduction 
 32 
tumour relapse is extremely common due to a variety of RTx resistance mechanisms. RAD51 
and other recombinogenic factors have been shown to be over-active in RTx-resistant tumours, 
and help such cells survive the genotoxic lesions.127 RAD51 knock-down has been shown to 
sensitise resistant tumour cells to RTx.128 Besides its application to RTx, RAD51 inhibition can 
synergise with other cancer-specific proteins, causing synthetic lethality in a variety of 
tumours. For example, activation-induced cytidine deaminase (AID) is an enzyme that is 
normally expressed in activated B-cells, causing mismatch mutations that are beneficial for 
antibody maturation in lymph nodes, and is tightly controlled to avoid unwanted DNA 
damage.129 Overexpression of AID is observed in many lymphoid and solid cancers, leading to 
genomic instability that contributes to tumorigenesis. RAD51 inhibition with a small molecule 
compound has been shown to be effective against AID-positive tumours in mouse xenograft 
models.130 Because several DSB repair pathways are available to healthy cells, specific RAD51 
inhibition may achieve a sufficient therapeutic window in tumours where synthetic lethality is 
possible. 
 
Name Structure Biochemical mechanism Potency Notes Ref 
DIDS 
 
Strand exchange inhibition via 
DNA binding competition. DNA 
mimic. 
 







Strand exchange inhibition via 
unknown mechanism.  
Strand exchange: IC50 




CYT-0851 n.a. n.a. AID+ cell killing: 






DNA binding inhibition. 
Covalent binding to Cys319 on 
protomer-protomer interface.  
DNA binding FP: IC50 
= 5-30 μM 
Cell sensitisation to 
MMS: 








DNA binding inhibition. Putative 
binding to protomer-protomer 
interface. 
DNA binding FP: IC50 
= 44 μM 





















binding. BRCA2 binding 
competition. 
ITC: KD = 366 nM 
FP: KD = 355 nM 
RAD51 foci inhibition 





Table 1. Small-molecule pharmacological modulators of RAD51 function reported in literature.  Compounds are 
depicted in a neutral ionisation state. AID+ denotes cells overexpressing activation-induced cytidine deaminase.  
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trial of a RAD51 inhibitor reported, a Phase I/II study of a small-molecule candidate CYT-
0851 developed by Cyteir Therapeutics, with the chemical series originally described in patent 
US10336746B1. No mechanism of action (MOA) or biochemical data have been reported for 
this compound. The scarcity of clinical investigations and pharmacological probes for RAD51 
is likely reflective of the challenges associated with targeting this protein, which presents 
challenging potential binding sites for inhibition. Targeting the ATP site may seem like a 
reasonable mechanism of action at first glance, yet its relatively flat and polar nature, as well 
as the need to compete with endogenous nucleotides, renders it sub-optimal. An overview of 
published pharmacological probes is provided in Table 1. One of the first RAD51 inhibitors 
reported, a DNA mimic DIDS is a chloride channel blocker that has been shown to 
competitively inhibit RAD51 DNA binding and downstream strand exchange.131 However, the 
low potency, high negative charge and potential lack of specificity would severely limit its 
pharmacological application. The RAD51:OE/BRCA2 binding interface is a protein-protein 
interaction that has instead gained attention as a druggable site for inhibition. Recently, a potent 
small-molecule RAD51 inhibitor (CAM833) disrupting the RAD51:OE/BRCA2 interface has 
been reported, with a peptidomimetic structure that binds at the FxxA site with a KD of 366 nM 
and inhibits IR-induced RAD51 foci formation at an IC50 of 5 μM in the A549 cell line.117 
CAM833 is therefore the first example of a biophysically, structurally and cellularly validated 
probe inhibiting RAD51 function. 
The DNA repair research community would benefit from novel, more potent RAD51 
inhibitors with validated MOAs. Moreover, such molecules may lead to the development of 
effective drugs for cancer treatment. Targeting protein-protein interactions (PPIs), such as the 
RAD51:OE/BRCA2 interface, is a challenging task due to the physicochemical nature of these 
interaction. The following chapter describes the issues surrounding PPI targeting, as well as a 
number of potential solutions. 
1.10 Pharmacology of protein-protein interactions 
 
Protein-protein interactions (PPIs) are specific physical contacts between proteins that 
exert a functional role in the organism. This is opposed to random encounters resulting from 
macromolecular crowding and non-specific interactions. PPIs are essential to almost all of the 
physiological processes in the cell, and their analysis is crucial for understanding normal 
organismal function and elucidating disease aetiology. Despite their critical role in the 
functioning of the cellular biochemical machinery, PPIs are under-represented as a target class 
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in the development of pharmacological probes in target-based drug discovery.136 Traditional 
medicinal chemistry as we know it today experienced dramatic advances in the second half of 
the 20th century, enabled by the myriad of novel organic synthetic reactions, recombinant DNA 
technology and an increase in assay throughput. This mode of drug discovery focused on 
modulating a limited number of privileged target classes, mainly enzymes, nuclear receptors, 
ion channels and GPCRs, that had native ligands, such as biochemical substrates, with 
molecular weights comparable to small-molecule compounds, as opposed to those targets that 
interact with large macromolecules.137 For example, many enzymes have active sites that bind 
small-molecule-like substrates at a well-defined cavity, containing a mixture of hydrophobic 
and polar features, which provides the drug designer with a convenient “druggable” orthosteric 
site for a medicinal chemistry work. PPIs, on the other hand, tend to exhibit substantially 
different physicochemical profiles. Interaction interfaces between proteins tend to be mediated 
by more shallow binding cavities and encompass much larger areas of the protein's surface.136 
This renders the development of pharmacological probes challenging, as it becomes 
increasingly difficult to achieve a sufficient number of favourable contacts between the protein 
and the synthetic compound. This limited druggability problem is particularly acute for 
intracellular PPIs that are inaccessible for alternative modalities of larger size, such as 
antibodies and other biologicals.  
 
Figure 11. Diagram showing some of the different therapeutic modalities that can modulate protein-protein 
interactions at various stages of a protein’s life cycle. Grey and purple surfaces represent two generic protein 
binding partners. Yellow spheres represent a small molecule inhibitor of the PPI.  
The need to expand the druggable target space beyond the privileged target families has 
been recognised by the biomedical community, and has spurred several international 
collaborative initiatives, such as Illuminating the Druggable Genome and Target 2035, that aim 
to harness state of the art advances in biology and chemistry to find pharmacological 
modulators of hitherto undrugged proteins.138 Therapeutic modalities that aim to modulate 
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pharmacology or exert their activity by changing the protein level or identity (Figure 11). 
Modalities that alter protein level or its identity, such as antisense oligonucleotides, protein 
degraders and gene therapy, can potentially circumvent the druggability problem completely, 
because high-affinity binding to a druggable functional site on the protein is not necessary. 
Such drugs are gaining ever-increasing prominence and are now mature fields of their own, yet 
have specific limitations that hinder widespread application. Traditional occupancy-based 
modalities bind the target and alter its function by virtue of direct physical contact. This is the 
core paradigm of most medicinal chemistry, and suffers from the classical druggability pitfalls, 
as a suitable functional site is required for targeting.  
Early-stage small-molecule drug development is in essence a multi-dimensional 
optimisation problem where the scientist iteratively improves on a number of pharmacological 
properties of a molecule in order for the drug to be efficacious. Among these, physicochemical 
properties of a compound are often maintained within what is termed the “drug-like space”, 
with particular constraints on molecular weight, hydrophobicity and hydrogen bond 
donor/acceptor count.139 A compound that is too large and hydrophobic is likely to have poor 
solubility and membrane permeability, leading to low bioavailability, as well as potential off-
target toxicity. There is a common (but not universal) trade-off between these properties and 
compound potency, that becomes particularly acute when targeting PPIs.  
A number of chemical and biological approaches that aim to overcome druggability 
limitations of PPIs have been applied in drug discovery.136 For example, fragment-based drug 
discovery (FBDD) is a methodological framework in medicinal chemistry that aims to sample 
ligand chemical space more efficiently during early-stage screening, leading to small-molecule 
binders with higher affinity than compounds discovered using more traditional high-throughput 
methods.140 In FBDD, libraries of fragment molecules containing low-complexity compounds 
of molecular weight of less than 300 Da are screened against a protein target using sensitive 
biophysical techniques such as NMR, SPR or X-ray crystallography, that allow the detection 
of weak affinities for molecules of such size. By virtue of covering a larger fraction of 
theoretical chemical space at a given molecular weight, as well as reduced conformational 
degrees of freedom, identified fragment hits are likely to a priori form more efficient contacts 
with the target than a drug-like hit from a high-throughput screen, thus providing more optimal 
starting points for their subsequent synthetic derivatisation. 
An alternative modality to small molecules for targeting PPIs are conformationally 
constrained macrocyclic peptides.  
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1.11 Peptide macrocyclisation 
 
Peptides have a long history of being used as therapeutics, with insulin being the best 
known and most widely administered peptide drug to this day, which was prepared and applied 
therapeutically as early as the 1920s.141 Traditional peptide therapeutics were typically isolated 
from mammalian sources and mimic endogenous peptide ligands in humans, and act by 
supplementing dysregulated pools of the endogenous molecule. More recently, spurred by the 
advances in biology and chemistry, fully synthetic peptides became the focus of many drug 
discovery projects, and the target space of peptide therapeutics expanded beyond proteins with 
well-established native peptide ligands.  
Peptide binders tend to have higher molecular weights and occupy larger binding 
interfaces than small-molecule drugs, and can therefore be more appropriate for the targeting 
of PPIs. Moreover, naturally occurring epitopes found in PPIs can be used as templates for the 
development of peptidic binders. Despite these positive attributes, peptide development has 
been hampered by a number of pharmacological pitfalls that are inherent to this modality and 
are primarily concerned with their ADME (Absorption, Distribution, Metabolism, Excretion) 
properties. A crucial disadvantage of peptides is their susceptibility to proteolysis in vivo by 
the plethora of proteases found in different physiological compartments both inside and outside 
the cell. Proteolytic cleavage makes peptides unsuitable for oral administration, as the various 
non-specific gastro-intestinal proteases completely ablate their oral bioavailability. IV-
administered peptides typically have very short plasma-stabilities due to proteolysis in plasma 
and rapid renal clearance. Moreover, as peptides tend to be large compounds with significant 
conformational flexibility and contain many polar functional groups, their application to 
intracellular targets is limited by their poor plasma membrane permeability. 
Peptide macrocyclisation is a drug discovery strategy where additional covalent 
linkages are introduced into a linear peptide with the aim of improving their pharmacological 
properties.142 Conformationally constrained peptides are much less likely to form a favourable 
fit with a protease active site, therefore macrocyclisation can profoundly enhance a peptide’s 
stability. Moreover, the pre-organisation of the peptide may result in higher binding affinity to 
the target, stemming from a reduced entropic penalty of binding. Crucially, peptide 
macrocycles can display an improved ability to cross the cell membrane and thus engage 
intracellular targets due to their smaller hydrodynamic radius and reduced conformational 
degrees of freedom. 
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Figure 12. Overview of peptide macrocyclisation methods. Pink helix represents a generic peptide of interest. 
(A) Main geometries of covalent linkages. (B) Representative stapling reactions of various types classified 
according to the number of reaction components and the type of amino acid that is being stapled. (C) Binder 
sequences can be obtained from different sources, such as existing natural epitopes or directed evolution. 
A variety of macrocyclisation strategies have been utilised in drug discovery and can 
be classified according to which parts of the peptide are linked (Figure 12A). Terminal amines 
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Alternatively, amino acid side-chains can be linked with the termini or another side-chain. 
Moreover, macrocyclisation can be classified as either one-component or two-component 
(Figure 12B). One-component reactions contain the reactive groups within the amino-acid 
residues of the linear peptide, and the covalent bridge is introduced in an intra-molecular 
fashion. For example, ring-closing metathesis (RCM) reactions incorporate non-natural amino 
acids with olefin side-chains that react form the macrocycle via metal-catalysed metathesis. 
Because all the reactive parts constituting the covalent linkage are introduced in the peptide 
from the outset, RCM is a one-component stapling reaction, meaning that no external reactive 
linker is necessary.  
In two-component reactions, a separate linker moiety is added that reacts with the two 
residues to join them (Figure 12B). For example, double copper-catalysed alkyne-azide 
cycloaddition (CuAAC) has been employed to cyclise peptidic inhibitors of the CK2α:CK2β 
kinase interaction.143 The authors used a bis-alkyne linker to connect two azidoalanine residues 
introduced into a natural epitope binding the target protein. Two-component reactions can also 
be performed with trivalent linkers that join three residues simultaneously, yielding bicyclic 
peptides. For example, 1,3,5-Tris(bromomethyl)benzene (TBMB) and other similarly 
electrophilic linkers have been reacted with phage display libraries of bicyclic peptides 
containing genetically encoded cysteines that were then selected against targets of interest in a 
directed evolution approach.144 
The nature of amino acids used for macrocyclisation has profound methodological 
implications for peptide development. Unnatural amino acids (UAAs) dramatically expand the 
chemical space and allow many different chemistries to be employed. The incorporation of 
UAAs into peptides is straightforward when done by solid-phase peptide synthesis (SPPS), as 
many Fmoc-protected amino acids are commercially available. However, for methods that 
require ribosomal synthesis, such as phage or mRNA display, UAAs present additional 
challenges, as native Aminoacyl-tRNA synthetases are not optimal for incorporating them into 
tRNA. Proteinogenic amino acids, on the other hand, permit only a handful of macrocyclisation 
reactions, but are compatible with a variety of recombinant expression systems. Recombinant 
methods can be advantageous in cases of long peptides, as synthesis becomes increasingly 
challenging, resulting in lower yields. Moreover, recombinant methods do not require the use 
of large volumes of hazardous solvents such as DMF. Cysteine in particular has found wide 
application for many bio-conjugation tasks, as its nucleophilic thiol side-chain can be reacted 
selectively with a variety of electrophilic groups. Many examples of cysteine-based 
macrocyclisation strategies have been reported.145,144,146 
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1.12 Peptide stapling  
Peptide stapling is a macrocyclisation approach in which the peptide is covalently 
cross-linked through the side-chains of two separate and amino acid residues (Figure 12B).147 
Traditionally, the term “stapling” has been used to describe specifically the side-chain to side-
chain macrocyclisation of α-helical epitopes. α-helices have been recognised to mediate a large 
fraction of PPIs, as shown by the analysis of complexes deposited in the PDB,148 and their 
regular shape and structural stability render α-helices attractive motifs for stapling. 
Historically, RCM has been the reaction of choice for α-helical stapling, as the length of the 
two alkene side-chains can be optimised to join various inter-residue distances, here referred 
to as “stapling architectures”.149 Peptides were typically obtained by taking the α-helical motif 
out of the parental polypeptide and the reactive residues introduced on the face opposite of the 
interface to minimise clashes with the binding partner. For simplicity, in this dissertation, the 
term “stapling” is applied to encompass side-chain to side-chain cyclisation of all secondary 
structure elements, such as β-hairpins and loops, as these are becoming increasingly commonly 
utilised. For example, Wendt and colleagues recently reported a successful campaign to inhibit 
Wnt signalling by targeting β-catenin with a head-to-tail linked β-sheet mimetic that has an 
additional inter-strand cysteine staple introduced in the middle.150 
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1.13 Aims and scope 
The high-affinity BRC repeats constitute an attractive template for developing peptidic 
RAD51 binders. Moreover, chimeric BRC repeat data suggests that improved binding can be 
achieved by domain shuffling or other sequence modifications. The key objective of this thesis 
is to expand our understanding of BRC repeat binding and integrate it with the latest advances 
in peptide stapling to obtain potent pharmacological probes that inhibit RAD51 function. To 
achieve this objective, the following specific aims were addressed: 
 
I. To characterise of the interaction between BRC8-2 and RAD51 
 
In order to ascertain the applicability of BRC8-2 for peptidic probe development, it is 
necessary to validate the preliminary data, which suggests that BRC8-2 is a more potent binder 
than its parental peptides, as well as BRC4. For this, I performed a biophysical evaluation of 
its binding to RAD51. To expand our understanding of the atomic determinants of the 
interaction, which is crucial in guiding subsequent design of molecular probes, a structural 
characterisation of the complex between BRC8-2 and RAD51 was done using X-ray 
crystallography. To further probe the finer atomic details of binding, I performed additional 
mutagenesis and biophysical experiments to support my structural analysis. The resulting data 
contribute to the present understanding of how BRCA2 exerts its RAD51-modulatory function. 
Moreover, the structure provided crucial information for the subsequent design of stapled 
peptides. 
 
II.  To develop a recombinant stapled peptide screening platform 
 
Peptide stapling presents a promising avenue for inhibiting RAD51, and the high-
affinity BRC8-2 repeat can be utilised as a template for this strategy. A robust approach for 
preparing and screening many stapled peptides with different architectures is necessary to 
obtain molecules with optimal characteristics. For this, I used a two-component cysteine-
stapling methodology that employs heterobifunctional divinyl linkers. To rapidly evaluate the 
different stapling architectures that can be introduced into this peptide, I devised a recombinant 
platform for the small-scale preparation and screening of cysteine-stapled peptides. 
 
III. To design, screen and characterise stapled BRC8-2 repeats 
 
The crystal structure of the BRC8-2:RAD51 complex can inform the design of cysteine 
pairs for stapling. Bis-cysteine mutants of BRC8-2 were rationally designed in a structure-
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guided manner in order to obtain RAD51 inhibitor peptides that are proteolytically stable and 
maintain high affinity binding. These were evaluated using the recombinant screening 
platform. Different stapling architectures were found to be compatible with high-affinity 
binding. Based on these findings, selected stapled peptides were prepared at higher scale and 
tested in a variety of biophysical and biochemical assays. Crystal structures of stapled BRC8-
2 peptides were determined, revealing the atomic-level features of the staple moiety. 
 
IV. Characterisation of the BRC:Rad51 interaction in L. infantum orthologs 
 
The protozoan Leishmania infantum is the causative agent of leishmaniasis and 
selectively disrupting its RAD51:BRCA2 ortholog interaction may lead to novel 
pharmacological interventions to tackle this disease. Understanding the structural and 
biophysical basis of this interaction and its comparison with the human orthologs would be a 
useful starting point for drug design. Using biophysical and structural approaches, I probed the 
binding characteristics of L. infantum BRC repeats. I determined novel structural features that 
define the binding of LiBRC1 to LiRad51. 
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2 Characterisation of a chimeric BRC8-2 repeat 
The microfluidic fluorescence polarisation measurements performed by Dr Laurens 
Lindenburg identified BRC8-2 as the highest affinity repeat, and its constituent modules as 
most potent contributors to binding. This high affinity binder can serve as a template for 
development of peptide-based pharmacological probes, as it provides an advantageous starting 
point for chemical and sequence optimisation. However, the high-throughput approach in 
which these peptides were screened is susceptible to systematic error, for example, if some of 
the BRC repeat sequences are consistently degraded by the proteases during their expression. 
In order to confirm these preliminary affinity values and to establish BRC8-2 as a functional 
Rad51 inhibitor, I prepared the peptide in highly pure, un-tagged form and evaluated it in a 
range of biophysical and biochemical assays. 
2.1 BRC8-2 is a potent inhibitor of RAD51 function in vitro 
 
Full-length human RAD51 forms polydisperse linear oligomers in solution, mediated 
by the inter-domain oligomerisation epitope (OE). Because both OE and BRC repeats directly 
compete for the same interface, biophysical measurements of BRC repeat binding to HsRAD51 
are complicated by the need to compete with RAD51 oligomerisation. A simplified, truncated 
construct, containing only the monomeric ATPase domain of RAD51, which is the bona fide 
binding partner of BRC repeats, would allow direct one-to-one affinity measurement. Previous 
attempts in our lab to isolate the ATPase domain of human RAD51, lacking the N-terminal 
domain and the oligomerisation epitope, failed due to the intrinsic instability of the truncated 
protein. Instead, I used a highly soluble thermostable surrogate protein HumRadA22, based on 
the archaeal RadA ortholog from Pyrococcus furiosus. This mutant was previously engineered 
in our lab and serves as a faithful mimetic of the human RAD51 ATPase domain, in which 
surface residues encompassing the FxxA and LFDE binding sites, as well as nearby regions 
have been mutated to the human sequence.111 
I recombinantly prepared BRC8-2, its parental repeats BRC2, BRC8, and the natural 
repeat BRC4. Briefly, peptides were expressed in E. coli as fusions to a GB1 protein expression 
tag, purified by IMAC, after which the tag was proteolytically removed with TEV protease, 
yielding free peptides that were then purified to homogeneity by reversed-phase 
chromatography (RPC), ensuring removal of degradation products. All of the peptides were 
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prepared in milligram quantities and were >90% pure as confirmed by HPLC and MS 
(Appendix 8.1 RP-HPLC chromatograms and MS spectra of purified peptides). 
Isothermal titration calorimetry (ITC) was used to determine peptide binding affinities 
to HumRadA22 (Figure 13A). The ITC data is broadly consistent with the affinity ranking 
initially observed by microfluidic FP, but important differences were observed. BRC4, the most 
potent natural binder according to previous reports, bound with a KD of 23 nM, which is 
consistent with the microfluidic FP value (38 nM) and other published affinities. The parental 
BRC8 repeat exhibited the lowest affinity in the set, with a KD of 56 nM, which is a 
significantly smaller KD value than one from microfluidic FP. Surprisingly, BRC2 appears to 
be a more potent binder than BRC4, with a KD value of 14 nM, as opposed to 278 nM in the 
microfluidic FP screen. These significant discrepancies can be attributed to a number of factors. 
First, the presence of a GB1 expression tag, as used in the microfluidic FP, may interfere with 
binding. Despite including a long, flexible linker between the tag and the peptide, it is possible 
that the GB1 domain forms non-specific interactions with some of the peptides, imposing an 
energetic penalty on binding, or, alternatively, it can have a direct steric clash with 
HumRadA22. More importantly, no downstream purification steps were employed after IMAC 
in the microfluidic FP screen, meaning that full-length peptides had to be quantified using SDS-
PAGE gel densitometry, possibly contributing to decreased accuracy in concentration. 
Gratifyingly, BRC8-2 was tightest binder as measured by ITC, with a KD of 4 nM.  
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Figure 13.  BRC8-2 is a potent RAD51 binder and a functional inhibitor. (A) Direct binding ITC titrations of 
BRC repeats with HumRadA22. In all titrations, 100 μM peptide was injected into cell containing 10 μM 
HumRadA22 over 19 injections. (B) Fluorescence polarisation (FP) competition assay titrations of BRC repeat 
peptides. Fluorescently labelled BRC4 (10 nM) probe was pre-incubated with 100 nM HumRadA22, to which 
peptide dilution series were added. Data shown are the means of triplicate measurements ± SD.  (C) 
Electrophoretic mobility shift assay (EMSA) of HsRAD51 (5 µM) with FAM-dT60 (100 nM) and various 
concentrations of competitor peptides. BRC8-2 can efficiently disrupt HsRAD51-ssDNA nucleofilament 
formation on the FAM-dT60 oligonucleotide. 
To further validate this affinity ranking, plate reader-based competition FP 
measurements were performed with the same peptides using a fluorescein-labelled BRC4 
peptide as probe (Figure 13B). Here, a similar trend is observed, with BRC8-2 being the most 
potent inhibitor, and BRC8 the least potent, with BRC4 and BRC2 spanning intermediate 
values.  
In a functional validation step, the same BRC repeat peptides were evaluated for their 
ability to inhibit full-length HsRAD51 function. Electrophoretic mobility shift assays (EMSAs) 
were set up by adding fluorescently tagged dT60 oligonucleotide to human RAD51 that has 
been pre-incubated with varying amounts of BRC repeat peptides. Reaction products were 
analysed on native PAGE. BRC8-2 was able to disrupt nucleofilament formation in a dose-
dependent manner, with a complete decrease in the amount of shifted dT60 at super-
stoichiometric peptide concentrations relative to RAD51. At the saturating conditions 
necessary for the assay, it is impossible to quantitatively compare inhibition by different 
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peptides. However, the EMSA data clearly demonstrates that BRC8-2 potently inhibits 
HsRAD51 function rather than just the archaeal surrogate HumRadA22.  
 
Peptide ITC KD, nM FP IC50 ± SE, nM FP KD, nM 
BRC2 14 331 ± 31 27 
BRC4 23 218 ± 32 14 
BRC8 56 1931 ± 165 203 
BRC8-2 4 158 ± 9  8 
Table 2. Data summary for ITC and FP measurements of BRC8-2, its parental repeats BRC8 and BRC2, as well 
as BRC4. Affinity ranking broadly confirms the trends from chimeric peptide screening experiments. 
2.2 BRC8-2 inhibits RAD51 foci in human cells 
 
RAD51 localisation at the sites of DSB repair can be observed by immunofluorescence 
(IF) as nuclear foci that form following treatment with ionising radiation. Previously, 
overexpression of BRC4 in human cells has been shown to inhibit foci formation by inhibition 
of BRCA2 mediator activity and RAD51 self-oligomerisation.108 Having validated the in vitro 
functional activity of BRC8-2, its inhibitory potential in cells was characterised. For this, I 
prepared a set of mammalian expression constructs containing the repeats BRC4 and BRC8-2 
fused to N-terminal GFP and a nuclear localisation signal, expressed under the CMV promoter. 
The subsequent cell-based experiments were performed by Dr Pedro Zuazua-Villar at our 
collaborator Prof Jessica Downs’ lab.  
U2OS cells were transfected with either of the two BRC repeat constructs, or with an 
empty GFP-NLS control. RAD51 foci were counted by IF microscopy in GFP-positive cells 
after exposure to ionising radiation, or in the absence of radiation treatment (Figure 14A). A 
small number of foci were detected in GFP-NLS control cells that were not subjected to any 
radiation treatment, likely arising as a result of replicative stress (Figure 14B,C). Treatment of 
GFP-NLS control cells with a 3 Gy dose of IR resulted in a large increase in the number of 
RAD51 foci, consistent with the formation of many DSBs (Figure 14B,C). In contrast, cells 
transfected with either BRC8-2 or the positive control BRC4 had a greatly reduced number of 
RAD51 foci both prior and after radiation treatment (Figure 14B,C). Variability in protein 
expression levels and transfection efficiency make a quantitative comparison of BRC4 and 
BRC8-2 mediated inhibition challenging. Both peptides appear to cause more than a two-fold 
decrease in foci formation compared to GFP-NLS control in both treated and untreated cells, 
with no significant difference.   
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Because homologous recombination is limited to the S and G2 phases of the cell cycle, 
change in RAD51 foci count can also reflect a larger population of cells being in the G1 phase. 
To account for this, cell cycle profiles were examined by flow cytometric measurement of DNA 
content (Figure 14D,E). No significant change in G1 populations was observed for BRC4 and 
BRC8-2 transfected U2OS cells, meaning that the differences in foci counts are not cell-cycle 
related.  
The IF experiments demonstrate that the chimeric repeat BRC8-2 is a potent inhibitor 
of Rad51 function in a cellular context, where it prevents translocation of RAD51 to sites of 
DNA damage. An increased pan-nuclear signal for RAD51 in cells transfected with BRC8-2 
was observed compared to GFP-NLS control cells (Figure 14F), consistent with a previously 
proposed mechanism of action in which BRCA2 sequesters RAD51 in a diffuse nuclear 
state.151 Acting as a competitor, BRC8-2 prevents the BRCA2-mediated recruitment of the 
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Figure 14. BRC8-2 impairs RAD51 foci formation in human U2OS cells. (A) Representative images of U2OS 
cells expressing GFP, GFP-NLS-BRC8-2, or GFP-NLS-BRC4. Cells were monitored 3 h after no treatment or 
irradiation with 3 Gy (3Gy 3h) for GFP fluorescence and stained with α-RAD51 and DAPI. (B) Dot plot graph 
from one biological replicate plotting the number of RAD51 foci per GFP positive cell. Median values are 
indicated with a bar. Statistical analysis was done using Kruskal Wallis rank sum test followed by Dunn’s 
procedure for pairwise comparison (*p <0.005, **p<0.001, n.s.= not significant). (C) Bar graph showing the 
average median RAD51 foci per GFP positive cell from three independent biological experiments. Data are 
presented as mean ± SEM, n = 3 biological repeats. **p<0.001, n.s.= not significant. (D) Representative cell cycle 
profiles from GFP positive cells analysed by flow cytometry 3 hours after no treatment or irradiation with 3 Gy 
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independent experiments ± SEM. (F) The pan-nuclear signal of RAD51 in GFP-BRC8-2 and GFP-BRC4 
expressing U2OS cells is greater than in the GFP control cells. Labels and conditions are the same as for (A). The 
arrows indicate GFP-positive cells. All experiments in this figure were conducted and the figure prepared by Dr 
Pedro Zuazua-Villar. 
2.3 X-ray crystallographic study of BRC8-2  
Having completed the functional survey of BRC8-2, I set out to investigate its binding 
mode with RAD51 and to elucidate the structural determinants of its high affinity interaction. 
For this, I decided to perform X-ray crystallographic studies of BRC8-2, as well as its parental 
repeats BRC2 and BRC8, in complex with RAD51. 
For successful X-ray crystallographic studies of macromolecular complexes, it is of 
paramount importance to minimise assembly heterogeneity and reduce conformational degrees 
of freedom within the assembly. WT human RAD51 forms linear oligomeric assemblies of 
varying length, where a flexible oligomerisation epitope (OE) of one RAD51 protomer 
interacts with the ATPase domain of a successive molecule. The polydisperse nature of such 
system and competition between the OE and the BRC repeat would strongly disfavour 
crystallisation. The C-terminal ATPase domain contains the bona fide interaction interface 
between RAD51 and BRC repeats, as elucidated by Pellegrini et al.,80 and should be on its own 
suitable for crystallographic studies. Unlike the approach taken by Pellegrini et al., where a 
fusion between the HsRAD51 ATPase domain and the repeat yielded a stable complex, I 
decided to express the binding partners as separate molecules. For this, the stable archaeal 
surrogate mimetic HumRadA22 was used again, as its previously determined apo structure 
closely matches the surface of WT HsRAD51 ATPase domain (PDB: 5KDD).  
Overexpression of small peptides in bacterial culture can be challenging, therefore BRC 
repeats were prepared as TEV-cleavable fusions to an N-terminal His8-GB1 expression tag. 
The two partners of the complex were expressed separately in bacterial cells. The N-terminally 
His8-GB1-tag BRC fusion-expressing cell lysate was loaded on a Ni-NTA column, followed 
by application of untagged HumRadA22 lysate, and subsequent elution (Figure 15A). The co-
precipitation approach produced high yields of complex which were then subjected to TEV 
cleavage, tag removal by reverse IMAC and final purification by size-exclusion 
chromatography (Figure 15A). In total, HumRadA22 complexes were purified with all three 
peptides (BRC2, BRC8, BRC8-2). 
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Figure 15. Preparation and crystallisation of BRC8-2:HumRadA22 complex. (A) Coomassie stained SDS-PAGE 
gel depicting the different steps of HsBRC8-2:HumRadA22 complex purification. Individual complex 
components were solubly expressed in E. coli. His-tagged GB1-BRC8-2 was loaded on Ni-NTA resin, followed 
by application of HumRadA22. The co-eluted complex shows little degradation of the GB1-fused BRC8-2 peptide 
and high purity. SEC of TEV-cleaved complex successfully separates remaining GB1 contaminants and results in 
pure complex (pooled fractions). T = total lysate, S = soluble lysate, FT = flow-through, W = wash. (B) 
Crystallisation drop and conditions for the BRC8-2:HumRadA22 crystal hit. (C) Asymmetric unit contents with 
each chain depicted in different colour.  
Concentrated HumRadA22-BRC repeat complexes were crystal-screened in 96-well 
MRC plate format using a variety of pre-mixed commercially available crystallisation screens, 
with ADP and Mg2+ used as stabilising cofactors. Of the four complexes screened, only BRC8-
2 yielded suitable diffracting crystals (Figure 15B). Diffraction data were successfully 
collected without further optimisation of the crystallisation condition. The crystal diffracted to 
1.9 Å resolution and the complex structure was determined (PDB ID: 6HQU). There are eight 
complexes in the asymmetric unit (Figure 15C), all of which are very similar to each other 
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peptide was visible in seven out of eight complexes. Electron densities for bound peptides were 
observed prior their fitting and refinement (Figure 16). In all complexes in the asymmetric 
unit, the overall conformation and binding mode of the peptide was near identical, but with 
varying extent of visible electron density. The best-defined complex chains B and J were used 




Figure 16. BRC8-2 peptide electron densities prior and after fitting of the peptide. Representative electron density 
maps are shown for the peptide chain J before the peptide has been modelled in (left) and after fitting with 
subsequent rounds of refinement (right). 
BRC8-2 forms a more extensive β-hairpin and a more optimal α-helix 
 
Comparison of the refined HumRadA22:BRC8-2 structure with that of the 
RAD51:BRC4 complex (PDB: 1n0w) reveals a similar overall topology (Figure 17A). As 
anticipated, FxxA residues Phe2058BRC8 and Ala2061BRC8 form extensive hydrophobic 
contacts with the FxxA binding site, identical to BRC4 (Figure 17B). Ala2061BRC8 is followed 
by a β-turn that is stabilised by the Thr2060BRC8 and Ser2060BRC8 side-chain hydroxyls, after 
which the peptide folds back in the opposite direction, resulting in a β-hairpin structure that 
extends the central β-sheet of monomeric RAD51 in an inter-molecular fashion. At the C-
terminal half, the BRC8-2 LFDE module acquires an α-helical secondary structure, and, 
similarly to BRC4, forms a second interface with HumRadA22.  The LFDE motif of BRC4 is 
replaced by LFSD in the BRC2 module, conserving hydrophobic and acidic hot-spot residues.  
Leu1240BRC2 and Phe1241BRC2 bind the same hydrophobic groove that the BRC4 LFDE motif 
interacts with (Figure 17C). Asp1243BRC2 forms a salt bridge with Arg270 (corresponding to 
Arg254 in HsRAD51), after which electron density becomes poorly defined at the C-terminus.  
 




Figure 17. Crystal structure of monomeric RAD51:BRC8-2 complex superposed with RAD51:BRC4. BRC8-2 is 
depicted in orange and yellow, corresponding to BRC8 and BRC2 sequences, respectively. BRC4 is shown in 
blue. Peptides were superimposed by aligning the structures of their respective protein binding partners. 
Monomeric RAD51 is represented by a gray surface. Selected residues of the monomeric RAD51 are depicted in 
grey. (A) Overall topologies of the two peptides. Phe and Ala residues of the FxxA motifs are shown. (B) 
Hydrogen-bonding network of the BRC8-2 β-hairpin. (C) LFDE interface with side-chains of crucial residues 
depicted. (D) Sequence alignment of BRC4 and BRC8-2 FxxA and LFDE modules. 
 
The most striking difference between the binding modes of the BRC4 and BRC8-2 
peptides is in the extent of the intra-molecular hydrogen-bonding network that forms the β-
hairpin in the FxxA module. In BRC8-2, the β-hairpin is significantly extended, with its N-
terminal end, before Phe2058BRC8, folded back towards the rest of the peptide and interacting 
with the anti-parallel strand downstream in sequence (Figure 17B). As a result, the hairpin 
feature spans residues Ser2053BRC8 to Thr1231BRC2, a total of 19 amino acids compared to just 
9 in BRC4. A likely structural determinant for the formation of the extended hairpin is 
Ser2056BRC8, whose side-chain fits tightly between the two anti-parallel strands of the peptide 
and the surface of monomeric RAD51 (Figure 17B). The Ser2056BRC8 side-chain hydroxyl 
forms a hydrogen bond with the carbonyl of Leu1227BRC2 and the NH of Phe2058BRC8, allowing 
the peptide to fold back on itself in a favourable manner. BRC4 has a bulky and hydrophobic 
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Leu1522 at the equivalent position of Ser2056BRC8, which is unlikely to satisfy the steric and 
electrostatic requirements of the topology observed in BRC8-2, forcing the N-terminus of the 
peptide to point away from the β-hairpin and the rest of the peptide. The extended β-hairpin is 
observed in all of the 7 peptides modelled in the asymmetric unit, independent of the different 
crystal packing interactions that surround them, which argues against the possibility of the 
conformation being a crystal packing artefact. The crystallographic data collection, processing 
and refinement statistics are provided in Appendix 8.7. 
Differences in binding mode are also evident at the LFDE modules of BRC4 and BRC8-
2. In BRC4, the interface-forming residue Val1542BRC4 has a bulky hydrophobic side-chain 
projected into the ATPase domain (Figure 17C). To accommodate this, BRC4 has to form an 
outward facing bulge, resulting in a disrupted secondary structure geometry that deviates 
significantly from an optimal α-helix. This residue is changed to Ala1237BRC2 in BRC8-2, 
causing a shift of the α-helix backbone towards the surface of the protein and resulting in a 
more helical geometry and tighter fit with HumRadA22 (Figure 17C). 
2.4 BRC8-2 residue-specific contributions to affinity  
The observed structural differences present several potential explanations for the high 
affinity binding seen for BRC8-2 and for the favourable interactions of its constituent modules, 
as expressed in terms of ΔΔG. To examine the contributions of these structural features to 
binding, a number of BRC8-2 mutants were prepared that introduce critical residues from 
BRC4 that were anticipated to reduce affinity based on the comparative analysis of the crystal 
structures (Figure 18A). BRC8-2S2056V has the hairpin-mediating Ser2056BRC8 mutated to a 
valine, like in BRC4. Similarly, BRC8-2A1237V introduces a valine in place of Ala1237BRC2, 
which was expected to disrupt helicity at the LFDE module, similarly to what is seen in BRC4 
structure. Moreover, a double mutant BRC8-2A1237V, S2056V, combining the two substitutions, 
was prepared to evaluate the cumulative effect of these changes. The peptides were evaluated 
in plate reader-based FP competition experiments (Figure 18B, Table 3). For the single 
mutants, a modest decrease in potency was observed, with KD values increasing approximately 
two-fold. A more pronounced drop in affinity was determined for the double mutant, 
approaching that of BRC4, suggesting an additive effect from the disruptive mutations, 
reverting the peptide to a more BRC4-like binding mode, and confirming the structural 
interpretation. Attempts to test these peptides in ITC were not successful, as significant heats 
of aggregation at the high concentrations required in the syringe prevented accurate 
measurements, likely stemming from the increased hydrophobic character of the mutants. A 
Pantelejevs, T.  Characterisation of a chimeric BRC8-2 repeat 
 53 
BRC8-2S2056A mutant was prepared instead, disrupting the hydrogen bonding pattern of 
Ser2056, but not introducing a BRC4-like valine. BRC8-2S2056A binding to HumRadA22 was 
measured by ITC and gave a KD of 6 nM, versus 4 nM for BRC8-2 (Figure 18C, Table 3). 
Accurate determination of low-nanomolar KD values by ITC is challenging due to uncertainty 
in isotherm fitting parameters, i.e., a very steep transition in heats at 1.0 molar ratio, therefore 
these differences cannot be deemed significant. However, there is an unambiguous difference 
in the enthalpy of binding (ΔHBRC8-2 = -7.00 kCal / mol vs ΔHBRC8-2S2056A = -5.29 kCal / mol), 
suggesting a different binding mode for the BRC8-2S2056A mutant.  
 
Figure 18. Specific residues in BRC8-2 contribute in a cumulative manner to high affinity binding. (A) Critical 
residues in BRC8-2 that were mutated to BRC4-like amino acids are highlighted in red. Ser2056 mediates the 
extended β-hairpin at the FxxA module, Ala1237 confers a more optimal helix on the LFDE module. (B) FP 
competition assay titrations of BRC8-2 mutants. Fluorescently-labelled BRC4 probe (10 nM) was pre-incubated 
with 100 nM HumRadA22, to which peptide dilution series were added. Data shown are the means of triplicate 
measurements ± SD. (C) ITC titrations of BRC8-2 and the BRC8-2S2056A mutant into HumRadA22. All ITC 
experiments were performed with 100 μM peptide in the syringe and 10 μM HumRadA22 in the cell. 
Interestingly, in the peptide shuffling matrix, the FxxA module from BRC3 has the 
second most favourable ΔΔGFxxA value after BRC8 (ΔΔGFxxA3 = -0.35 kCal/mol, Figure 10F) 
and this module contains a threonine at the position equivalent to Ser2056BRC8, which may 
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similarly enable an extended hairpin conformation by hydrogen-bonding to backbone amides. 
To further investigate this hypothesis, BRC3:HumRadA22 complex was also purified and 
crystallisation screening carried out, which yielded a number of hits, however, none of these 
diffracted. 
 
Peptide ITC KD, nM FP IC50 ± SE, nM FP KD, nM 
BRC8-2 4 158 ± 9 7 
BRC8-2S2056V - 228 ± 10 16 
BRC8-2A1237V - 191 ± 8 12 
BRC8-2S2056V,A1237V - 285 ± 13 21 
BRC8-2S2056A 6 - - 
BRC8-2F2058W - 115 ± 10 3 
Table 3. Summary table of BRC8-2 mutant binding data. 
Previous work on FxxA motif tetrapeptides and full-length BRC repeats has shown that 
replacing the phenylalanine with a tryptophan causes an increase in binding affinity.152,81 To 
probe whether this modification can be utilised in the context of a BRC repeat in order to 
improve the binding affinity of BRC8-2, a mutant BRC8-2F2058W peptide was also prepared and 
tested in the FP assay (Figure 18B).  The peptide displays a marginally higher affinity over 
BRC8-2, an observation that needs further validation given the small effect size (BRC8-2 IC50 
= 158 ± 9 nM, BRC8-2F2058W IC50 = 115 ± 10 nM). The improved binding of a BRC8-2F2058W 
mutant and other similar sequence-activity relationships can be utilised in the development of 
BR8-2 based pharmacological probes as a means of increasing target affinity. 
2.5 Conclusions 
 
The microfluidic FP screening of chimeric BRC repeats derived through modular 
recombination had produced novel sequences that exhibited improved binding over the eight 
wild-type repeats. Intrigued by the increased affinity of the chimeric repeat BRC8-2, I 
undertook an extensive examination of this peptide. The sum of biophysical and biochemical 
data obtained strongly supports BRC8-2 as a novel high affinity peptide. Using both ITC and 
FP experiments, I confirmed that BRC8-2 binds more strongly than any of the parental repeats 
or BRC4. Moreover, the crystal structure of BRC8-2:HumRadA22 complex shed new light on 
our understanding of BRC repeat-RAD51 interactions by highlighting novel structural features 
that modulate binding affinity.  
Pantelejevs, T.  Characterisation of a chimeric BRC8-2 repeat 
 55 
High affinity epitopes can be effectively utilised as templates for the development of 
peptide-based pharmacological probes. For example, stapled peptides based on the p53 tumor 
suppressor protein are being investigated in the clinic as inhibitors of the MDM2 proto-
oncogene.153 The biophysical, biochemical and cellular data presented in this chapter provide 
a clear rationale for investigating BRC8-2 as a template for the design of peptidic RAD51 
inhibitors. Moreover, the crystal structure allows for the rational, structure-based introduction 
of chemical modifications, for example, it can guide the placement of covalent linkages during 
peptide macrocyclisation. With this information at hand, I undertook the task of developing 
BRC8-2 into a potent inhibitor of human RAD51 using a peptide stapling approach.  
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3 Development of RAD51-targeting stapled peptides 
3.1 Introduction 
RAD51 presents several potential approaches for its inhibition. A classical small-
molecule targeting of the enzymatic ATPase active site may be used to inhibit active NF 
formation, diminishing the strand exchange activity of RAD51. However, an enzymatic 
mechanism of action is likely to be challenging due to the highly conserved nature of the 
nucleotide binding site and the need to compete with the abundance of cytosolic nucleotide co-
factors. For example, ATP is present in the cell in millimolar amounts, and binds RAD51 with 
micromolar affinity, meaning that a successful enzymatic small-molecule inhibitor would need 
to be of low nanomolar potency to achieve high occupancy, a formidable task for the relatively 
shallow and dynamic nucleotide interface.  
Alternatively, the BRC repeat FxxA and LFDE module interfaces could be targeted to 
inhibit BRCA2 binding and/or self-oligomerisation. The high-affinity BRC8-2 repeat provides 
an attractive starting point for the development of macrocyclic peptide probes, as it 
encompasses a functional binding interface and contains a large number of residues with 
solvent-exposed side chains that can used for covalent linking in a peptide stapling approach. 
The peptide’s low-nanomolar affinity can support high target occupancy, provided that cellular 
uptake is sufficiently high.  
Evaluating all of the possible combinations of linked residues on the peptide would be 




combinations of a single cysteine pair. For a 12 aa peptide, this means 66 possible pairs, 
whereas for a 32 aa BRC repeat this number increases to 496. Each type of chemical linker 
favours a range of inter-residue distances and macrocycle conformations and stapling residues 
can be introduced with this in mind. Linkers are small molecules with only a few intramolecular 
conformational degrees of freedom and thus impose a constraint on inter-cysteine distances, 
which significantly narrows down the search space if one seeks to preserve peptide binding. 
The above-described crystal structure of the shuffled BRC8-2 repeat can be used to inform the 
rational design of stapling positions to be introduced in the sequence. 
In this work, I decided to use a cysteine-reactive stapling methodology to obtain 
macrocyclic peptide RAD51 inhibitors, utilising BRC8-2 as a high-affinity template. The 
potential advantages of different stapling methods have been considered in Section 1.12 
Peptide stapling. Moreover, my decision to develop a recombinant methodology rather than 
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use standard SPPS protocols was motivated by the fact that bacterial culture is more widely 
applicable to academic biology labs lacking the infrastructure for organic synthesis and 
procedures for disposal of large volumes of organic solvents, such as DMF. Successful 
application of recombinant peptide stapling could encourage the adoption of this method in the 
wider scientific community. 
A set of divinyl linkers developed at the lab of Prof David Spring (Department of 
Chemistry, University of Cambridge) were used in this project. Composed of a heterocycle 
core and two electrophilic vinyl arms, these linkers act as Michael acceptors in reaction with 
cysteine thiols (Figure 19). Initially developed for irreversible re-bridging of reduced antibody 
disulfides, these linkers comprise a new generation of bio-conjugation reagents that 
demonstrate many advantages over traditional labelling and stapling chemistries. Importantly, 
these linkers: 
 
1. Show exceptional selectivity over other nucleophilic side-chains and N-terminal 
amines. 
2. Are applicable in a wide range of aqueous and organic conditions. 
3. Result in irreversible and stable thioether products. 
 
Figure 19. Divinyl linkers for cysteine stapling of peptides. (A) A diagram depicting the components of a divinyl 
linker. Reactive electrophilic arms are 1,3 to each other and each arm reacts with a cysteine thiol. The core 
heterocycle acts as scaffold and fine-tunes the reactivity of the vinyl groups. (B) Divinyl linkers used in this study. 
Divinylpyrimidine (DVP) contains an aminopyrimidine moiety and is less reactive. Acetyl-divinyltriazine (DVT-
Ac) is a more soluble and more reactive triazine core linker.  (C) A diagram depicting a stapling reaction of bis-
cysteine helical peptide at i,i+7 residue positions encompassing approximately two helical turns.  
It has been previously shown that these linkers can efficiently constrain α-helical motifs 
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macrocyclic structure that encompasses two helical turns.146 It is also anticipated that, with 
appropriate geometry considerations, these linkers can be applied to non-helical peptide folds.  
3.2 A recombinant approach for peptide stapling 
Introduction of a covalent linkage between different side-chains of a peptide can have 
a range of both beneficial and detrimental effects on peptide binding. Conformational changes 
imposed by the linkage can prevent the peptide from achieving an optimal binding mode and 
cause a drop in affinity. For example, a linker can completely disrupt α-helical secondary 
structure if the stapled residues are not optimally spaced. Moreover, the linker itself can clash 
sterically with the protein if introduced on a helical face that is not sufficiently solvent-exposed. 
On the other hand, stapling at an optimal position can have a positive contribution to affinity 
through pre-organisation of peptide conformation resulting in a reduction of entropic penalty, 
as well as through favourable linker-protein contacts. Rapid screening of different stapled 
peptides would allow for early identification of residue positions that are most optimal for 
linkage. To evaluate the effect of introducing cysteine linkages on BRC repeat binding, a small-
scale recombinant production methodology was trialled. In this approach, bis-cysteine mutants 
were expressed in bacterial culture, purified and stapled at small scale in as few steps as 
possible, while obtaining sufficient purity and yields for biochemical evaluation. The two main 
obstacles to achieving successful production and isolation of linear peptides from bacterial 
cultures are low yield and proteolytic degradation, with the latter often contributing to the 
former. To address these methodological issues, an expression plasmid containing optimal 
expression tags for this purpose was designed (pPEPT1, Figure 20A). Using this vector, the 
peptide of interest (POI) was produced as a fusion to an N-terminal GB1 protein tag, derived 
from the B1 domain of streptococcal G protein. The GB1 tag is a small, monomeric and highly 
soluble globular protein domain that is very efficiently expressed in E. coli. On the C-terminus 
of the expressed construct a His8-tag was introduced for the purification of the peptide fusion 
using immobilized metal affinity chromatography (IMAC) on Ni-NTA resin. The N-terminus 
of the construct also contains a Strep-II tag for a possible affinity purification on Strep-Tactin 
resin. The peptide DNA insert can be rapidly prepared using oligonucleotide annealing or one-
pot PCR assembly and introduced seamlessly into the digested vector using sequence and 
ligation independent cloning (SLIC). 
A bis-cysteine BRC8-2 model peptide (SP2) was designed for the testing and 
optimisation of this stapling methodology. The GB1-peptide fusion was expressed in 10 ml E. 
coli culture and purified on a 100 µl Ni-NTA spin column. As analysed by SDS-PAGE, the 
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fusion is overexpressed and efficiently purified from the bacterial culture (Figure 20B). The 
peptide runs at a higher molecular weight than calculated, a common phenomenon observed 
with GB1. 200 µl of ~100 µM GB1-peptide could be prepared in such way.  
 
Figure 20. A recombinant stapled peptide preparation platform. (A) Illustration of the expression cassette used in 
the pPEPT1 vector for the preparation of GB1-fused stapled peptides (B) Purification of a GB1-fused model 
peptide SP2 from a small-scale (10 ml) E. coli culture. T = total lysate, S = soluble lysate, FT = flow-though, Ni 
= Ni-NTA elution (C) An illustration of the small-scale stapled peptide preparation work-flow.  
Having established that high levels of protein expression are achievable with this 
system, a general procedure for small-scale stapling of recombinant peptide fusions was 
devised (Figure 20C). Using this approach, the linker was added directly to the Ni-NTA 
output, after which the reaction was quenched and the product used in biochemical evaluation 
without any further purification steps, as the reagents are not expected to interfere with in vitro 
assays. The divinyl linkers used in this study have been reported to react rapidly and selectively 
with reduced cysteines. A successful divinyl stapling reaction has a two-step mechanism: the 
first step is a bimolecular Michael addition reaction between an electrophilic vinyl arm of the 
linker molecule and a deprotonated thiol nucleophile from one of the cysteines within the 
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peptide (Figure 21A). This is followed by a unimolecular ring closing reaction of the reaction 
intermediate 2, where the second vinyl arm reacts with the second cysteine sulfhydryl, again 
through a Michael addition, giving a stapled peptide 3. The intramolecular macrocycle closing 
step is in competition with an undesired bimolecular side-reaction, where a second linker 
molecule reacts with the remaining free cysteine (Figure 21B). This results in a double-linker 
product 4 that does not form the correct covalent linkage between cysteine side-chains and is 
therefore of no pharmacological utility compared to the linear peptide.  
 
 
Figure 21.  Curly arrow mechanisms for a bis-cysteine peptide reacting with a divinyl linker. (A) Reaction 
pathway for the formation of the correct stapled peptide product 3 via an intramolecular ring closing reaction of 
the intermediate 2. (B) Reaction pathway for the formation of an undesired double-linker product 4 via a second 
DVP linker addition. 
A number of kinetic factors influence the rates of these competing steps and favour the 
formation of either product. The first-order reaction rate for the macrocycle closing can be 
expressed as the product of the rate constant k1 and concentration of the intermediate 2 (Figure 
21A), whereas the attachment of the second linker follows second order kinetics and depends 
on concentrations of both intermediate 2 and the concentration of the divinyl linker (Figure 
21B). If the concentration of the linker is decreased, the rate of the initial bimolecular addition 
is slowed down proportionally to this change in concentration. Thus, the unimolecular 
macrocycle closing reaction that follows is also slowed down to the extent that there is less 
intermediate 2 available. On the other hand, the bimolecular second linker addition is slowed 
down both due to lower intermediate 2 concentrations, and as a result of less free DVP linker 
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this undesired reaction more and favour the formation of the correctly stapled product. A 
convenient way to maintain the linker concentration low, while achieving quantitative stapling 
of the peptide, is to use pseudo-dilution, an approach where one of the reactants is titrated into 
the reaction vessel in incremental amounts and is allowed to react before further addition of the 
same reactant.  
The suitability of pseudo-dilution was tested on small-scale preparations of the bis-
cysteine mutant GB1-SP2 in combination with the DVT-Ac linker. Several titration conditions 
were trialled with varying volumes and time-points of linker addition (Figure 22A). While this 
is not a comprehensive scan of a large number of possible reaction conditions, a sufficient 
optimum could be established for use in subsequent screens of BRC8-2 mutants. Products were 
analysed by intact MS and relative sizes of mass peaks were used as a metric for purity. 
Chromatographic estimation of yields was not possible because the GB1-fused products are 
physico-chemically too similar to be separated on any matrix. 
Representative mass spectra of the different conditions are provided in Figure 22B. In 
all of the conditions tested, the most abundant peak corresponds to the correctly stapled peptide 
6 with an N-terminal methionine cleavage (m = 14773.97 Da). A smaller peak is also present 
corresponding to N-terminal Met-Ser cleavage of the same species (peptide 5, m = 14686.89 
Da, Δm = 87.08). Double-linker by-products (peptide 7, m = 14994.2 Da) were also observed, 
and were favoured by faster linker titration, e.g. when comparing condition a and condition b. 
In addition to this, impurities of dimeric nature were detected at masses approximately twice 
the GB1-SP2 construct (condition i). These peaks correspond to a range of disulfide- and 
divinyl-linked adducts (Figure 23A). The pKa of the free cysteine thiol is around 8 and 
cysteines within the context of a peptide or protein chain can exhibit a wide range of pKa 
values. The propensity of the cysteine side-chain to form disulfides is therefore susceptible to 
modulation by pH at the near-physiological conditions used here. Decreasing the pH from 8 to 
7 caused a significant decrease in the abundance of the dimeric species (condition h), while the 
drop from pH 7 to pH 6 did not have any further observable effect.  
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Figure 22. GB1-fused bis-cysteine peptide stapling optimisation.  (A) A detailed overview of the stapling 
reactions conditions tested. Samples a-i represent combinations of titration timing, pH, and reducing agent 
parameters. Each reaction was done in 0.5 ml (final) at room temperature on a rotating mixer. (B) Mass spectra 
of representative stapling conditions from (A). 5 to 9 denote the different molecular species observed.  
A critical consideration in cysteine bio-conjugation reactions is the application of a 
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agents, particularly thiol-based ones, are susceptible to reactivity with the linker electrophile. 
TCEP has been commonly applied as a selective, non-thiol reducing agent, for example, in 
maleimide-coupling reactions.154 Here, inclusion of even a relatively low concentration (0.5 
mM) of TCEP in the divinyl stapling reaction resulted in the formation of undesired Cys-linker-
TCEP adducts. The phosphine group of TCEP is nucleophilic and can react with the vinyl arms 
via Michael addition. In fact, alkyl phosphine addition to acrylamide has been suggested as a 
novel click reaction for bio-conjugation.155 The putative structures of the observed TCEP 
adducts are shown in figure Figure 23B. To overcome this limitation, GB1-SP2 was reduced 
on-resin with a TCEP-containing wash, after which the construct was washed with buffer 
lacking the reducing agent, and eluted shortly thereafter. Stapling was performed immediately 
on the eluted protein. At pH 7.0, disulfide formation rate is expected to be negligible relative 
to the Michael addition reaction, and the optimised condition h yielded the desired single-
stapled product with very minor (<5%) formation of undesired by-products as analysed by MS 
(Figure 22B). The reaction is robust, resulting in highly pure product when performed with a 
range of different bis-cysteine mutants (Section 3.3 and Appendix 8.2 Representative protein 
LC-MS spectra of GB1-fused stapled peptides).  
 
Figure 23. By-products of cysteine stapling. (A) Some of the dimeric species that may arise as a result of linking 
of two peptides though disulfide bridges or through the linkers, or both. (B) Schematic illustration of the putative 
TCEP adducts observed by MS.  
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3.3 Design and screening of stapled RAD51 binders based on the 
chimeric BRC8-2 repeat 
With an optimised stapling procedure at hand, I proceeded with the design of BRC8-2 
bis-cysteine mutants to be evaluated, with the following objectives in mind: 
 
1. To introduce covalent linkages that would encompass a significant fraction of the 
BRC8-2 template, including the hot-spot motifs that are critical for binding.  
2. To evaluate a variety of stapling architectures, including non-helical motifs in the 
macrocycle. 
3. To decrease the size of the stapled peptides by truncating parts that are not essential 
for binding. 
 
Peptides were designed in a structure-guided manner, informed by the crystal structure 
of the BRC8-2 complex (Figure 24 & Figure 25A). Two design strategies were employed. In 
a traditional helical stapling approach, different i,i+7 Cys pairs were introduced at the solvent-
exposed face of the α-helical part of the LFDE module (peptides SP1, SP2, SP8, and SP9). For 
example, in SP2, a Thr1231 residue at the start of the α-helix is replaced by a cysteine, which 
is then linked to another cysteine in place of Val1238, both of which are solvent-exposed, are 
found on the same face of the α-helix and have a continuous unoccupied space available 
between the two side-chains, allowing the linker to be accommodated by the α-helical surface. 
It can be inferred from the BRC8-2 complex X-ray structure that a different stapling 
arrangement at the helix, e.g. i,i+8, where Thr1231 is linked to Lys1239 instead, would likely 
result in a clash between the linker and the side-chain of Gln1235.  
In a different approach, stapled BRC8-2 mutants were designed with at least one 
cysteine at the non-helical β-hairpin substructure of the peptide (SP10, SP12, SP13, SP14, 
SP16). The advantage of such stapling architecture is that a larger portion of the template can 
be cyclised, leading to potentially higher proteolytic protection, as well as increased pre-
organisation of the peptide. Placement of cysteines in these mutants was guided by the X-ray 
model and did not conform to sequence constraints, spatial distances permitted by the linker 
molecule were considered instead. For example, SP12 links a solvent-exposed Phe2055 near 
the N-terminus of β-hairpin with Leu1234 at the middle of α-helix of the LFDE module.  
Pantelejevs, T.  Development of RAD51-targeting stapled peptides 
 65 
 
Figure 24. Designs of stapled peptides based on the BRC8-2:HumRadA22 complex structure. BRC8-2 backbone 
is depicted in orange and yellow, corresponding to BRC8 and BRC2 sequences, respectively. Residues mutated 
to cysteines are rendered in red. Dotted lines represent the approximate direction of the intended staple moiety.  
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Rather than using the full-length BRC8-2 sequence template, SP10, SP12 and SP13 
were designed with N-terminal truncations in order to sterically and conformationally 
accommodate the backbone rearrangements that were anticipated to result from stapling. In a 
more extreme example of truncation, peptides SP1, SP14 and SP16 were designed to 
significantly decrease peptide size while maintaining either the FxxA or LFDE module. 
Previously, a BRC4 half-peptide encompassing residues Pro1519-Val1532 was shown to bind 
RAD51 with a KD = 36 μM.117 It is possible that the superior BRC8-2 template may improve 
on this significantly, allowing the development of probes that are reduced in size and therefore 
more likely be cell-permeable.  
A negative control peptide SP7 was designed with one cysteine replacing the Ser2059 
from the FxxA motif (FSTA in BRC8-2) and another placed at Thr1231 of the LFDE module. 
Such a mutant is expected to have a significant drop in affinity upon stapling, as a result of the 
bringing together of two amino acids that are not in close proximity in the BRC8-2 binding 
mode, causing a disruption of the peptide fold.  
All of the designed GB1-fused mutants were successfully purified from bacterial 
cultures and subsequently modified with the DVT-Ac linker. To examine the effect of 
introducing a covalent staple on affinity, a mock reaction was done in parallel for each peptide 
by splitting the Ni-NTA purification output, and adding TCEP + DMSO to the mock control 
reaction instead of the divinyl linker. TCEP is added to the mock reaction to prevent disulfide 
formation over the reaction time-course. The mutant cysteine thiols are designed to be solvent 
exposed based on the X-ray structure and the peptide binding mode is expected to 
accommodate these mutations without interference with affinity. Comparison with the reduced 
cysteine control, rather than just the cysteine-less BRC8-2, provides a more detailed 
examination of the modulation of binding by the stapling procedure. For example, a significant 
increase in affinity upon stapling would suggest that either the peptide becomes pre-organised 
and therefore has a lower entropic penalty of binding, or, alternatively, that the linker itself is 
forming constructive interactions with the target. Such observations would strongly support the 
choice of a particular stapling architecture over alternative designs.  
 Correct products were confirmed by MS for a number of the stapled peptide fusions 
with minimal impurities, and show very similar compositions to the initially optimised test 
conditions (Appendix 8.2 Representative protein LC-MS spectra of GB1-fused stapled 
peptides). Peptides were evaluated for binding to HumRadA22 using the same fluorescence 
polarisation (FP) competition assay described in Section 2.1.  
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Representative FP assay measurements are shown in Figure 25B, with stapled peptide 
binding in green and mock reactions in red. The negative control repeat SP7 ha a KD of 39 nM 
in the free thiol state, whereas the stapled product has a KD of 149 nM, a more than three-fold 
drop in affinity, confirming the modulation of binding by stapling. Gratifyingly, repeat mutants 
SP2, SP8, SP9, SP10, SP12 and SP13 all bind with high affinity following stapling (Figure 
25A). For these peptides, differences in KD were minimal between the corresponding stapled 
and mock reaction products, and all of these peptides bound with KD values of 15-60 nM in 
either form. SP12 bound more tightly after stapling and has the highest affinity observed 
amongst all of the mutants. 
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Figure 25. Screening of stapled BRC8-2 peptides. (A) Bis-cysteine mutants designed based on the BRC8-2 
sequence and prepared in small-scale. FP KD values are shown on the left.  (B) FP competition assay graphs for 
representative peptides. Fluorescently-labelled BRC4 probe (10 nM) was pre-incubated with 100 nM 
HumRadA22, to which GB1-peptide dilution series were added. Data shown are the means of triplicate 
measurements ± SD.   
None of the truncated peptides SP1, SP14, SP16 bound to saturation at the tested 
concentrations, either in stapled or unstapled form, reiterating the previously published 
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observations that the simultaneous binding of both FxxA and LFDE motifs is critical for high 
affinity interaction of BRC repeats with RAD51 (Figure 25A). While its binding could not be 
fitted, SP14 showed the most substantial displacement of the fluorescent probe of the three 
short peptides, with an IC50 around 10 μM. Interestingly, SP14 appears to bind more strongly 
after stapling (Figure 25B), indicating the stapling architecture is beneficial, despite an overall 
low affinity.  
The small-scale preparation and screening of cysteine-stapled peptides established that 
rational, structure-based macrocyclisation can be applied to the chimeric BRC8-2 repeat. 
However, none of the repeats, either stapled or mock, bound with a higher affinity than the 
equivalent GB1-BRC8-2 template construct (KD = 11 nM), suggesting that the introduction of 
the cysteine staple may be slightly detrimental for binding. 
3.4 Optimisation of stapled BRC8-2 peptides 
The small-scale screening data provided a detailed description of the effect of different 
stapling geometries on binding, however, the resulting products are not applicable in cell assays 
or for crystallographic studies. Scale-up and removal of tags is necessary to obtain the peptide 
in sufficient yields and a pharmacologically relevant form.  The screening data were used to 
inform the design and preparation of BRC8-2 bis-cysteine mutants as free peptides, lacking 
any expression and purification tags. The preparation work-flow is illustrated in Figure 26A. 
Peptides were cloned into vectors having an N-terminal His8-tag, followed by a GB1 tag and a 
TEV site. This allows the separation of the peptide from all of the fusion tags using a single 
TEV cleavage step. After expression in litre-scale E. coli cultures and purification on Ni-NTA 
resin, the linear peptides were cleaved with TEV protease, reverse-purified in a second IMAC 
step to remove the released N-terminal tags, followed by reversed-phase chromatography 
(RPC), which allowed the separation of degradation products from the full-length peptide. 
After this, the linear bis-cysteine peptides were stapled with a divinyl linker and purified by 
RPC again. Pseudo-dilution conditions required for the correct product formation were applied 
similarly to the screening protocol but adjusted for a larger reaction volume. 
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Figure 26. Preparation of stapled BRC8-2 peptides. (A) A diagram outlining the procedure for recombinant 
expression and purification of linear bis-cysteine peptides, and their subsequent stapling. Peptide is expressed as 
a fusion to an N-terminal His8-GB1 tag and purified by an initial IMAC capture step. Cleavage with TEV protease 
and a reverse IMAC step then ensures removal of the tag. The linear peptide is then purified by RPC (typically 
C18 column), followed by stapling and a final C18 RPC step. (B) Prep-grade RPC (C8) trace of the TEV-cleaved 
linear SP2 after a reverse IMAC step (C) Crude reaction product the same peptide after stapling with DVT-Ac 
under pseudo-dilution conditions. (D) Analytical HPLC trace (top) and MS spectrum (bottom) of the SP2 final 
product. 
SP2 was selected initially to evaluate the scale-up approach. RPC purification of the 
cleaved linear intermediate gave high yield (>10 mg) of the full-length product Figure 26B. 
Because the two cysteines had been reduced with TCEP prior the application onto the RPC 
column, and peptide was kept in acidic conditions during and after the first RPC step, no 
subsequent addition of reducing agent was required. The DVT-Ac Linker was titrated into 
phosphate-diluted pooled RPC fractions with magnetic stirring, forming a highly pure stapled 
product with no detectable double-linker contaminant (Figure 26C,D). Notably, a simplified 













































SP2 (stapled) C18 RP-HPLC crude
B, %
Abs. 214 nm, mAu
B
, %
















SP2 (linear) C8 RP-HPLC crude
B
, %
Abs. 214 nm, mAu
B, %
C
Pantelejevs, T.  Development of RAD51-targeting stapled peptides 
 71 
once. Here, the reaction products elute as two peaks with the second peak corresponding to the 
double linker product (data not shown). This again emphasises the need for careful 
consideration of reaction kinetics to obtain the correct stapled peptide.  
 
Figure 27. Biophysical and functional characterisation of stapled BRC8-2 peptides. (A) Sequences of stapled 
peptides prepared in free form with critical features highlighted: FxxA motif (red), overhangs for TEV cleavage 
(green), nucleophilic cysteines (yellow), functional mutations (blue). (B) ITC titrations of stapled peptides into 
HumRadA22.  
Binding of SP2 was evaluated by ITC, confirming nanomolar binding to HumRadA22 
humanised surrogate protein (Figure 27B). SP2 also inhibited human RAD51 nucleoprotein 
filament formation in vitro as shown by EMSA (Figure 28).  
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Two new peptides were then designed in a round of sequence optimisation with the aim 
of improving physicochemical properties (SP24 and SP30, Figure 27A). SP24 is based on the 
SP2 cysteine design and contains the same helical stapling architecture at the LFDE module. 
SP30 is based on SP12 and contains a more distant i,i+18 linkage in sequence across the two 
modules. The optimised peptides were significantly truncated at both termini compared to their 
parental sequences in order to decrease size with the aim of achieving improved membrane 
permeability. The peptides were also optimised to decrease negative charge, which has been 
likewise shown to be important for cellular uptake. First, the negatively charged DVT-Ac linker 
was exchanged for a neutral DVP (Figure 19B). Secondly, Asp1243 from the LFDE motif 
(LFSD in BRC8-2) was now at the C-terminus, meaning that this residue would carry two 
negative charges. To prevent this, Asp1243 was mutated to a glycine in both SP24 and SP30. 
In the context of BRCA2, this residue interacts with RAD51 surface arginines through its acidic 
side-chain. A flexible glycine was deemed sufficient for binding, as the terminal carboxylate 
is only one carbon closer to Cα and can mimic the acidic side-chain of Asp1243. Moreover, a 
solvent-exposed Glu1232 was mutated to a glutamine to further decrease negative charge.  
Gratifyingly, the resulting peptides were found to bind HumRadA22 with affinities that 
are comparable to SP2, despite losing more than a quarter of residues (Figure 27B). Moreover, 
placement of a terminal glycine instead of Asp1243 at the LFDE motif (LFSD in BRC8-2) did 
not severely impair binding. SP24 and SP30 also inhibited nucleofilament formation in EMSA 
assays utilising full-length human RAD51 at comparable levels to BRC8-2 (Figure 28). 
 
 
Figure 28. Competition electrophoretic mobility shift assays (EMSA) demonstrating the effect of stapled peptides 
on RAD51 nucleoprotein filament formation. 
3.5 Proteolytic stability of stapled BRC8-2 peptides 
A key objective of peptide stapling is to protect the linear sequence against proteolytic 
cleavage by the different proteases that are ubiquitous in the cell and physiological fluids. To 
evaluate this in the context of BRC8-2 peptides, I set out to investigate the effect of their 
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incubation with human serum. Because BRC8-2 peptides are large relative to many therapeutic 
peptides, traditional HPLC-based approaches may not be sensitive enough to detect cleavage 
of small fragments. I devised an activity-based assay instead. Briefly, 200 μM peptide was 
incubated with 20% human serum at 37°C and aliquots taken at various time-points and 
quenched with DMSO:ethanol to remove serum proteins. The quenched products were then 
tested by FP for their ability to inhibit HumRadA22:BRC4-fluor interaction.  
 
Figure 29. Activity-based serum stability assay of stapled peptides SP24 and SP30. Peptides were incubated 
with 20% serum at 37°C, after which serum proteins were removed by DMSO:ethanol precipitation. 
Fluorescently-labelled BRC4 probe (10 nM) was pre-incubated with 100 nM HumRadA22, to which serum-
treated peptide dilution series were added. Data shown are the means of triplicate measurements ± SD.   
Remarkably, both peptides tested (SP24 and SP30) had no noticeable decrease in activity 
even after 24 h of incubation with human serum. This could indicate either that the peptides 
lack labile proteolytic recognition sequences, or, if such sequences exist, that they are indeed 
protected by the covalent staple. Unfortunately, I was not able to evaluate the stability of 
unstapled control peptides with reduced cysteines, as these aggregated during the quenching 
step, therefore it was not possible to directly compare the effect of a covalent linkage between 
the cysteines. Furthermore, the cytoplasm is likely to present a more challenging proteolytic 
profile, and serum data cannot be simply extrapolated. Nevertheless, the fact that there was no 
loss of function observed after 24 h is very encouraging. 
3.6 Modular functionalisation of stapled peptides 
Both solid-phase and ribosomal peptide synthesis approaches have the advantage of 
using repetitive cycles of identical reactions to incorporate diverse building blocks with 
different side-chain chemistries. This makes peptidic probes suitable for modular design, where 
independently-developed functional elements are combined using robust and predictable 
orthogonal reactivities. Such modular design paradigms are finding increasing application in 
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biomedical sciences. For example, peptides that bind a particular target have been linked to 
anti-cancer cytotoxins, radioligands, proteolysis-targeting E3 ligase ligands, cell-penetrating 
motifs, among other functional elements. For two-component macrocyclisation reactions, the 
linker can provide an additional vector for such derivatisation. The linker can be developed and 
prepared separately from the linear peptide, allowing many functionalities to be combined with 
different linear peptide sequences. The divinyl linkers, for example, can be derivatised at the 
5-position that is symmetrical to the two vinyl arms. Previous work using these linkers as 
antibody-labelling agents has shown that a cytotoxic payload can be attached via the linker to 
an antibody that then efficiently kills cancer cells.156 
Despite efforts to decrease size, the RAD51-targeting stapled peptides reported above 
are large molecules that may not have sufficient membrane permeability. Cell-penetrating tags 
have been applied to a variety of cargoes, including therapeutic peptides, as a means to improve 
uptake.157 These tags usually incorporate basic, cationic amino acid residues or synthetic 
mimics thereof. In order to improve cellular uptake, I designed SP31, a modified peptide based 
on the stapling architecture of SP30, with a recombinantly encoded polyarginine (Arg9) cell-
penetrating peptide (CPP) at the N-terminus (Figure 30). The highly charged tag was placed 
at the N-terminus rather than the C-terminus in order to avoid perturbing the electrostatic 
contacts between Gly1243 and RAD51 surface arginines.  
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Figure 30. Modular design of CPP-tagged and fluorescently-labelled peptides. (A) Sequences of peptides SP31 
and SP32. Both contain identical cysteine mutations and Arg9 tags but use different linkers. (B) Cation 
exchange step for the purification of linear SP31 after TEV-cleavage and removal of the GB1 tag. (C) Click-
compatible DVP alkyne linker used for the preparation of SP32. (D) Modification of DVP-alkyne linker after 
stapling to yield the fluorescent peptide SP32. 
SP31 was purified using a modified version of the recombinant approach described in 
3.4 Optimisation of stapled BRC8-2 peptides. Initial attempts to use the same protocol failed, 
as the TEV-cleaved peptide strongly adsorbed through the polyarginine tag to the silica matrix 
of the C8 column in the first RPC step and could only be removed by a high-salt / GndCl wash.  
Instead, a cation exchange step was implemented using SP Sepharose resin that efficiently 
purified the cleaved linear peptide (Figure 30). After stapling with a DVP linker, the resulting 
product can be efficiently purified on a C18 RPC column. 
To aid a further derivatisation step, a click-compatible linker DVP-Alkyne (Figure 
30C) was kindly prepared by Andrew Counsell from Prof David Spring’s lab (Department of 
Chemistry). The alkyne handle can be used for addition of a variety of azide-tagged molecules. 
Pantelejevs, T.  Development of RAD51-targeting stapled peptides 
 76 
This new linker was used to prepare SP32, which is identical to SP31, but with a fluorophore 
attached using copper(I)-catalysed azide-alkyne cycloaddition (CuAAC). A rhodamine-110-
based green fluorophore was used instead of the more popular Alexa dyes, as it has a net neutral 
charge, unlike Alexa-488, which carries two negatively charged sulfonate moieties that can 
reduce cell uptake. The modification in SP32 was intended for the tracking of cellular uptake 
and distribution of the peptide in cells by fluorescence microscopy.  
3.7 Cell-based activity  
At the time of submission of this dissertation, purified stapled peptides SP24, SP30, 
SP31 and SP32 have been provided to our collaborator Jessica Downs’ lab for evaluation in 
RAD51 foci inhibition assays, analogous to what was reported with transfected BRC8-2. The 
resulting data will be included in future publications describing this work.  
3.8 Double-stapled BRC8-2 peptides 
The BRC repeats are large peptides that require the binding of both FxxA and LFDE 
modules for high-affinity interaction. This presents a particular challenge for intracellular 
targeting, as proteolytic liability is expected to increase with chain length. Moreover, larger 
peptide size is expected to be detrimental for membrane permeability. While stapling may 
mitigate these issues, it is conceivable that macrocyclisation of increasingly distant amino acids 
might not be sufficient. Several examples of double-stapled peptides have been reported in the 
literature that aim to introduce more stringent conformational constraints on the peptide 
through the introduction of two staple moieties, connecting two pairs of amino acid side-
chains.158  
Motivated by the success of divinyl-cysteine stapling of RAD51 binding peptides, I 
attempted to prepare double-stapled BRC8-2 peptides that would extend the potentially 
beneficial effect of macrocyclization to as large fraction of the peptide chain as possible. It was 
anticipated that simple addition of a reactive divinyl linker to the four-cysteine peptide would 
result in a complex mixture of products, as there are 3 possible linkage combinations in case 
of a complete reaction of such a peptide with two linkers. This makes recombinant preparation 
of such peptides challenging due to the need to separate these products. To this end, I tried two 
different methodologies. The first one involved template-assisted stapling of peptides pre-
bound to the target protein. The second approach used solid-phase peptide synthesis (SPPS) of 
BRC8-2 four-cysteine mutants with orthogonal cysteine protecting groups. Unfortunately, 
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none of the approaches yielded the desirable products at sufficient purity. Nevertheless, I 
anticipate that with further optimisation of reagents and conditions, double-stapled BRC8-2 
peptides can be prepared, and I discuss future steps to achieve this afterwards. 
 
Figure 31. Double-stapled BRC8-2 peptides that were designed in an attempt to increase the extent of 
conformational restraint. 
3.8.1 Template-assisted double stapling 
I hypothesised that pre-binding to a protein target may direct the reactive linker arms 
to form the desired linkage geometry, as opposed to a mixture of products. In the case of BRC8-
2, I envisaged that introducing one pair of cysteines at the LFDE helix and another at the FxxA 
hairpin, while constraining the peptide conformation by binding to HumRadA22, which does 
not contain cysteines, might guide the reaction steps via physical separation of cysteine pairs. 
With this in mind, peptide SP19 was designed (Figure 31), containing an N-terminal cysteine 
pair from SP10 and a C-terminal cysteine pair derived from SP9, both of which maintained 
binding in the screening experiments. 
SP19 was expressed as fusion to N-terminal GB1 expression tag and a C-terminal His-
tag and purified by IMAC. Stapling reactions were performed with the DVP linker under 
pseudo-dilution conditions in an identical manner to the screening experiments in Section 3.3. 
Two reactions were done in parallel, one containing just the GB-fused peptide, and another a 
stoichiometric excess of HumRadA22. Despite applying a gradual titration of DVP, undesired 
three-linker adducts made up a significant fraction of the product, as detected by MS. 
Remarkably, adding the template appears to favour the formation of an undesired three-linker 
adduct. It is possible that the presence of template inhibits the intramolecular ring closing step 
by restricting the conformational freedom of the peptide, and thus increases the probability that 
the second cysteine will react with a free linker molecule. These experiments were also 
repeated with SP21, in which the first cysteine has been moved back by one position, intending 
to make it more accessible for ring closing. However, the same effect on the number of linkers 
is observed. Due to the unfavourable outcome of these reactions, the linkage species for the 
DVP2 product were not investigated further.  
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Figure 32. Template-assisted double-stapling. Mass spectra of GB1-SP19 and GB1-SP21 stapled with DVP linker 
alone or in the presence of a twofold stoichiometric excess of HumRadA22. 
3.8.2 SPPS with orthogonal cysteine protecting groups 
SPPS allows for the incorporation of a diverse set of synthetic amino acids that are not 
typically accessible through ribosomal synthesis. For the purpose of double-stapling, cysteine 
residues with orthogonal protecting groups at the thiol side-chains can be introduced into a 
peptide to control the macrocyclisation geometry through sequential deprotection-stapling 
steps. Orthogonal cysteine protecting groups have been utilised for the specific sequential 
conjugation of two different cytotoxic drugs to an antibody.159 For such directed modification 
of BRC8-2 stapled peptides, I implemented trityl and S-tButyl, a pair of orthogonal protecting 
groups for thiol moieties that require different conditions for removal (Figure 33B). Trityl is 
acid-labile and eliminates during the global deprotection step with TFA. S-tButyl is stable in 
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Figure 33. Solid-phase peptide synthesis of double-stapled peptides using orthogonal cysteine protecting groups. 
(A) Double-stapled peptides designed for SPPS preparation. (B) Reaction scheme for double-stapling of peptides 
using orthogonal cysteine protecting groups. (C) UV spectrometric quantification of coupling efficiency for each 
amino acid and LCMS analysis of the crude product from the global deprotection of SP17. (D) LCMS analysis of 
the crude product from the global deprotection of SP19. (E) LCMS analysis of the crude product (top) and RPC 
peak (bottom) from the global deprotection of SP19 after swapping Cys protecting groups.  
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SP17 was designed in an attempt to combine the stapling architectures from SP9 and 
SP12 (Figure 33A). Synthesis of SP17 was attempted on an automated peptide synthesiser 
using standard Fmoc chemistry on RINK amide resin with amidation and acylation of C and N 
termini, respectively. HPLC and MS analysis of a small-scale preparation of SP17 after TFA 
deprotection shows a product of extremely low yield, despite using double couplings and 
microwave assisted synthesis (Figure 33C). Peptide yield can be affected by a multitude of 
factors, such as on-resin aggregation, deletions due to inefficient coupling or side-reactions 
with the reactive cleaved protecting group moieties.160 Synthesis failure tends to be sequence 
context-dependent, and hard to predict beforehand, and increases in severity with peptide 
length. In the case of BRC8-SP17, the highest-intensity peak in the crude deprotected product 
appears to be a Val deletion. This is further corroborated by the absorbance measurements 
during Fmoc-piperidine release, which shows a marked drop for the Val amino acid (Figure 
33C). 
An SPPS preparation of SP19 was also attempted using the same conditions as for 
SP17.  Small-scale global deprotection products were analysed by HPLC and MS, and reveal 
higher yield of the correct species, having N-terminal S-tBut protected and C-terminal 
deprotected Cys pairs (Figure 33D). In an attempt to improve on this, I decided to modify the 
SP19 preparation by swapping the two pairs of orthogonal cysteine protecting groups, with the 
two Fmoc-Cys(S-tBut)-OH amino acids now being incorporated into the C-terminal Cys 
positions corresponding to the LFDE α-helix. The resulting TFA test cleavage product for the 
alternative preparation is more pure compared to previous syntheses, with expected m/z peaks 
being clearly dominant (Figure 33E, top). This shows that a simple modification to the SPPS 
protocol design can have profound effects on product quality. The RP-HPLC elution profile of 
SP19 global deprotection crude product contains a number of overlapping peaks, indicating a 
chemically heterogeneous mixture. The fractions at the absorbance maximum, i.e. the major 
product, contain the correct peptide at higher purity, as evidenced by LCMS (Figure 33E, 
bottom). Encouraged by this, I attempted to scale up the purification to amounts suitable for 
downstream stapling reactions. Unfortunately, increasing the amount of peptide in the global 
deprotection step led to a massive drop in purity even when the total reaction volume was 
adjusted proportionally to the amount of resin used. Due to the limited ability to attend the 
Department of Chemistry facilities during the COVID-19 pandemic, SPPS-based preparation 
of SP19 and other double-stapled peptides was not pursued further. 
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3.9 Conclusions  
In this chapter, I have presented the successful application of a novel work-flow for the 
recombinant preparation and in vitro screening of cysteine-stapled peptides. The method can 
be applied for rapid and cost-effective evaluation of cysteine-stapling architectures to select 
lead designs for scale up and further optimisation. For this, I have combined a set of streamlined 
molecular biology and chemical biology methods. Sequence and ligation-independent cloning 
(SLIC) of peptide-coding DNA inserts circumvents the need for digesting and re-purifying the 
insert with endonucleases, which is typically done during restriction cloning. The use of a 
single E. coli strain (T7Express) reduces the time from cloning to protein purification, as there 
is no need to re-transform the vector into a separate expression strain. A single IMAC 
purification step allows many bis-cysteine peptides to be purified in parallel without the need 
for RP-HPLC steps, whereas stapling under pseudo-dilution conditions ensures quantitative 
conversion of the linear precursor into the correct macrocycle product. If appropriately 
planned, the production of these GB1-fused stapled peptides can be executed in three days from 
assembly PCR to the final stapling reaction (Figure 34). This methodology can be generalised 
to a variety of targets that have a suitable binding epitope, in particular, when structural data is 
available to guide staple design. I anticipate that it can also be expanded to different linker 
chemistries, as well as trivalent linkers that form bicyclic peptides. Moreover, this methodology 
can also be applied to evaluating sequences derived from the directed evolution of stapled 
peptides. For example, peptides selected by phage display may be evaluated in a similar way.  
 
 
Figure 34. A best-case timeline of stapled peptide production using the small-scale recombinant work-flow. 
The screening of different stapling architectures on BRC8-2 has shown that a variety 
of positions in the sequence can be covalently linked without disrupting binding. Crucially, 
both traditional helical staples and alternative architectures with large sequence distances are 
tolerated. For example, in the case of the SP13, an i, i + 22 architecture was obtained while 
maintaining nanomolar affinity. It is likely that the N-terminal fragment of BRC8-2, preceding 
the fixed hot-spot residue Phe2058, can tolerate conformational rearrangements to 













00:00 h 24:00 h 48:00 h 72:00 h
FP
Pantelejevs, T.  Development of RAD51-targeting stapled peptides 
 82 
It was not possible to significantly reduce the size of BRC8-2, as residues on both 
modules appear to be critical for binding, and macrocyclisation does not compensate for the 
loss of affinity when these critical contacts are removed.  Several approaches may be used in 
future to improve the binding of significantly truncated BRC8-2 peptides, thus reducing the 
overall size of the peptidic probe. For example, SP14, containing the FxxA but not the LFDE 
motif, showed weak binding in the FP assay that appears to improve upon stapling (Figure 
25B). This peptide may be affinity matured using a directed evolution method, such as phage 
or yeast display in combination with a soft randomisation mutagenesis161 in which residues are 
varied but biased towards the original sequence. Alternatively, one could use error-prone PCR 
to introduce mutations at random positions of the SP14 DNA insert and then select for 
improved binders using the aforementioned directed evolution approaches. Furthermore, 
rational design may be applied to introduce sequence modifications that increase binding 
energy. For example, in Section 2.4 BRC8-2 residue-specific contributions to affinity I have 
shown that mutating Phe2056 to a tryptophan has a beneficial effect on binding. Synthetic 
fragment hits that bind RAD51 may be conjugated to the peptides, similarly to what was done 
in during the development of peptidomimetic CAM833.117 Such modifications can contribute 
to an additive effect on affinity.  
Using recombinant methods, I was able to purify stapled peptides SP2, SP24 and SP30 
as free peptides in >10 mg quantities, which provided sufficient material for biophysical and 
biochemical studies. ITC measurements show that all three peptides bind with nanomolar 
affinities that are slightly inferior to the BRC8-2 template (Figure 27B). SP2 appears to be the 
tightest binder, which is consistent with it having the least truncated template. SP24 and SP30 
were significantly truncated and contained a number of charge-modifying mutations, yet 
experienced only a marginal drop in affinity compared to SP2.  
Because the initial screening was done with a monomeric HumRadA22 archaeal 
surrogate protein, there was a concern that binding to this model molecule would not translate 
to full-length human RAD51. Gratifyingly, SP2, SP24 and SP30 peptides are able to disrupt 
the RAD51-ssDNA nucleoprotein filament in vitro, which is the desired functional 
consequence of these pharmacological probes.  
Regrettably, I was not able to obtain double-stapled peptides with two cysteine pairs 
covering an increased fraction of the BRC8-2 template. Preventing the formation of mixed 
linkages during double stapling requires spatial or temporal separation of the two addition steps 
in order to obtain the desired product. In this chapter, I had optimised the initial steps necessary 
for an SPPS-based preparation of SP19, however, the synthesis was not brought to conclusion. 
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I anticipate that the strategy that I outline can be successfully finalised, but will require 
significant optimisation of purification steps, for example, through focused RP-HPLC 
gradients. Moreover, finding an optimal reducing agent and reaction conditions for the 
deprotection of S-tBut cysteines may be challenging.  
Alternatively, I propose a biological approach for double-stapled peptide preparation 
using split inteins. Inteins are a class of proteins that catalyse their own excision out of a 
polypeptide sequence and re-ligate their terminal flanking regions (exteins) in a process called 
“protein splicing”.162 A subtype of this reaction called trans-splicing involves inteins that are 
split, usually into one significantly larger, globular fragment, and a smaller peptidic fragment, 
that reconstitute the full-length intein upon mixing and undergo splicing.162 Trans-splicing has 
been applied to various biotechnological applications, such as fluorescent or isotope labelling 
of proteins.162 For the purpose of preparing double stapled peptides, one can envisage that trans-
splicing may be applied as a means to spatiotemporally separate the two stapling steps. By 
preparing the two stapled halves of a peptide separately, each containing a pair of cysteines, 
and then ligating them via trans-splicing, one could ensure tight control over the two steps. For 
this to be successfully applied, several caveats have to be considered, such as the promiscuity 
of the intein at the terminal flanking sequences (-2, -1, +1, +2 etc), which will be different for 
each peptide, as well as the presence of catalytic cysteines, which can also react with the 
electrophilic linker. 
Intrigued by how the staple moiety behaves at the atomic level, I set out to determine 
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4 Structural studies of stapled BRC8-2 peptides 
4.1 Introduction 
Our ability to predict the effect of macrocyclisation on the pharmacological properties 
of a peptide remains poor. Structural data can elucidate some of the underlying phenomena at 
the atomic level and guide the design of new molecules. Only a few structures of Cys-stapled 
macrocycle peptide complexes have been reported, including bicyclic peptides (for example, 
PDB: 6Y13, 5EEQ, 5VK0, 4OS5). While it has been shown that the divinyl linker DVT-Ac 
can staple i, i+7 architecture on α-helical peptides,146 the conformation of the linker and its 
effect on the helix geometry are unclear. Screening and optimisation of stapled BRC8-2 
peptides, as described in Chapter 3, demonstrated that a wide-range of cysteine linkage 
architectures were tolerated, and high-affinity binding was maintained, albeit with a drop in KD 
compared to the template peptide. Importantly, stapled peptides with large inter-cysteine 
sequence distances and loop-like architectures were successfully prepared and applied as 
RAD51 inhibitors in vitro. Aiming to understand how the introduction of a staple moiety affects 
the binding mode and geometry of these peptides, I set out to determine the crystal structures 
of the peptides SP2, SP24 and SP30. 
4.2 Crystal structures of SP2, SP24 and SP30 
Peptide:HumRadA22 complexes were screened in in 96-well MRC plate format using 
a variety of commercially available screens. Crystals were obtained for all three complexes, 
and diffraction data were collected without further optimisation of conditions. The best-
diffracting crystals produced data at resolutions 3.0, 1.6 and 1.2 Å for HumRadA22 complexes 
of SP2, SP24 and SP30, respectively. It is possible that the lower resolution observed for SP2 
stems from the extended flexible termini of this peptide having higher conformational 
heterogeneity and producing less optimal packing.  
In all three complexes, electron densities are defined for peptide residues Ser2056-
Asp/Gly1243, including the stapled cysteines and their linkers (Figure 35A-C). In the low-
resolution SP2 complex structure, the DVT-Ac linker is seen as an electron density blob located 
between the two cysteine sulphurs, and the conformation of this moiety is not clear at the 
atomic level. By contrast, in the SP24 complex structure, which connects analogous cysteines 
on the C-terminal α-helix, the DVP linker can be observed in atomic detail and its conformation 
can be modelled accurately (Figure 35B). The two arms of the DVP linker in SP24 have 
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acquired different orientations relative to the heterocycle core. The first arm, connected to 
Cys1231, has the C1-C2 bond perpendicular to the pyrimidine ring, whereas in the arm linking 
Cys1238, the bond is nearly co-planar. In both arms, the C1-C2 bond and the C-S bonds are in 
a trans conformation. Thus, the overall geometry of the staple minimises strain while 
accommodating the Cys-Cys Cα distances imposed by the helix on the two cysteines. The 
linker SP24 does not interact with HumRadA22, but its core heterocycle stacks on top of 
endocyclic Leu1234, which is at +3 relative to the first cysteine of the peptide, creating a small 
hydrophobic core. 
The helical geometry of the C-terminal LFDE α-helices in SP2 and SP24 structures is 
not perturbed by the introduction of the staple, with near-identical distances between cysteine 
α-carbons compared to BRC8-2. Moreover, alignment of isolated LFDE helices from these 
peptides with BRC8-2 has a backbone Cα RMSD values 0.235 and 0.310 Å, indicating minimal 
effect of i,i+7 stapling on secondary structure (Figure 35D). The low-strain linker 
conformation and unperturbed helicity observed in SP2 and SP24 crystal structures support the 
application of divinyl linkers as a general strategy for stapling α helical motifs using an i,i+7 
architecture.  
In the SP30 structure, the DVP linker can be modelled into electron density connecting 
distant residues Cys2055 on the FxxA module and Cys1234 on the LFDE α-helix (Figure 
35C). Linker arm density is clearly defined on the Cys1234 side (LFDE module), whereas 
Cys2055 appears more disordered (FxxA module), and fitting the residue to the electron 
density is more ambiguous. The linker core is situated between the side-chains of HumRadA22 
Gln213 and Gln217, making surface contacts with these residues. Linker arms of SP30 acquire 
a different arrangement compared to the helical architectures. Both C1-C2 bonds are 
perpendicular to the pyrimidine core. The C1-C2 bond at Cys1234 and C-S bond at Cys2055 
are in a gauche conformation. This linker conformation in SP30 appears to be necessary to 
accommodate the different cysteine pair orientation and shorter S-S distance, compared to the 
i,i+7 peptides.  
Pantelejevs, T.  Structural studies of stapled BRC8-2 peptides 
 86 
 
Figure 35. Crystal structures of stapled peptides SP2 (red), SP24 (green) and SP30 (blue) in complex with 
HumRadA22 (grey surface). BRC8-2 is depicted for comparison in orange/yellow (FxxA/LFDE module). (A, B 
and C) Weighted 2mFo-DFc electron density maps after modelling of the peptide at 1σ level overlaid with the 
modelled peptide chains (top panels) and close-up images of staple moieties (bottom panels). (D) Alignment of 
the LFDE α-helices from the three stapled peptides and BRC8-2 based on backbone α-carbons of the helix. (E) A 
shift in the LFDE modules of SP24 and SP30 compared to SP2 and BRC8-2. (F) Rotation of the LFDE α-helix 
in SP24 results in a shift of Leu1240 and Phe1241 side-chains relative to their binding mode in BRC8-2. C-
terminal Gly1243 forms a salt bridge with HumRadA22 Arg270 (HsRAD51 Arg254), replacing an acidic side-
chain. (G) Sequences of the crystallised stapled peptides aligned to BRC8-2. 
All three stapled peptides maintain the critical FxxA and LFDE motif contacts that are 
conserved in BRC4 and BRC8-2. Remarkably, the LFDE modules of SP24 and SP30 undergo 
substantial movement relative to HumRadA22 and the rest of the peptide (Figure 35E). The 
observed motion affects more than a half of the peptide, encompassing residues Lys1226 to 
Glu1243. The movement is concomitant with a rotation of the LFDE α-helix around its helical 
axis, leading to the re-organisation of Leu1240 and Phe1241 side-chains in their cognate 
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hydrophobic clefts (Figure 35F). It is reasonable to hypothesise that the shift of the LFDE 
module is a consequence of the C-terminal Asp1243Gly mutation, which was introduced to 
minimise the overall negative charge of the peptide. The carboxylate terminus of the flexible 
glycine residue is one carbon shorter compared to an aspartate side-chain, and rotation of the 
LFDE helix brings it closer to Arg270 (HsRAD51 Arg254) in the SP24 structure, in order to 
maintain the terminal salt bridge (Figure 35F).  
Despite containing the hairpin-mediating Ser2056, all three peptides SP2, SP24 and 
SP30 have lost the extended β-hairpin fold that was seen for BRC8-2 (Figure 35E). Instead, 
Ser2056 and Gly2057 residues, preceding the FxxA phenyl, point away from the peptide. This 
re-arrangement was anticipated in SP30, where the stapling architecture was designed to link 
the N-terminus of the peptide with the LFDE helix, whereas in SP2 and SP24 the cause for this 
movement is not immediately obvious. The cysteine mutations and the linker in SP2 and SP24 
do not sterically preclude any of the interfaces necessary for hairpin formation. As with all 
comparative analyses involving backbone movements, one cannot exclude crystal-contact 
induced effects. In the SP2 crystal structure, the two complexes in the asymmetric unit have 
non-crystallographic symmetry and their FxxA modules of the two peptides form reciprocal 
symmetric contacts, which may explain the different conformation. However, in the case of 
SP24, other complex molecules are not in close contact with N-terminal part of the peptide and 
there is a large solvent channel above it instead. It is therefore not clear why the extended β-
hairpin fold has been lost for the two peptides.  
4.3 Pre-organisation of stapled peptides 
Previous reports of stapled peptide development have demonstrated that peptide 
stapling can pre-organise free peptide in solution by restricting the number of degrees of 
freedom towards the desired conformation. In particular, rationally introduced staples have 
been shown to enforce the secondary structures of α-helices, thus stabilising the bound state of 
a helical epitope.163 This effect has also been hypothesised to be responsible for the improved 
membrane permeability of stapled peptides.  
To evaluated if Cys-divinyl stapling can similarly pre-organise peptide conformation, I 
analysed the SP24 and SP30 using circular dichroism (CD) spectroscopy. For this, non-stapled 
versions of all three bis-cysteine peptides were prepared with reduced thiols to prevent disulfide 
bridge formation. Stapled peptides were also compared with the linear full-length BRC8-2 
repeat. 
Pantelejevs, T.  Structural studies of stapled BRC8-2 peptides 
 88 
 
Figure 36. Circular dichroism (CD) spectra of BRC8-2 template and stapled peptides. Dashed lines indicate 
reduced free thiol versions of the bis-cysteine mutant. Data shown are smoothened values from three scans. 
A mixed secondary structure composition is apparent from the CD spectra of all the 
peptides tested, with global minima around 200 nm indicative of a random coil, and a smaller 
local minima at 225 nm suggesting α-helical character (Figure 36). Covalent stapling of SP30 
has slight effect on the relative magnitudes of these minima, suggesting a small decrease in 
random coil, with a concurrent increase in α-helix or β-sheet (Figure 36, blue curves).  SP30 
was designed with the intention of stabilising a large loop-like structure, part of which forms a 
β-hairpin. It is impossible to infer from the CD spectra of SP30 whether the bound 
conformation is pre-organised. 
SP24, on the other hand, shows significant increase in α-helical character upon stapling, 
as evidenced by an increase in negative molar ellipticity in the 210-230 nm range (Figure 36, 
green curves). SP24 was designed with the intention to stabilise the helical secondary structure 
via the introduction of i,i+7 cysteines, and the CD data confirm this effect.  
4.4 Conclusions 
In this chapter, I have presented the complex structures of the three BRC8-2 stapled 
peptides SP2, SP24 and SP30, which have illuminated important characteristics of the staple 
moiety. The linker was shown to adopt a variety of conformations to accommodate different 
stapling architectures, while minimising steric and torsional strain. Introduction of i,i+7 staple 
at the LFDE helix in SP2 and SP24 did not perturb helical geometry, endorsing the general 
applicability of this stapling chemistry towards helical epitopes. The linker orientation 
observed in SP2 and SP24 is likely to translate to other helices and can inform the rational 
design of binders for other targets. Based on the observed conformations, one could fine-tune 
the positions of cysteines to prevent steric clash between linker and target protein and 
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encourage favourable contacts. Moreover, in the case of SP24, the linker was shown to stack 
on top of an endocyclic residue side-chain, which adds an additional dimension for sequence 
optimisation. For example, introduction of an aromatic side chain at +3 position relative to the 
first cysteine may further stabilise the helical fold via π-stacking with the core heterocycle.   
The three crystal structures validate the design strategies that were implemented in the 
initial design of these peptides. In the case of SP2 and SP24, the cysteines were introduced in 
place of solvent exposed side-chains at the LFDE helix to avoid steric clash with the protein. 
Truncations at the C-terminus were introduced in SP24 and SP30, as residues after Asp1243 
appear to contribute little to binding. Confirming this, the truncated residues do not have 
defined electron density in the SP2 structure, suggesting that they are disordered and not bound. 
Mutating the terminal Asp1243 to glycine removed an unnecessary and potentially detrimental 
negative charge, while preserving a salt bridge with Arg270, as shown by the complex 
structure. The structure of SP30 confirms the successful linking of two distal sites on the 
peptide, connecting the LFDE helix with the N-terminus of the peptide without disrupting 
crucial contacts or secondary structure. 
The structural data suggest new modifications for future optimisation of these stapled 
peptides. For example, one could attempt expanding the stapling architecture of SP2 and SP24 
by introducing an additional third cysteine at the N-terminus and using a symmetric trivalent 
linker to create a bicyclic peptide. In fact, our collaborators at Prof David Spring’s group 
attempted the preparation of trivinyl linkers akin to the divinyls used here, yet they were found 
to be chemically unstable for this application. Alternatively, one could use alkyne or azide-
derivatised divinyl linkers as a means of connecting a third side-chain of a click-compatible 
unnatural amino acid. By introducing a second macrocycle one may further improve the 
proteolytic stability and other properties of the RAD51-targeting stapled peptide.  
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5 BRC:Rad51 interaction in Leishmania infantum 
5.1 Introduction 
Protozoan parasites are causative agents of a number of neglected tropical diseases.120 
Rad51 has been shown to have specific roles in the life cycles of a number of these organisms, 
making it an attractive potential therapeutic target. Selectively inhibiting Rad51 in protozoans, 
such as T. brucei, P. falciparum or L. infantum, may provide new avenues for fighting these 
devastating infectious diseases. This process can be accelerated by improved structural and 
biophysical understanding of the interactions that this protein makes. In this work, I focus on 
the Rad51:BRCA2 interaction axis in L. infantum, the causative agent of leishmaniasis, a 
tropical disease which in its visceral form can be fatal if untreated. 
A detailed study conducted by Genois et al. provides the first examination of the 
Rad51:BRCA2 interaction in this organism.164 L. infantum BRCA2 ortholog (LiBRCA2) was 
shown to be critical for maintaining genomic integrity in the protozoan, as LiBRCA2-null 
mutants displayed a decreased growth phenotype, impaired homologous recombination and 
chromosomal instability.164 Moreover, in the absence of LiBRCA2, L. infantum Rad51 
(LiRad51) was not able to localise to the nucleus. In vitro, LiBRCA2 was shown to promote 
LiRad51:ssDNA binding and D-loop formation, and inhibit LiRad51:dsDNA binding. 
Moreover, an N-terminal fragment of LiBRCA2, containing the only two BRC repeats 
(LiBRC1 and LiBRC2), likewise stimulated ssDNA NF formation.164  
In this chapter, I set out to investigate the LiBRC:LiRad51 interaction in L. infantum to 
build upon the findings described above. I conduct a detailed examination of the structural 
determinants of LiBRC repeat binding and show that novel structural features define this 
interaction.  
5.2 Sequence analysis of orthologous BRC repeats highlights 
potential differences in binding 
Sequence alignment and comparison of conserved amino acids is a simple yet powerful 
approach to detect critical sequence features with functional roles. In order to evaluate the 
possible ways in which protozoan parasite BRC repeat binding to Rad51 might differ from 
those in human and other orthologs, repeat sequences from a set of representative model 
organisms were aligned with the BRC repeats from several important protozoan parasites. 
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Sequence conservation for the alignment was then quantitively evaluated using the 
BLOSOM62 scoring matrix (Figure 37). As anticipated, the Phe and Ala residues of the FxxA 
motif are almost universally conserved and are amongst the highest-scoring residues. 
Interestingly, a number of repeats contain a glycine instead of an alanine at the FxxA domain 
in several evolutionarily distant species, such as Ustilago maydis, where it is found on the 
single BRC repeat, and L. infantum BRC2. Another highly conserved feature is the SGK/R 
motif that forms the β-hairpin of the FxxA module, as observed in the structures of HsBRC4 
and HsBRC8-2 (positions 13-15 in Figure 37). In particular, the high conservation of glycine 
is indicative that the β-turn is maintained across highly divergent organisms as a universal 
structural feature. C-terminal from the β-turn, a ΦxΦ motif can be identified, consisting of two 
conserved hydrophobic residues (Φ) separated by a non-conserved, solvent-exposed residue 
(positions 17-19 in Figure 37). Although the two hydrophobic residues are not buried within 
pockets like in the FxxA and LFDE motifs, their high conservation suggests that the continuous 
interface formed by these aliphatic side chains is crucial for the folding and binding of repeat. 
Unexpectedly, at the LFDE motif, the first residue (position 30 in Figure 37) appears to be 
rather poorly conserved. Instead, closer examination of sequences reveals that the protozoan 
organisms included in this analysis have charged or polar residues at this position, whereas in 
the so-called higher eukaryotes it is always occupied by a hydrophobic amino acid. 
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Figure 37. Sequence alignment of BRC repeats from a set of representative organisms and protozoan parasites. 
The grey bars on top represent BLOSUM62 alignment scores. Conserved residues are coloured using the default 
ClustalX colour scheme.  
5.3 Purification of the L. infantum Rad51 ATPase domain  
To investigate the interactions between the two L. infantum BRC repeats and LiRad51, 
a monomeric version of LiRad51 was necessary, as the oligomeric full-length protein is not 
suitable for biophysical and crystallographic studies of BRC repeat binding due to competition 
with self-oligomerisation and conformational heterogeneity. Purification of the ATPase 
domain of LiRad51 lacking the OE and the NTD was therefore attempted. The sequence 
corresponding to LiRad51 residues 134-376 (LiRad51ATPase, Uniprot: A4I3C9_LEIIN, Figure 
38A) was codon-optimised for expression in E.coli, synthesised and cloned into pHAT2 
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bacterial expression vector containing an N-terminal His8-tag. Small-scale expression tests 
showed that the protein can be produced in soluble form when expression is induced overnight 
at 15 °C. Scaling up to a larger culture volume and IMAC with Ni-NTA resin resulted in high 
amounts of purified protein, however, the product formed a viscous solution immediately after 
elution, followed by precipitation of insoluble aggregates.  
 
Figure 38. Purification of monomeric LiRad51 ATPase domain. (A) Schematic drawing of domain organisation 
of full-length LiRad51 and LiRad51ATPase. An N-terminal putative disordered region is depicted in white. (B) 
Differential scanning fluorimetry of LiRad51ATPase with sulphate and phosphate additives. All reactions were done 
with IMAC-eluted LiRad51ATPase in 50 mM Tris pH8.0, 150 mM NaCl. (C) Size-exclusion chromatography trace 
with LiRad51ATPase monomeric peak eluting at around 75 ml.  (D) Coomassie-stained SDS-PAGE gel of fractions 
from the run shown in (C). 
To improve solubility, I carried out a screen of stabilising buffer components using 
differential scanning fluorimetry (DSF). A 96-well format standardised screen available in our 
lab was used that covers a range of pH values, buffers, salts and additives that can improve the 
stability of the protein in solution. The fitted ΔTm values suggested that the monomeric 
LiRad51ATPase is stabilised by phosphate and sulphate anions. In a subsequent buffer 
optimisation, lithium sulphate exerted a very large thermal shift in a concentration-dependent 
manner (Figure 38B). Crystallographic studies have shown that free inorganic phosphate can 
bind the Rad51 P-loop in place of nucleotide phosphates. It is possible that both phosphate and 
the similarly tetrahedral sulphate anions exert their stabilising effect through this interaction. 
Alternatively, it is also possible that the anions stabilise the protein surface elsewhere. Informed 
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by this result, sulphate was included in the purification, which, gratifyingly, enabled the 
production of stable LiRad51ATPase in >10 mg quantities (Figure 38C,D). 
5.4 LiBRC1 binds LiRad51 more strongly than LiBRC2 
To qualitatively evaluate the interaction between the two L. infantum BRC repeats and 
LiRad51, an affinity co-precipitation assay was done using proteins expressed in E. coli. The 
two BRC repeats were cloned into the pPEPT1 expression vector, harbouring an N-terminal 
StrepTag-GB1 fusion and a C-terminal His8-tag. All GB1 fusion constructs were expressed in 
10 ml E. coli cultures and their bacterial lysates were loaded on Ni-NTA resin, followed by 
application of similarly prepared LiRad51ATPase lysate. Imidazole-eluted fractions were 
analysed by SDS-PAGE (Figure 39B). It is evident that LiBRC1 pulls down LiRad51ATPase in 
stoichiometric amounts, suggesting a strong interaction, whereas only trace amounts of 
LiRad51ATPase are seen in the LiBRC2 pull-down.  
To enable the routine measurement of affinities for ligands binding at the LiRad51 
ATPase domain, I developed a fluorescence polarisation (FP) assay based on the LiBRC1-
LiRad51 interaction. For this, I prepared a fluorescently-labelled LiBRC1 peptide by 
conjugating a fluorescein fluorophore using cysteine-maleimide chemistry. Direct FP titration 
of LiRad51ATPase into this probe gave a KD of 0.165 μM (Figure 39C). Competition 
experiments using purified GB1 fusion constructs were then set up, giving KD values of 0.29 
μM and 13.55 μM for GB1-LiBRC1 and GB1-LiBRC2, respectively (Figure 39D). The 
competition FP measurements together with the pull-down data strongly indicate that LiBRC1 
is a higher affinity repeat, and LiBRC2 a much weaker binder. Moreover, the affinity for 
LiBRC1 was significantly lower than the nanomolar KD values reported for high affinity human 
BRC repeats. To exclude fusion partner-induced effects, I also prepared LiBRC1 as a free 
peptide and measured its binding to LiRad51 using ITC, which gave a KD of 0.65 μM, 
excluding the possibility that the GB1 tag is detrimental to binding. 
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Figure 39. LiBRC1 is a more potent binder of LiRad51 than LiBRC2. (A) Sequence alignment of the two L. 
infantum BRC repeats with HsBRC4, and point mutants LiBRC1.1 and LiBRC2.1. Competition FP binding results 
are shown on the left. (B) Coomassie stained SDS-PAGE gel analysis of L. infantum BRC repeat affinity pull-
down of LiRad51ATPase (C) Direct FP titration of LiRad51ATPase into fluorescein-tagged LiBRC1 (5 nM). Data 
shown are the means of triplicate measurements ± SD.  (D) Competition FP titrations of GB1-fused LiBRC1 and 
LiBRC2. Fluorescently-labelled LiBRC1 probe (5 nM) was pre-incubated with 500 nM LiRad51ATPase, to which 
GB1-LiBRC dilution series were added. Data shown are the means of triplicate measurements ± SD.  (E) ITC 
binding measurement of LiBRC1 peptide binding to LiRad51ATPase.  
With an KD of 13.55 μM, LiBRC2 is a much weaker binder than LiBRC1. Previous 
studies on human repeats have shown that BRC5 is the lowest affinity repeat within BRCA2, 
which has been rationalised by the mutation of an alanine to a serine in the FxxA motif of 
BRC5. I hypothesised that the same effect may be responsible for the decreased affinity in 
LiBRC2, which harbours a glycine instead of the alanine at the equivalent position. To test this, 
Pantelejevs, T.  BRC:Rad51 interaction in Leishmania infantum 
 96 
a rescue mutant was prepared with the alanine re-introduced (LiBRC2.1, Figure 39A). 
However, this did not bring about any significant increase in affinity, resulting in a similar KD 
of 10.39 μM. This lack of effect prompted me to further investigate the role of the FxxA alanine 
in binding, and an FxxG mutant of LiBRC1 was prepared (LiBRC1.1, Figure 39A). A threefold 
decrease in KD was observed for this mutant, suggesting that, while the methyl group of the 
FxxA alanine contributes to binding, it is not essential in some contexts. It is thus reasonable 
to suggest that other factors besides the loss of alanine from the FxxA motif are responsible for 
the low affinity of LiBRC2. For example, LiBRC1 Ser117 is likely involved in the stabilisation 
of the β-turn at the FxxA module, analogously to HsBRC4 and HsBRC8-2, and the equivalent 
position corresponds to an arginine in LiBRC2, which would not be able to mediate such an 
intra-molecular contact. 
5.5 LiBRC1 binding studied by X-ray crystallography 
 
To date, there are only two BRC:Rad51 complex structures available in the public 
domain: the BRC4 complex reported by Pellegrini et al.80 and the BRC8-2 structure presented 
in Section 2.3 X-ray crystallographic study of BRC8-2. Only a handful of reports investigate 
BRC repeat binding in organisms other than humans and no structural or biophysical studies 
have been presented. Motivated by the potential for targeting the BRCA2:Rad51 axis in 
protozoan diseases, I set out to determine the LiBRC1:LiRad51 complex structure by X-ray 
crystallography. 
 To reduce the flexibility and conformational heterogeneity of the complex, I designed 
a deletion mutant of the LiRad51 ATPase domain by removing the DNA-binding loop L2, 
which in the absence of DNA is typically disordered (LiRad51ATPase,ΔL2, Figure 38A). The L2 
loop is not involved in the binding of BRC repeats by Rad51, as it is located distal to the 
interaction interface. The LiBRC1:LiRad51 complex was purified from E. coli by IMAC co-
precipitation, in an analogous manner to the HsBRC8-2 complex presented in Section 2.3. 
Crystallisation trials were performed in 96-well MRC plate format using a variety of 
commercial sparse-matrix screens and varying conditions such as protein:precipitant volumes 
and addition of ADP/Mg2+ cofactors. A single crystal was obtained, for which a full diffraction 
dataset was collected to 2.15 Å resolution. Initial phase determination of the structure factors 
was done using molecular replacement with Pyrococcus furiosus RadA ATPase domain as a 
search model (PDB: 4A6P). After several rounds of refinement, positive electron density 
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difference was clearly observed for the LiBRC1 peptide and the binding mode could be 
determined (Figure 40A).  
The overall fold of the LiBRC1 peptide is similar to what has been reported for HsBRC4 
(Figure 40B). The Phe113 and Ala116 hot-spot residues bind the two hydrophobic FxxA site 
pockets on the ATPase domain in an identical manner to BRC4. The β-turn, mediated by 115-
TASGK-119, is also preserved and closely resembles the human BRC4 in its hydrogen-
bonding pattern, with a Thr115 side-chain stabilising the turn through hydrogen bonding. 
Remarkably, an extended β-hairpin fold, akin to the one determined for the BRC8-2 repeat 
(Section 2.3), is also formed by the LiBRC1 peptide (Figure 40B). A Thr111 residue, 
positioned at -2 to the FxxA motif, mediates a hydrogen bonding network that allows the 
peptide to fold back on itself, similarly to Ser2056 in the HsBRC8-2 structure (Figure 40C). 
The Thr111 side-chain hydroxyl forms stabilising hydrogen bonds with the Phe113 and Val121 
backbone amides from the two anti-parallel strands of the hairpin. The methyl group of Thr111 
side-chain is accommodated by a less bulky Val123 in LiBRC1, compared to BRC4 Ile1534 
(Figure 40C).  Remarkably, the extended β-hairpin fold promotes the LiBRC1 peptide to fold 
into a small hydrophobic core mediated by the side-chains of LiBRC1 Val109, Thr111, Val123 
and Leu128, as well as LiRad51 surface residues Leu241, Gln242, Ala245, Met246 (Figure 
40C). Leu112, which precedes Phe113, forms additional hydrophobic contacts with a 
hydrophobic cleft formed by LiRad51 His235, Leu239 and Gln242. The sum of these 
observations suggest that LiBRC1 forms considerably more hydrophobic interactions at the 
FxxA site compared to the previously elucidated human repeats.   
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Figure 40. Crystal structure of LiBRC1 in complex with LiRad51ATPase. (A) LiBRC1 peptide 2Fo-Fc electron 
density map at 1σ (B) Overall binding mode of LiBRC1 superposed with HsBRC4 and HsBRC8-2. (C) Detailed 
view of the extended β-hairpin fold formed by LiBRC1 (D) Arg124-mediated electrostatic contacts with LiRad51, 
further stabilised by a hydrogen bond with Ser127. 
The α-helix of the LiBRC1 LFDE module starts with a cationic Arg124 residue that 
forms electrostatic contacts with LiRad51 Glu249 side-chain (Figure 40D). A similar 
interaction has not been observed for HsBRC4 or HsBRC8-2, despite HsRAD51 also 
containing a glutamate at the equivalent position. Ser127, which is one helical turn away from 
Arg124, also interacts with Glu249, in a manner that resembles Ser1538 from HsBRC4. 
Remarkably, the LiBRC1 LFDE module has no electron density defined beyond residue 
Gln129. This observation was not anticipated, as previous work has stressed the importance of 
the C-terminal LFDE module for BRC repeat binding.81 In particular, the hot-spot residues of 
the LFDE motif, corresponding to RLGD in LiBRC1, have been shown to be critical for the 
binding of BRC4 in vitro and the function of BRCA2 in cells,81 yet, in the case of LiBRC1,  
these residues have no discernible electron density even after the rest of the peptide has been 
modelled and several rounds of refinement done. In a crystallographic system there is always 
a possibility that the binding mode is distorted by lattice packing artefacts, for example, to 
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accommodate steric clashes with nearby molecules. Upon closer examination of the packing 
environment around the LFDE interface, a sufficiently large solvent channel is formed around 
the expected LFDE-binding region was observed and no unmodelled electron density seen 
elsewhere, suggesting that the peptide C-terminus is disordered. To ensure that the peptide was 
not degraded by bacterial proteases during purification, the complex was analysed by protein 
LCMS, and the full-length species were identified (Appendix 8.3 Protein LCMS spectrum of 
LiBRC1:LiRad51 complex). 
 
Figure 41. LFDE motif binding is not observed in the LiBRC1:LiRad51 crystal structure. (A,B) Comparison of 
the binding mode of C-terminal LFDE motif residues in (A) HsBRC4 and (B) LiBRC1. The difference in 
hydrophobic pocket depth is clearly apparent. (C,D) Comparison of the residues involved in the formation of the 
LFDE-binding cognate hydrophobic pockets in (C) HsRAD51 and (D) LiRad51.  
The crystal structure suggests a binding mode for LiBRC1 in which the LFDE motif 
does not form critical contacts with the ATPase domain. Comparison of the LiRad51ATPase 
surface at the LFDE interface with that of the human RAD51 reveals structural features that 
further corroborate this hypothesis (Figure 41). The LiRad51 surface region corresponding to 
the pocket on HsRAD51 where BRC4 Leu1545 and Phe1546 bind, presents a significantly 
more shallow cavity compared to HsRAD51(Figure 41A,B). The different topology results 
from several mutations in the LiRad51 protein relative to HsRAD51. A Tyr205 in the human 
protein stacks on top of the Phe1548 side-chain, creating a tight pocket for the phenyl group. 
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This is mutated to Leu241 in LiRad51, a side-chain that is unable to provide equivalent buried 
area (Figure 41C,D). Instead, Leu241 interacts with the hydrophobic core described above, 
formed by the more N-terminal LiBRC1 residues. Similarly, Met251 in HsRAD51 corresponds 
to Ser287 in LiRad51, leading to a less pronounced hydrophobic cavity at the LFDE site. 
In sum, the crystallographic structure of the LiBRC1:LiRad51 complex reveals a BRC 
repeat binding-mode defined by the following novel structural features: an extended β-hairpin 
at the N-terminus of FxxA module, a small hydrophobic core formed by a number of sequence-
distant residues, and a lack of any interaction with LiRad51at the C-terminal LFDE motif.  
5.6 C-terminal LiBRC1 residues are not critical for binding 
The crystallographic model prompted me to further investigate the importance of C-
terminal LiBRC1 residues for binding. For this, a set of LiBRC1 mutant constructs were 
designed and purified as fusions to an N-terminal GB1-tag and a C-terminal His8-tag (Figure 
42). These were tested in the FP competition assay described above. Two mutants with 
extended N- or C- termini containing additional residues from the full length LiBRCA2 protein 
were first evaluated to account for the possibility that the initial choice of cut-off failed to 
capture enough of the repeat sequence (LiBRC1.2 and 1.3). Little change in affinity was 
observed for these longer repeats, which validates the initially delineated repeat boundaries.  
 
Figure 42. L. infantum BRC repeat constructs were purified and tested for LiRad51ATPase binding in an FP 
competition assay.  Columns on the left show fitted FP assay IC50 values ± SE of fit and calculated KD values.  
I then proceeded with a step-wise deletion approach, in which 1-2 residue fragments 
were sequentially removed from the C-terminus to map the binding contributions of the LFDE 
module, a significant part of which lacks any electron density in the crystal structure of the 
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complex. Interestingly, C-terminal deletions were tolerated without significant loss of affinity 
up to, and including, removal of Arg134 (LiBRC1.7, Figure 42). This implies that the 134-
RLGD-137 tetrad, whose residue positions correspond to the canonical LFDE motif in humans, 
is not critical for the binding of L. infantum BRC1 repeat to the LiRad51 ATPase domain.  
The most C-terminal residue observed in the crystal structure is Gln129. Further 
truncations up until this residue result in a gradual decrease in affinity, reaching a KD of 8.7 
μM for LiBRC1.11, signifying an important contribution to binding by the 130-KVAE-133 
tetrad, which is likewise not seen in the crystal structure. Removal of LiBRC1 Glu133 causes 
a more than four-fold drop in KD, implying that this residue makes a significant contribution to 
binding (LiBRC1.8, Figure 42). It is not immediately apparent from the complex structure how 
this residue may contribute to binding, as there are no nearby LiRad51 side-chains bearing a 
positive charge to form salt bridges with. It is possible that, rather than interacting with 
LiRad51, it stabilises the repeat conformation, for example, by interacting with the cationic 
Lys130 on the same helical face or by stabilising the overall charge of the peptide. 
Bulk removal of the remaining helical residues 125-RESLQ-129 diminished binding 
even further, resulting in only residual displacement of the FP probe at the highest ligand 
concentrations in the assay. It is likely that this drop is to a large extent caused by the loss of 
of Leu128, which contributes to the hydrophobic core that is formed at the edge between the 
β-hairpin and the α-helix of LiBRC1.  
To confirm these sequence-activity relationships in the context of the full-length 
LiRad51 protein, I performed electrophoretic mobility shift assays (EMSA), in which LiBRC1 
and its truncation constructs LiBRC1.7, 1.9 and 1.11 were tested for their ability to inhibit the 
formation of LiRad51-ssDNA nucleoprotein filament. Both LiBRC1 and LiBRC1.8 inhibited 
NF formation in a dose-dependent manner to comparable levels (Figure 43, top). In line with 
the FP measurements, LiBRC1.10 and 1.12 were much less potent inhibitors of NF formation 
(Figure 43, bottom).  
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Figure 43. EMSA competition assay evaluating the ability of LiBRC1 truncation mutants to inhibit LiRad51 
nucleoprotein filament formation. 5 μM LiRad51 was pre-incubated with GB1-fused LiBRC1 or its truncation 
mutants, after which FAM-labelled ssDNA (dT60, 100 nM) was added to the reaction. Products were resolved on 
a 1xTBE native 2% agarose gel.   
5.7 Discussion 
 
In this chapter, I have shown that the two BRC repeats from the L. infantum BRCA2 
ortholog bind the LiRad51 ATPase domain, with LiBRC1 manifesting an almost 50 times 
higher affinity than LiBRC2, as measured by an FP competition assay. This represents the first 
instance where the BRC repeat:Rad51 interaction is confirmed for a non-human BRCA2 
ortholog. Depending on the assay, LiBRC1 bound LiRad51ATPase with KD in the range of 165-
650 nM, which is at least several times weaker than what has been previously reported for the 
tightest-binding human repeat BRC4. A crystal structure of the LiBRC1:LiRad51ATPase complex 
was determined and revealed that LiBRC1 residues 134-RLGD-137, corresponding to the 
conserved LFDE motif in humans, do not form ordered contacts with LiRad51ATPase. 
Subsequent truncation mutagenesis experiments confirmed that, indeed, this C-terminal region 
of LiBRC1 is not critical for binding.  
Comparative analysis with the human proteins can help rationalise the lack of 
interaction observed for the 134-RLGD-137 tetrad from the point of view of the repeat 
sequence, or, alternatively, by looking at the complementary surfaces formed by the ATPase 
domains. The human BRC repeat LFDE motifs are defined by two strongly conserved features. 
First, two bulky hydrophobic residues, such as Trp, Leu, Phe and Val, are conserved at tthe 
first two positions of the motif in all the human repeats. Secondly, an acidic residue at the last 
position forms a salt-bridge with Arg250 or other nearby arginines on human RAD51. The 
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shape of the first two side-chains appears to be less critical than their hydrophobic nature, as 
evidenced by the different combinations seen in the eight human BRC repeats. Moreover, 
Rajendra and Venkitaraman showed that exchange of one hydrophobic residue for another is 
not disruptive for binding, and can in fact bring about improved affinity, such as when Leu1545 
is replaced by a tryptophan in HsBRC4.81 In LiBRC1, on the other hand, there is just a single 
hydrophobic residue present in the tetrad that corresponds to the LFDE motif, which drastically 
reduces the buried hydrophobic surface area attainable upon binding. Buried hydrophobic 
contacts tend to contribute significantly to free energy of binding in protein-protein 
interactions, therefore it is reasonable to assume that the RLGD tetrad would result in a weaker 
energetic contribution, even if compensatory contacts, for example, a salt bridge involving 
Arg134, were present. The cognate surface of the LiRad51 ATPase domain also appears less 
conducive to the binding of an LFDE-like moiety, as the hydrophobic pockets are less 
pronounced.  
Remarkably, the repeat manifests nanomolar binding despite lacking the LFDE-like 
interaction. Unlike HsBRC4, the N-terminus of LiBRC1 peptide forms an extended β-hairpin, 
which results in a hydrophobic core folding on top of the ATPase domain surface, as well as 
hydrophobic contacts formed by a nearby Leu112. I propose that these additional hydrophobic 
interactions partially compensate for the lack of a functional LFDE motif and ensure a high 
affinity interaction for the L. infantum BRCA2 ortholog to localise Rad51 to the sites of DNA 
damage and stimulate nucleofilament formation on resected ssDNA. The case of LiBRC1 
therefore presents a distinct mode of BRC repeat binding for the evolutionary distant L. 
infantum. Interestingly, the sequence distance between the two BRC repeats in the L. infantum 
BRCA2 ortholog is much smaller than in human BRCA2, that is, ~6 residues, depending on 
where repeat boundaries are defined. This means that, in order for the protein to engage more 
than one Rad51 molecule simultaneously, as has been previously shown for BRCA2, the C 
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6 Conclusions and future directions 
6.1 Structural insights into the RAD51:BRCA2 axis 
Mechanistic details of how BRC repeats exert their function in the context of the full-
length BRCA2 protein are not clear, but the interaction has been described for isolated repeats. 
In evolving eight anciently divergent BRC repeats in mammals, Nature has provided a pool of 
sequences with varying binding properties. In work leading to this dissertation, systematic 
shuffling of these sequences revealed module-specific contributions to affinity and yielded 
chimeric repeats with improved binding affinities over any of the natural sequences.  
Intrigued by these findings, in this work I have elucidated novel structural features that 
define the binding of BRC repeats, advancing our understanding of homologous 
recombination. In the crystal structure of BRC8-2, an extended β-hairpin, mediated by a 
Ser2056 at -2 positions to the FxxA motif, encompasses a much larger N-terminal boundary of 
the repeat to what has been previously delineated as important for binding.80 Remarkably, an 
almost identical structural feature, mediated by a Thr111 at the analogous -2 position, was also 
observed in my subsequent investigation of the L. infantum BRC1:Rad51 complex. In the case 
of L. infantum, the β-hairpin permits the formation of additional hydrophobic contacts by the 
repeat, and I propose that this structural feature achieves high-affinity binding in the absence 
of a functional LFDE motif. It is possible that other repeats harbouring a hydroxyl-containing 
Ser/Thr at -2 to FxxA will form such a structural feature in other organisms. For example, the 
human BRC3 carries a threonine at the analogous position and its FxxABRC3 module has the 
second-highest average energetic contribution to binding after FxxABRC8 (ΔΔG = -0.35 and -
0.96 kCal/mol, respectively), which further substantiates a role for this residue in high-affinity 
binding. In Arabidopsis, two out of four repeats have a Thr at this position, four out of six in 
P. falciparum, while trypanosomatids (Leishmania and Trypanosoma species) have it in all of 
their BRC repeats.  
By investigating the BRC:Rad51 interaction in L. infantum, I have demonstrated that 
the C-terminal region of BRC repeats, and in particular the LFDE motif, is not a universal pre-
requisite for high-affinity binding, despite previous reports demonstrating that it is 
indispensable for a functional RAD51:BRCA2 interaction in human cells.81 It is intriguing why 
such differences have evolved in these phylogenetically distant organisms. Homologous 
recombination has to be carefully balanced, and perhaps by evolving alternative determinants 
of BRC binding affinity, an organism can fine-tune BRCA2 ortholog activity at the protein 
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level. An important question then arises: is affinity the only determinant of BRC repeat 
function? Carreira and Kowalczykowski have shown that human BRC1-4 have a distinct set of 
functions from BRC5-8.107 Several reports, including the microfluidic FP experiments 
discussed in Section 1.7, have confirmed that BRC1-4 have higher affinities over BRC5-8. It 
therefore appears that affinity is indeed the main determinant of function. The BRC8-2 repeat 
would provide an interesting case for testing this, as it is a structurally and biophysically 
described high affinity binder with constituent modules from both groups of repeats. If affinity 
is the only determinant of function, then BRC8-2 is expected to behave like BRC repeats 1-4, 
whereas the low affinity BRC2-8 will functionally resemble repeats 5-8. 
 Previous work has shown that BRC repeats as individual molecules are inhibitory to 
nucleofilament formation and strand exchange but become stimulatory when part of a larger 
multivalent system, such as the BRCA2 protein or dimeric GST fusions. Shivji et al. have 
demonstrated that a BRCA2 fragment encompassing the eight BRC repeats (BRCA2BRC1-8) 
binds and stabilises the Rad51-ssDNA NF, and stimulates strand exchange.165 It is not clear 
how such a multivalent system binds the NF without disrupting it by displacement of the 
oligomerisation epitope. Perhaps the interaction is mediated via a different set of high-avidity 
interactions that are not in direct competition with FxxA-mediated RAD51 oligomerisation. 
One possibility is that the LFDE module residues may mediate this interaction, since they bind 
outside the FxxA site. Superposing the BRC4:RAD51 complex with the nucleofilament 
structure suggests that this binding mode may be permissible and would only require a shift in 
the flexible N-terminal domain (Figure 9D). Interestingly, in the study by Carreira and 
Kowalczykowski, BRC5 was found to be the most potent stimulator of Rad51-ssDNA complex 
formation, while the repeat shuffling experiments show that it has the weakest-binding FxxA 
module.107 BRC8, on the other hand, was the least potent NF stimulator in the weak-affinity 
BRC5-8 set, while having the tightest-binding FxxA module and the second-weakest LFDE 
module, as shown by the shuffling experiments. This suggests that the nucleoprotein filament-
stabilising function is LFDE-module dependent and is in counteracted by inhibitory nature of 
the repeat as a whole. It is possible that the two BRC repeats in L. infantum have similarly 
differentiated roles. LiBRC1 may be the high affinity repeat, equivalent to HsBRC1-4, that 
sequesters Rad51 to ssDNA and increases nucleation, the weaker-binding LiBRC2 may then 
stabilise the nascent nucleofilament.  
The work presented here provides an improved structural understanding of modular 
contributions to binding. Future studies should investigate the functional consequences of BRC 
repeat modules in more detail. For example, it would be interesting to see if the high-affinity 
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LFDEBRC2 module in isolation or as multimeric species may be able to bind and stabilise the 
NF in the absence of an FxxA module.  
6.2 A novel way of screening stapled peptides 
Understanding the structural basis of protein-protein interaction can inform drug 
discovery efforts, and the binding epitopes can themselves serve as templates for inhibitor 
design. In this work, I have utilised the high affinity BRC8-2 repeat for the development of 
stapled peptide RAD51 inhibitors. In order to test different stapling architectures, I developed 
a work-flow for the recombinant preparation and early-stage screening of stapled peptides and 
tested its applicability to RAD51. The approach demonstrates that stapled peptides can be 
prepared and evaluated in a laboratory that lacks organic synthesis facilities. Moreover, this 
method allows parallelisation, since HPLC purification, which can be a bottleneck for SPPS, 
is not required. The overall cost of consumables and reagents is also likely to be smaller. The 
described methodology can be applied to a range of therapeutic targets. It will be most suitably 
applied to similar cases, where a high affinity linear epitope can be extracted from a PPI.  
More work is needed to evaluate the scope of the stapled peptide screening approach. 
For example, is it translatable to other types of Cys-reactive chemistries?  Dibromoxylene 
linkers have been utilised to introduce a shorter, more constrained cysteine staple that is most 
optimal for a single helical turn (i,i+4),166 yet it is unclear if one can achieve the same product 
purity with these alternative linkers as was done with divinyls. It is also not clear if non-helical 
moieties can be stapled efficiently with other linkers, as was shown here. Depending on the 
target, the range of downstream screening assays can likewise be expanded. For example, in 
vitro assays such as Förster resonance energy transfer (FRET), homogenous time-resolved 
fluorescence (HTRF) and AlphaScreen (PerkinElmer), among others, should in principle be 
compatible with the work-flow.  
6.3 Targeting RAD51 with a new modality 
One of the main challenges of contemporary drug discovery is the so called 
“undruggable” proteome, defined by targets that are not easily addressable by conventional 
small-molecule approaches. Until recently, RAD51 could be classified as undruggable due to 
the physicochemical nature of the interactions that need to be disrupted in order to inhibit it. 
The recent report of a small-molecule compound targeting the FxxA site to inhibit RAD51 
function represents a ground-breaking step in drugging this target.117 Here, I have shown for 
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the first time that an alternative modality – stapled peptides – can be employed to this end. The 
in vitro and structural analyses reported here support the application of stapled peptide based 
on BRC repeats towards disrupting RAD51:BRCA2 and RAD51:DNA interactions. Cellular 
experiments with the reported peptides are still in progress and will be the ultimate measure of 
utility for these molecules.  
I anticipate that the results presented here will motivate further efforts of targeting 
RAD51 with macrocyclic peptides. Follow-up work should focus on optimisation of the 
various pharmacological properties of stapled BRC repeats to ensure target occupancy in vivo. 
Increasing affinity is the most obvious direction, because low- or sub-nanomolar affinities can 
allow even poorly permeable peptides to achieve high target engagement. The molecules 
developed in this work present plenty of avenues for increasing affinity, such as those discussed 
in Section 3.9. Structural information from orthologous repeats can also be utilised to design 
additional interactions. For example, a salt bridge was observed between LiBRC1 Arg124 and 
LiRad51 Glu249, which may be re-capitulated in BRC8-2 by mutating the equivalent Ser1230 
to an arginine, since there exists a reciprocal surface glutamic acid on HsRAD51. Moreover, 
decreasing size of the peptides can improve their membrane permeability. The observation that 
LiBRC1 does not need the LFDE motif for high affinity binding is encouraging, since it 
suggests that BRC8-2 may be further truncated at the C-terminus, granted that compensatory 
binding features are introduced elsewhere, resulting in a significantly smaller molecule. For 
example, one may attempt to recreate the additional hydrophobic contacts observed in LiBRC1. 
Double stapling may be pursued further to improve proteolytic resistance and even allow for 
oral delivery in vivo. For example, in a study of HIV fusion inhibitors, hydrocarbon double-
stapling of 37-residue peptides resulted in remarkable oral bioavailability profiles in mice.167 
Generalised rules have been applied for hydrocarbon stapling of helical motifs, such as 
which aliphatic side-chain lengths are most appropriate for each inter-residue distance.149 For 
less regular structural motifs, however, bespoke design is required. In this study, structure-
guided design was paramount to the successful application of stapling to a diverse set of staple 
architectures. In future development of RAD51-targeting peptides, in silico methods, such as 
molecular dynamics simulations, may be applied to evaluate in advance a much larger initial 
library of peptides, which can then be triaged into a smaller set to be prepared synthetically. 
This would allow for the early identification of stapling architectures that are conducive to high 
affinity binding. 
The increasing amount of structural and biophysical data on targeting Rad51 and other 
poorly-druggable proteins may be utilised for a more multi-faceted approach of probe design. 
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For example, previously identified fragment hits could be integrated into bespoke unnatural 
amino acids and incorporated into stapled peptides for more efficient binding. Combining the 
expanding toolkit of different chemical and biological methods will enable the development of 
more sophisticated ways of targeting the high-hanging fruit of the proteome.  
7 Materials and methods 
7.1 Vectors for bacterial expression of peptides 
Throughout this work, peptides were recombinantly expressed in E. coli as fusions to a 
GB1 tag, a protein domain derived from the streptococcal protein G that manifests high 
solubility and superior expression levels. For this purpose, three expression vectors were 
employed: pEXP-NHis-GB1 (Dr Aleksei Lulla, unpublished, Addgene #112565), pOP3BT (Dr 
Marko Hyvönen, unpublished, Addgene #112603) and pPEPT1. pOP3BT and pEXP-Nhis-
GB1 were previously developed at our lab and available in-house. pPEPT1 was designed and 
constructed during the project. Plasmid sequence and map for pPEPT1 is shown in Appendix 
8.4. 
7.2 Sequence and ligation independent cloning (SLIC) of BRC repeat 
peptides 
Peptide-coding DNA inserts were designed using the DNAWorks online application,168 
while optimising codon usage for E. coli expression. DNA oligonucleotides for the assembly 
of these fragments were generated using the same software and 15-20 nt linkers were appended 
to the 5' ends of the outermost forward and reverse oligos for sequence and ligation independent 
cloning (SLIC). The inserts were then synthesised by assembly PCR using Pfusion DNA 
polymerase (New England Biolabs) with standard reaction conditions. Each assembly PCR 
reaction contained 1 μM of the outermost oligos and 0.02 μM of each internal oligo. Inserts 
were then purified by gel extraction using the GeneJet gel extraction kit (Thermo Scientific). 
For each of the peptides, all of the oligos as well as the recipient vector digest, are provided in 
Appendix 8.5  Oligonucleotides for assembly PCR and cloning. 
10 µl SLIC reactions were prepared as follows: purified insert at 2-10 ng/μl (final), cut 
vector at 4-20 ng/μl (final), 1x NEB Buffer 2.1 (New England Biolabs). Then, 0.2 µL (0.6 U) 
of T4 DNA polymerase (New England Biolabs) was added to each reaction and incubated for 
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1-5 min at RT, after which 1 µl of 100 mM of either dGTP or dCTP was added to stop the 
exonuclease activity. Reaction was further incubated for 1 minute at RT, after which it was 
heated for 5 minutes at 65 °C to deactivate the T4 polymerase, after which the PCR tubes were 
left at room temperature for 10-20 minutes for the complementary resected ends of the insert 
and vector to anneal. Whole reaction mixtures were then used to transform chemicompetent 
T7Express E. coli cells (prepared in-house from a New England Biolabs stock). Correct clones 
were then determined by colony PCR and Sanger sequencing. 
7.3 Sequence and ligation independent cloning of LiRad51 constructs 
LiRad51-coding (Uniprot: A4I3C9_LEIIN) gene was codon optimised for expression 
in E. coli and purchased as a synthetic gene from ThermoFisher. The full sequence of the 
synthetic gene is provided in Section 8.6 LiRad51 synthetic gene. LiRad51 construct inserts 
were prepared by PCR, using the synthetic gene as template. All of the vectors, primers and 
restriction enzymes are provided in Appendix 8.5  Oligonucleotides for assembly PCR and 
cloning. Full-length LiRad51 was cloned into pEXP-MBP as fusion to N-terminal His8-MBP. 
LiRad51ATPase was cloned into pHAT2 as fusion to an N-terminal His8-tag. LiRad51ATPase,ΔL2 
was cloned into pBAT4, lacking any fusion tags. SLIC cloning was done in an identical manner 
to Section 7.2 Sequence and ligation independent cloning (SLIC) of BRC repeat peptides. 
7.4 Purification of monomeric HumRadA22 
Humanised archaeal surrogate protein HumRadA22 is based on the monomeric ATPase 
domain of PfRadA. A glycerol stock of BL21(DE3) E. coli carrying a pBAT4 vector with a 
HumRadA22 insert lacking any expression tags was provided by Dr Marko Hyvönen. The 
construct has been described previously.111 These cells were plated on LB agar supplemented 
with ampicillin (100 μg/ml) and grown overnight at 37 °C. Next day, cells were scraped and 
used to inoculate 1L 2xYT medium. Liquid media cultures were grown for 3-5 h until OD600 = 
1, after which expression was induced with IPTG (400 μM) for 3 hours at 37 °C. After protein 
expression, cells were centrifuged at 4000 g for 25 min and resuspended in 25 ml of buffer A: 
20 mM MES pH 6.0, 1 mM EDTA and stored at -20 °C for later use. 
Frozen cells were thawed and lysed either using an Emulsiflex homogeniser (Avestin) 
or by sonication. Lysates were kept on ice. Lysate was centrifugated at 35000 xg for 40 min 
and soluble fraction was removed with a 25 ml serological pipette, and was filtered using a 40 
μm syringe filter. The lysate soluble fraction was loaded on a HiTrap SP HP 5 ml column 
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(Cytiva), which was then washed with 5 CV buffer A. 10-20 CV gradient of buffer B (20 mM 
MES pH 6.0, 1 mM EDTA, 1 M NaCl) was used to elute the bound HumRadA22 protein.  
Cation-exchange fractions were analysed by SDS-PAGE and those containing the 
protein were pooled and concentrated to 2 ml volume using a 10 kDa MWCO spin concentrator. 
The sample was then centrifuged for 2 min at 15000 xg and loaded on a Superdex 200 16/60 
size exclusion column (GE Lifesciences) equilibrated with 20 mM CHES pH 9.5, 100 mM 
NaCl, 1 mM EDTA HumRadA22. The monomeric protein eluted as single peak at about 75 ml 
elution volume. Fractions containing the purified protein were pooled, concentrated and stored 
at -80 °C. 
7.5 Purification of monomeric LiRad51ATPase 
T7Express E. coli cells carrying pHAT2 plasmid (Dr Marko Hyvönen, unpublished, 
Addgene #112583) expressing N-terminally His8-tagged LiRad51ATPase were plated from 
glycerol stocks on LB agar supplemented with ampicillin (100 μg/ml) and grown overnight at 
37 °C. Next day, cells were scraped and used to inoculate flasks containing 1 L of 2x YT 
medium supplemented with 100 μg/mL ampicillin. Cultures were grown at 37°C until OD600 
of ~0.5, after which temperature was decreased to 15 °C. Once the desired temperature was 
reached, expression was induced with IPTG (400 μM) overnight. Next day, cells were 
resuspended in 25 mL of nickel buffer A (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 20 mM 
imidazole) and frozen. Later, cells were thawed and supplemented with DNase I (100 μL, 2 
mg/mL) and AEBSF (1 mM), and lysed on an Emulsiflex C5 ho3mogenizer (Avestin) or by 
sonication. Cell lysate was centrifuged at 40000 xg for 30 min and supernatant collected. Lysate 
was loaded on a 3 mL Ni-NT A agarose matrix (Cube Biotech), after which column matrix was 
washed with 10 CV Nickel Buffer A. LiRad51ATPase was eluted with 12 ml nickel buffer B (50 
mM Tris-HCl pH 8.0, 150 mM NaCl, 200 mM imidazole). Protein was concentrated to 2 ml 
on a centrifugal filter (Amicon, MWCO 10 000 Da) and loaded on a Superdex 75 16/60 HiLoad 
size exclusion column equilibrated with 20 mM Tris pH 8.0, 100 mM NaCl, 100 mM Li2SO4. 
Fractions containing monomeric LiRad51ATPase were pooled, concentrated and flash-frozen.  
7.6 Purification of BRC repeat:HumRadA22 peptide complexes  
E. coli BL21(DE3) or T7Express cells carrying the pOP3BT-BRC and pBAT4-
HumRadA22 plasmids were separately plated on LB agar supplemented with ampicillin (100 
μg/ml) and grown overnight at 37 °C. Next day, cells were scraped and used to inoculate 
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separate flasks containing 1 L of 2x YT medium supplemented with 100 μg/mL. Cultures were 
grown at 37°C until OD600 of ~1, after which expression was induced with IPTG (400 μM) for 
three hours. Cells were resuspended in 25 mL of nickel buffer A (50 mM Tris-HCl pH=8.0, 
150 mM NaCl, 20 mM imidazole) and frozen. Later, cells were thawed and supplemented with 
DNase I (100 μL, 2 mg/mL) and AEBSF (1 mM), and lysed on an Emulsiflex C5 homogenizer 
(Avestin) or by sonication. Cell lysate was centrifuged at 40 000 xg for 30 min and supernatant 
collected. GB1-BRC lysates were loaded on a 3 mL Ni-NT A agarose matrix (Cube Biotech), 
followed by the application of HumRadA22 lysate from equal culture volume. Column matrix 
was washed with 10 column volumes Nickel Buffer A. Complex was eluted with nickel buffer 
B (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 200 mM imidazole) into 2 ml fractions.  Fractions 
containing the complex were pooled (~10 ml total) and buffer exchanged back into nickel 
buffer A on a PD-10 desalting column (Cytiva). Buffer exchanged nickel output was incubated 
with 100 μL of 2 mg/ml TEV protease overnight at 4°C. GB1 fusion partner was then removed 
from the solution by a second Ni-NTA affinity step, collecting the flow-through that contains 
the complex. Flow-through was concentrated on a centrifugal filter (Amicon, MWCO 3000 
Da) to 2 ml and loaded onto a Superdex 75 16/60 HiLoad size exclusion column (Cytiva), 
previously equilibrated with 20 mM CHES pH 9.5, 100 mM NaCl, 1 mM EDTA. The complex 
eluted at ~75 ml, fractions were analysed by SDS-PAGE. Fractions containing the complex 
were pooled and concentrated to 0.45 mM for crystallisation trials. 
7.7 Purification of the LiBRC1: LiRad51ATPase,ΔL2 complex 
LiBRC1:LiRad51ATPase,ΔL2 complex for crystallisation was prepared in an otherwise 
identical manner to Section 7.6 Purification of BRC repeat:HumRadA22 peptide complexes, 
except for the following differences. LiRad51ATPase,ΔL2 expression was induced overnight at 
15°C. Ni-NTA buffers were supplemented with 100 mM Li2SO4. SEC was done using the 
following buffer: 20 mM Tris pH 8.0, 100 mM NaCl, 100 mM Li2SO4, 1 mM EDTA. 
7.8 Purification of GB1-LiBRC fusions  
GB1-LiBRC fusions were purified using a two-stage process.  A C-terminal His tag is 
used in the first capture step, followed by a second anion exchange step that takes advantage 
of the highly negatively charged N-terminal GB1, ensuring that only species containing both 
terminal fusions are recovered and no significant BRC repeat degradation products are present 
in the final product.  
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T7Express E. coli cells carrying pPEPT1 plasmids expressing GB1-fused LiBRC repeat 
constructs were plated directly from glycerol stocks onto LB agar supplemented with 
ampicillin (100 μg/ml) and grown overnight at 37°C. Next day, cells were scraped and used to 
inoculate separate flasks containing 1 L of 2x YT medium supplemented with 100 μg/mL 
ampicillin. Cultures were grown at 37 °C until OD600 of ~1, after which expression was induced 
with IPTG (400 μM) for three hours. Cells were resuspended in 25 mL of nickel buffer A (50 
mM Tris-HCl pH 8.0, 150 mM NaCl, 20 mM imidazole) and frozen. Later, cells were thawed 
and supplemented with DNase I (100 μL, 2 mg/mL) and AEBSF (1 mM), and lysed on an 
Emulsiflex C5 homogenizer (Avestin) or by sonication. Cell lysate was centrifuged at 40 000 
xg for 30 min and supernatant collected. GB1-LiBRC lysate was loaded on a 3 mL Ni-NTA 
agarose matrix (Cube Biotech), after which column matrix was washed with 10 column 
volumes Nickel Buffer A. Bound protein was eluted with 10 ml nickel buffer B (50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 200 mM imidazole). The sample was diluted to 80 ml Q-A buffer 
(20 mM Tris-HCl, pH 8.0, 1 mM EDTA) and loaded on a HiTrap Q 5 ml column, which was 
washed with 8 CV of the same buffer, after which the GB1-LiBRC fusion was eluted with a 
linear 0-100% gradient of Q-B buffer (20 mM Tris-HCl, pH 8.0, 1 M NaCl, 1 mM EDTA). 
Peak fractions containing the desired product were pooled, concentrated and flash-frozen for 
storage.  
7.9 Preparation of stapled peptide:HumRadA22 complexes for 
crystallography 
Stapled peptide complexes were re-constituted from purified peptides and 
HumRadA22, rather than co-precipitated from lysate, like was done for linear BRC repeat 
complexes. Peptides were added at a 1.5 stoichiometric excess to HumRadA22 in its size-
exclusion buffer, to a final concentration of 0.75 and 0.5 mM for the peptide and protein, 
respectively.  
7.10 Purification of full-length human RAD51 
Full-length HsRAD51 was prepared based on a protocol developed at the lab of Prof 
Luca Pellegrini (Department of Biochemistry, Universiy of Cambridge). E. coli BL21(DE3) 
Rosetta2 cells carrying a pRSF-Duet plasmid co-expressing wild-type HsRAD51 and a BRC4 
sequence fused to an N-terminal His-MBP tag were kindly provided by Dr Joseph Maman. 
Cells were plated from a glycerol stock on LB agar supplemented with kanamycin (25	μg/mL) 
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and chloramphenicol (34	μg/mL), and grown overnight at 37°C.  Next day, cells were scraped 
and used to inoculate 1 L of 2xYT medium supplemented with same antibiotics. Cells were 
grown at 37°C with shaking at 200 RPM until an OD600 = 0.6, afer which they were cooled 
down to 18°C and expression induced with IPTG (400 μM) overnight. Cells were resuspended 
in 25 mL of buffer Ni-A-300 (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole, 1 
mM TCEP) and frozen. Later, cells were thawed and supplemented with DNase I (100 μL, 2 
mg/mL) and AEBSF (1 mM), and lysed on an Emulsiflex C5 homogenizer (Avestin) or by 
sonication. Cell lysate was spun down at 40 000 g for 30 min, after which the soluble fraction 
was loaded on a HisTrap HP 5 ml column (Cytiva). The column was washed with 8 CV Ni-A-
300 buffer, after which MBP-BRC4:RAD51 complex was co-eluted with buffer Ni-B-300 (50 
mM Tris-HCl, pH 8.0, 300 mM NaCl, 200 mM imidazole, 1 mM TCEP). 
The sample was then diluted with Heparin-A buffer (20 mM HEPES pH 7.4, 50 mM 
NaCl, 1 mM EDTA, 1 mM TCEP) and loaded on a HiTrap Heparin HP 5 ml column. During 
this step, RAD51 oligomerises on the heparin matrix, which acts as a DNA mimic, and 
dissociates from the MBP-BRC4 fusion, which is removed in flow-through and wash steps. 
Column was washed with 8 CV Heparin-A buffer, after which the protein was eluted with a 20 
CV, 0-100% linear gradient of Heparin-B buffer (20 mM HEPES pH 7.4, 1 M NaCl, 1 mM 
EDTA, 1 mM TCEP). RAD51 was concentrated, flash-frozen with liquid nitrogen and stored 
for future use.  
7.11 Crystallography of RAD51:BRC repeat complexes 
Crystallisation condition screens of linear and stapled BRC repeat complexes were 
performed in a generally similar manner. Protein solutions were maintained at 0.5 mM 
concentration, which amounts to around 10 mg/ml, in their respective SEC buffers. 
ADP/MgCl2 was added to the protein solution in some of the screens to a final concentration 
of 20 mM. It is important to note that during complex preparations, in the final SEC steps, all 
of the buffering agents were kept at a low concentration of 20 mM to allow for effective 
screening of different pH values in the crystallisation screens employed, which typically 
employ 100 mM buffer concentrations.  
Crystallisation screening was done in 96-well MRC plates using the sitting-drop vapor 
diffusion technique and a variety of commercial crystallisation screens. A Mosquito liquid 
handling robot (TTP Labtech) was used to dispense protein and reservoir solutions in sub-
microlitre volumes. Typical drops contained 200:200 and 400:200 nl of protein:crystallisation 
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solutions, while the reservoir contained 80 µl of crystallisation solution. Plates were stored at 
17°C in a RockImager crystallisation hotel (Formulatrix) and imaged regularly.  
Crystal hits were fished with mounted loops and flash-frozen in liquid nitrogen. 
Additional cryoprotectant was not added before freezing of crystal hits. Diffraction data were 
collected on Diamond Light Source (Harwell, UK) beamlines i03, i04, i04-1 and i24. Full 
native datasets with goniometer sweeps of at least 180° were collected to ensure completeness 
of diffraction data. For HumRadA22 complexes, molecular replacement phasing method was 
used with the apo HumRadA22 structure (PDB: 5KDD) as a search model. For 
LiRad51ATPase,ΔL2 complexes, human Rad51 ATPase domain was used as search model (PDB: 
1N0W). Molecular replacement was done with Phaser.169 The structures were refined without 
BRC repeats first and the peptides were built into the clearly visible electron density manually. 
Manual refinement was done in Coot170 and automated refinement with phenix.refine169 and 
autoBUSTER171. Crystallisation conditions, as well as data collection and refinement statistics, 
are provided in Appendix 8.7 Crystallographic conditions and data collection/refinement 
statistics. 
7.12 Small-scale preparation of stapled peptides  
T7Express E. coli cells carrying pPEPT1 vectors with GB1-fused BRC repeat bis-
cysteine mutants were plated directly from glycerol stocks of sequence-verified clones onto LB 
agar supplemented with ampicillin (100 μg/ml) and grown overnight at 37°C. Next day, enough 
cells to cover a plastic inoculation loop were scraped and transferred to 10 ml of 2xYT medium 
supplemented with ampicillin (100 μg/ml) in a 50 ml centrifuge tube. The tubes were left only 
partially sealed for aeration and autoclave tape was applied to keep the lid in a fixed position. 
Cultures were incubated at 37°C with shaking at 200 RPM for 4 h or until they were very turbid 
(OD600 = 3-4). Alternatively, rather than growing the cells in the morning, a single colony can 
be picked from the agar plate using a pipette tip and used to inoculate the 10 ml culture, which 
is then grown overnight (~16 h) at 37°C with shaking. Protein expression was induced by the 
addition of IPTG (400 μM) for three hours at 37°C. After expression, cells were centrifugated 
and pellets frozen at -20°C. 
Cells were thawed at room temperature by resuspension in 1 ml of lysis buffer: PBS, 
20 mM imidazole, 1 mM TCEP, 1 mM EDTA, 0.1% Triton X-100, 0.2 mg/ml lysoszyme, 1 
mM AEBSF, 10 µg/ml DNase I. Lysate was incubated for 10min at room temperature on a 
rotating mixer. Lysates were spun down in a 2 ml tube on a bench-top centrifuge at 15 000 g 
for 10 min and supernatant collected by aspiration. 200 µl of re-suspended Ni-NTA resin (100 
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µl of set resin, Cube Biotech) was washed twice with 1 ml of MilliQ water and resuspended in 
200 µl PBS. The resin was mixed with the soluble lysate and incubated on a vertical rotating 
shaker for 5 min at room temperature, after which it was applied in two portions to a 0.5 ml 
spin column and centrifugated for 1 min at 1000 xg to remove the buffer. Same centrifuge 
settings were also used for subsequent wash and elution steps. The resin was washed with a 
total of 1 ml of PBS + 20 mM imidazole containing 1 mM TCEP, followed by a 0.5 ml wash 
using the same buffer without any reducing agent. The second wash step is crucial to remove 
any residual TCEP prior to elution, as the nucleophilic reducing agent will form undesired side-
products upon reaction with the divinyl linker. The GB1-BRC repeat was eluted with 0.5 ml 
PBS + 200 mM imidazole, and the elution immediately used for subsequent stapling reactions.  
Two otherwise identical solutions of stapled and free thiol control peptide were 
prepared. To this end, the Ni-NTA elution output was split into 2x250 µl halves. 2 mM divinyl 
linker solution in DMSO was gradually titrated into the stapled sample to achieve pseudo-
dilution conditions and drive single linker macrocycle closing. At the same time, an identical 
volume of DMSO control without any linker was added to the other 250 µl bis-cysteine peptide 
solution. 1 mM TCEP was added to the control reaction but not the stapling reaction to maintain 
free sulfhydryl groups in the control peptides. At the end of the titration, reactions were 
quenched with 10 mM TCEP.  
Both the stapled and control reactions were concentrated to 100 µl on a 3 kDa MWCO 
spin filter (Amicon) and used in subsequent experiments. Concentration of the unstapled GB1-
BRC control reaction product was spectrophotometrically measured on a Nanodrop 1000 or 
Nanodrop One device using absorbance at 280 nm. Concentration measurements of stapled 
peptides are complicated by the presence of the aromatic pyrimidine or triazine moieties in the 
linker molecules that also absorb at 280 nm. Considering this, matching concentrations were 
assumed for the corresponding stapling/control reaction products, since both reaction inputs 
come from the same Ni-NTA resin elution and identical final volumes were obtained during 
linker or DMSO control additions and subsequent concentration steps. 
7.13 Solid-phase peptide synthesis (SPPS) 
Solid-phase peptide synthesis was done using Fmoc chemistry on a CEM Liberty 
Automated Microwave Peptide Synthesiser. Merck Rink Amide resin LL (0.29-0.39 mmol/g, 
286 mg per reaction) was used. Peptide couplings were conducted with Fmoc-protected amino 
acids (5 equiv in DMF), DIC/Oxyma Pure (5/10 equiv) in DMF as the coupling reagent, and 
N,N-diisopropylethylamine (10 equiv) in NMP as the base. Double coupling was used for all 
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amino acids, with 25 W power at 75 °C over 15 min (50 °C for cysteine amino acids). Fmoc 
deprotection was carried out using 20% piperidine in DMF, with 45 W power at 75 °C over 3 
min. N-termini were capped with acetic anhydride. Cleavage from resin and global 
deprotection was carried out with a cocktail of 92.5% trifluoroacetic acid, 2.5% water, 2.5% 
DCM and 2.5% triisopropylsilane for 2h at 45 °C in a sand bath. Cleavage solution was 
evaporated under nitrogen and reaction products precipitated using ice-cold diethyl ether, after 
which the products were resuspended in varying water/acetonitrile solutions.  
7.14 Liquid chromatography mass spectrometry (LC-MS) 
Protein intact mass was measured on a Xevo G2-S Q-TOF mass spectrometer coupled 
to an Acquity UPLC system using an Acquity UPLC BEH300 C4 column. 0.1% formic acid 
in ultrapure water was used as buffer A, with a 5-95% linear gradient of buffer B (95% 
acetonitrile, 0.1% formic acid) at a flow rate of 0.2 mL min-1. The electrospray source was 
operated with a capillary voltage of 2.0 kV and a cone voltage of 40 V. Nitrogen was used as 
the desolvation gas at a total flow of 850 L h-1. Total mass spectra were deconvoluted from the 
ion series using the MaxEnt algorithm pre-installed on MassLynx software (v.4.1 from Waters) 
according to the manufacturer’s instructions.  
LC-MS for peptides having molecular weight less than 5 kDa was done on a waters 
Acquity H-Class UPLC with an ESCi Multi-Mode ionisation Waters SQ Detector 2 
spectrometer. Buffer A: 2 mM ammonium acetate, 0.1% formic acid in 95/5% 
water/acetonitrile. Buffer B: 100% acetonitrile, 0.1% formic acid. Column: AQUITY UPLC 
CSH C18, 2.1*50 mm, 1.7 μm, 130 Å; gradient: 5-95% B over 3 min. 
7.15 Peptide concentration measurements 
Many of the purified peptides lacked side chains suitable for conventional UV-Vis 
concentration determination at 280 nm. Instead, vacuum-dried peptides were resuspended in 
MilliQ water and their concentration was determined by measuring 205 nm absorbance using 
the Scopes method172 on a Nanodrop One UV-VIS spectrophotometer (ThermoFisher). 
7.16 Recombinant expression and purification of linear peptides 
T7Express E. coli cells carrying pOP3BT plasmids expressing GB1-fused BRC repeat 
were plated directly from glycerol stocks of sequence-verified clones onto LB agar 
supplemented with ampicillin (100 μg/ml) and grown overnight at 37 °C. Next day, cells were 
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scraped and used to inoculate separate flasks containing 1 L of 2x YT medium supplemented 
with 100 μg/mL ampicillin. Cultures were grown at 37 °C until OD600 of ~1, after which 
expression was induced with IPTG (400 μM) for three hours. Cells were resuspended in 25 mL 
of nickel buffer A (50 mM Tris-HCl pH=8.0, 150 mM NaCl, 20 mM imidazole) and frozen. 
Later, cells were thawed and supplemented with DNase I (100 μL, 2 mg/mL) and AEBSF (1 
mM), and lysed on an Emulsiflex C5 homogenizer (Avestin) or by sonication. Cell lysate was 
centrifuged at 40000 xg for 30 min and supernatant collected. GB1-BRC lysate was loaded on 
a 3 mL Ni-NT A agarose matrix (Cube Biotech), after which column matrix was washed with 
10 column volumes Nickel Buffer A. GB1-BRC repeat was eluted with 12 ml nickel buffer B 
(50 mM Tris-HCl pH 8.0, 150 mM NaCl, 200 mM imidazole).  The eluent was buffer 
exchanged back into nickel buffer A on a PD-10 desalting column (Cytiva). Buffer exchanged 
GB1-BRC fusion (~18 ml) was incubated with 100 μL of 2 mg/ml TEV protease overnight at 
4°C. The GB1 tag was then removed from the solution by a second Ni-NTA affinity step, 
collecting the flow-through that contains the BRC peptide. The flow-through was acidified 
with HCl to pH 2-4 and acetonitrile was added to 10%, after which the solution was centrifuged 
at 10000 xg for 15 min to remove aggregates. The acidified flow-through was then applied to 
an ACE C8 300 4.6 x 250 mm semi-prep RP-HPLC column equilibrated with RPC buffer A 
(10% acetonitrile, 0.1% TFA) and peptides were eluted with a 20 CV gradient of RPC buffer 
B (90% acetonitrile, 0.1% TFA). BRC repeat peptides typically elute at 20-40% buffer B. Peak 
fractions were analysed by LCMS and pooled for drying under vacuum. If necessary, an 
additional purification step on a ACE C18 300 4.6 x 250 mm semi-prep RP-HPLC column was 
included at the end, using identical buffers to the C8 step.  
Dried peptides were resuspended either in MilliQ water or a buffer of interest. Because 
most of the BRC repeat peptides lack any tryptophan/tyrosine residues, estimation of 
concentration using absorbance at 280 nm is not possible, therefore concentration was 
determined using 205 nm absorbance using the Stokes method on a Nanodrop One UV-VIS 
spectrophotometer (ThermoFisher).  
7.17 Stapling of recombinantly prepared BRC repeat free peptides 
Cysteine-stapled BRC repeat peptides lacking any fusion tags were first expressed 
recombinantly and purified in an identical fashion to the Section 7.16 Recombinant expression 
and purification of linear peptides. 1 mM TCEP was included in all purification steps to 
maintain cysteine thiols in a reduced state. After the C8 RPC step, rather than drying the peptide 
under vacuum, peak fractions corresponding to the cleaved peptide were pooled and diluted 5x 
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in PBS + 10 mM EDTA in a 50 ml centrifuge tube. A small stir rod was added to the tube, 
which was then placed on a magnetic stirrer. A syringe was filled with 20 mM linker in DMSO 
which was then gradually added to the mixture by piercing the centrifuge tube lid. To maintain 
pseudo-dilution conditions, linker was injected in 50 µl increments every two minutes, to a 
final concentration of 2 mM, ensuring at least 2x stoichiometric excess of linker over peptide. 
The reaction mixture was then quenched with 5 mM TCEP, filtered through a 0.45 μm filter 
and acidified with HCl to pH ~3. Stapled peptide was then purified by a on a ACE C18 300 4.6 
x 250 mm semi-prep RP-HPLC column with a 0-100% gradient of A: 0.1% TFA, B: 90 % 
MeCN + 0.1% TFA. Peak fractions containing the desired product were pooled and dried under 
vacuum.   
7.18 Isothermal titration calorimetry (ITC) of BRC repeat binding  
Peptides were resuspended in MilliQ water to 10 times the desired concentration in the 
syringe. This was then diluted 10x with the ITC buffer to obtain the final titrant solution. 
HumRadA22 was buffer-exchanged on a NAP-5 desalting column into ITC buffer and protein 
concentration was adjusted to 10:9 of the desired final value. One ninth volume of MilliQ water 
was added to the solution to bring the protein concentration to the desired final value, while 
maintaining identical buffer:MilliQ volume proportions in both the syringe and the cell. ITC 
was carried out using a Microcal ITC200 instrument at 25°C with a 5.00 μCal reference power 
DP value, stirring speed of 500-750 rpm, 2 sec filter period. Injection spacing, speed and 
volume, cell/syringe concentrations as well as the number of injections were adjusted for each 
peptide and its binding properties. ITC data were fitted using a single-site binding model using 
the Microcal ITC data analysis program in the Origin 7.0 package. Data points affected by 
baseline spikes were omitted from the analysis. ITC buffer: 20 mM CHES pH 9.5, 150 mM 
NaCl, 0.1% Tween-20.  
7.19 HumRadA22 fluorescence polarisation (FP) competition assay 
HumRadA22 competition assay was a modified version of a protocol described 
previously.111 Fluorescein-labelled HsBRC4 probe for this assay was kindly provided by Dr 
Laurens Lindenburg (Hollfelder group, Department of Biochemistry, University of 
Cambridge). Black 384-well flat-bottom microplates (Corning #3821) were used with a 40 µl 
final reaction volume in all measurements. Following buffer conditions were used: 20 mM 
CHES pH 9.5, 150 mM NaCl, 0.1% BSA, 0.1% Tween-20. Each reaction contained 100 nM 
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HumRadA22 and 10 nM BRC4-fluorescein. Two-fold serial dilutions of the peptide were 
added to the reactions. A free probe control reaction containing only 10 nM BRC4-fluorescein 
was used to calibrate gain and focal height. FP measurements were performed on a Pherastar 
FX (BMG Labtech) plate reader equipped with an FP 485-520-520 optic module.  Binding 
curves were fitted using the four-parameter logistic model with a variable Hill slope using 
Prism software (Graphpad). Regression fitting was performed using the least squares 
optimisation algorithm. KD values were estimated from the fitted IC50 parameters using a 
previously reported equation.173  
7.20 LiRad51ATPase fluorescence polarisation (FP) competition assay 
Experiments were prepared in an identical manner to Section 7.19 HumRadA22 
fluorescence polarisation (FP) competition assay, except for the differences described here. 
Following FP buffer was used: 50 mM Tris pH 8.0, 150 mM NaCl, 100 mM Li2SO4, 1% BSA, 
0.1% Tween-20. Each reaction contained 5 nM of Fluor-NCys-LiBRC1 probe and 500 nM of 
LiBRC1ATPase. 
7.21 Circular dichroism (CD) spectroscopy 
For CD measurements, dried peptides were dissolved in MilliQ water to 0.3 mg/ml, and 
then two-fold diluted in 20 mM sodium phosphate, pH 7.4, giving a final solution of 0.15 mg/ml 
peptide in 10 mM sodium phosphate. CD spectra of selected peptides were recorded on an 
AVIV 410 circular dichroism spectropolarimeter using a 1 mm path length quartz cuvette. 
Measurements were done at 25 °C, with a 185-260 nm range, 1 nm bandwidth, 5 s averaging 
time and 0.3 s settling time. Spectra were prepared as smoothed average of three scans and 
normalised against blank solvent.  
7.22 Electrophoretic mobility shift assay (EMSA) 
The ability of linear and stapled BRC repeat peptides to dissociate RAD51-ssDNA 
nucleofilament was evaluated using an electrophoretic mobility shift assay (EMSA). RAD51 
DNA-binding reactions (40 μl) were set up in 50 mM HEPES pH 7.4, 150 mM NaCl, 10 mM 
MgAc2, 2 mM CaCl2, 1 mM TCEP, 1 mM ATP. 5 μM full-length human RAD51 was incubated 
with varying concentrations of BRC repeats for 10 min at room temperature, followed by the 
addition of 100 nM fluorescently labelled FAM-dT60 oligonucleotide, and further incubation 
at 37 °C for 10 min. Control reactions were set up with free FAM-dT60 probe and FAM-dT60 
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+ 5 μM RAD51. 10 μl of reactions were then loaded on a 1xTBE non-denaturing acrylamide 
gel (5%) and run at 100 V for 1:30 h at 4 °C. The gel was directly visualized on a Typhoon 
FLA 9000 imager (GE Healthcare) using FAM channels. 
EMSAs with LiRad51 were performed in identical manner but were resolved on a 2% 
agarose gel, running for 6 min at 250 V / 4°C, rather than on an acrylamide gel. This is because 
it is impossible to resolve the LiRad51 NF on the smaller pores of an acrylamide gel, 
presumably due to the highly disordered N-terminal region of LiRad51, which increases the 
hydrodynamic radius of the complex.  
7.23 Peptide serum stability assay 
Peptides were diluted to 600 μM in PBS. Human serum (Sigma-Aldrich, #H4522) was 
diluted to 30% in PBS and incubated at 37 °C for 10 min. 200 µl of peptide solution were added 
to 400 µl of 30% serum, giving a final concentration of 200 μM and 20% for peptide and serum, 
respectively. Mixtures were incubated in 1.5 ml tubes at 37 °C on a Thermomixer R 
(Eppendorf). 50 µl aliquots were taken at specific time points and quenched with 100 µl of 1:1 
ethanol:DMSO, incubated for 3 min and then centrifugated at 13000xg for 5 min to remove 
precipitating serum proteins. The supernatant was then two-fold serially diluted and used in FP 
competition reactions as described in 7.19 HumRadA22 fluorescence polarisation (FP) 
competition assay. Changes in IC50 over different incubation time-points were monitored as an 
indicator of detrimental proteolytic degradation. 
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8 Appendix 




Species m/z calculated m/z found 
M+2H 2289.01 2289.8 
M+3H 1526.34 1527.1 
M+4H 1145.00 1145.6 





Species m/z calculated m/z found 
M+3H 1578.47 1579.1 
M+4H 1184.10 1184.8 
M+5H 947.48 947.9 




























BRC4 C18 RP-HPLC 220 nm
B
, %






Species m/z calculated m/z found 
M+3H 1516.01 1516.4 
M+4H 1137.26 1137.8 
M+5H 910.01 910.4 






Species m/z calculated m/z found 
M+2H 2176.90 2177.2 
M+3H 1451.60 1451.9 
M+4H 1088.95 1089.4 

































BRC8-2 C18 RP-HPLC 220 nm
B
, %







Species m/z calculated m/z found 
M+3H 1455.62 1455.9 
M+4H 1091.96 1092.6 






Species m/z calculated m/z found 
M+2H 2190.92 2191.0 
M+3H 1460.95 1461.1 
M+4H 1095.96 1096.4 






Species m/z calculated m/z found 
M+2H 2196.95 2196.8 
M+3H 1464.97 1464.7 
M+4H 1098.98 1098.8 














BRC8-2 S2056V C18 RP-HPLC 220 nm
B
, %






Species m/z calculated m/z found 
M+2H 2168.43 2168.7 
M+3H 1445.95 1446.6 






Species m/z calculated m/z found 
M+2H 2289.97 2290.7 
M+3H 1526.98 1527.5 
M+4H 1145.48 1146.0 










































Species m/z calculated m/z found 
M+2H 1483.72 1483.3 
M+3H 989.48 989.3 
M+4H 742.36 742.0 





Species m/z calculated m/z found 
M+2H 1527.267276 1526.9 
M+3H 1018.513943 1018.2 
M+4H 764.137276 764.0 










































SP31 C18 RP-HPLC 220 nm
B
, %
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* = TFA counterions 
Species m/z calculated m/z found 
M+4H 1144.08 1144.0 
M+5H 915.46 915.3 
M+6H 764.58 762.9 





Species m/z calculated m/z found 
M+4H 1340.48 1340.5 
M+5H 1072.58 1072.7 
M+6H 895.77 894.0 





Species m/z calculated m/z found 
M+3H 1396.24 1395.8 
M+4H 1047.43 1047.2 
M+5H 838.15 838.0 



















SP32 220 [Abs 220 nm, mAu]
B
, %
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Species mass (calc), Da mass (obs), Da 
GB1-SP2-DVT-Ac (-Met1) 14773.97 14774.00 
GB1-SP2-DVT-Ac (-Met1, -Ser2) 14686.89 14687.00 






Species mass (calc), Da mass (obs), Da 
GB1-SP10-DVT-Ac (-Met1) 14251.46 14251.5 
GB1-SP10-DVT-Ac (-Met1, -Ser2) 14164.38 14164.5 













Species mass (calc), Da mass (obs), Da 
GB1-SP11-DVT-Ac (-Met1) 14210.4 14210.2 
GB1-SP11-DVT-Ac (-Met1, -Ser2) 14123.33 14122.9 





Species mass (calc), Da mass (obs), Da 
GB1-SP12-DVT-Ac (-Met1) 14500.64 14500.5 
GB1-SP12-DVT-Ac (-Met1, -Ser2) 14720.87 14720.5 





Species mass (calc), Da mass (obs), Da 
GB1-SP15-DVT-Ac (-Met1) 14760.97 14760.7 
GB1-SP15-(DVT-Ac)2 (-Met1) 14981.2 14981.2 
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8.3 Protein LCMS spectrum of LiBRC1:LiRad51 complex 
 
Species m/z calculated m/z found 
M+5H (C1) 732.04 732.02 
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8.4 Vector map for the pPEPT1 expression cassette 
pPEPT1
 
- Unique cutters are shown in bold 
  
Unique Cutters Bold
Sequence:  pPEPT1.dna  (Circular / 4689 bp)
Enzymes:  Unique & Dual Cutters  (68 of 666 total)
Features:  14 total







T A A T A C G A C T C A C T A T A G G G A A T T G T G A G C G G A T A A C A A T T C C T C T A G A A A T A A T T T T G T T T A A C










T T T A A G A A G G A G A T A T A T C C A T G T A T C G A T T A A A T A A G G A G G A A T A A A C C A T G T C T G C T T G G A G C




His Pro Gln Phe Glu Lys
(in frame with Strep-Tag II)
Ser Gly Thr Ser Gly Thr
1 5 10
Tyr Lys Leu Ile Leu Asn Gly Lys Thr Leu
Strep-Tag II GB1
C A C C C G C A G T T C G A G A A A T C T G G C A C T A G T G G C A C C T A C A A A C T G A T C C T G A A C G G T A A A A C C C T
G T G G G C G T C A A G C T C T T T A G A C C G T G A T C A C C G T G G A T G T T T G A C T A G G A C T T G C C A T T T T G G G A
AccI
260
15 20 25 30
Lys Gly Glu Thr Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr
GB1
G A A A G G T G A A A C C A C C A C C G A A G C T G T A G A C G C T G C T A C T G C T G A A A A A G T T T T C A A A C A G T A C G
C T T T C C A C T T T G G T G G T G G C T T C G A C A T C T G C G A C G A T G A C G A C T T T T T C A A A A G T T T G T C A T G C
325
35 40 45 50
Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr Val Thr
GB1
C T A A C G A C A A C G G T G T G G A C G G T G A A T G G A C C T A C G A C G A C G C T A C C A A A A C C T T C A C G G T T A C G
G A T T G C T G T T G C C A C A C C T G C C A C T T A C C T G G A T G C T G C T G C G A T G G T T T T G G A A G T G C C A A T G C
BsaIBsaIBamHIAcc65I KpnI
390
Glu Ser Gly Thr
1 5
Glu Asn Leu Tyr Phe Gln Gly
(in frame with TEV site)
Ser Asp Pro Gly Asp Pro Lys Val Ser Asp Pro
GB1 TEV site
G A A A G C G G T A C C G A A A A C C T G T A C T T C C A G G G A T C C G A C C C T G G A G A C C C G A A G G T C T C T G A C C C










His His His His His His His His *
8xHis SP6 promoter
T G G C T C G A G C C A T C A C C A T C A C C A T C A C C A T C A C T A A G C T T G A G T A T T C T A T A G T G T C A C C T A A A
A C C G A G C T C G G T A G T G G T A G T G G T A G T G G T A G T G A T T C G A A C T C A T A A G A T A T C A C A G T G G A T T T
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8.5  Oligonucleotides for assembly PCR and cloning 
Insert Vector  Res. enzyme(s) No Sequence 
































SP7 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGTTAACTCTTCTGCGTTCTCTGGTTTCTGCACCGCGTCTGGTAAAAAACTGAACGTTTCTTGCGA 
2 ATGGCTCGAGCCAGGGTCAGAGATGTTTTCGATGTCGGAGAACAGTTTAACCGCCTTCTGCAGCGCTTCGCAAGAAACGTTCAGTTTT 
SP8 pPEPT1 BsaI 1 TTCCAGGGATCCGACCCTGTTAACTCTTCTGCGTTCTCTGGTTTCTCTACCGCGTCTGGTAAAAAACTGAACGTTTCTACCTGTG 
2 ATGGCTCGAGCCAGGGTCAGAGATGTTTTCGATGTCGGAGAACAGACAAACCGCCTTCTGCAGCGCACAGGTAGAAACGTTCAGT 
SP9 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGTTAACTCTTCTGCGTTCTCTGGTTTCTCTACCGCGTCTGGTAAAAAACTGAACGTTTCTACCGAAG 
2 ATGGCTCGAGCCAGGGTCAGAGATGTTTTCGATGTCACAGAACAGTTTAACCGCCTTACACAGCGCTTCGGTAGAAACGTTCAGT 
SP10 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGCGTGTGGTTTCTCTACCGCGTCTGGTAAAAAACTGAACGTTTCTTGTGAAGCGCTGCAG 
2 ATGGCTCGAGCCAGGGTCAGAGATGTTTTCGATGTCGGAGAACAGTTTAACCGCCTTCTGCAGCGCTTCACAAGAAA 
SP11 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTTCTTGTTTCTCTACCGCGTCTGGTAAAAAACTGAACGTTTCTTGTGAAGCGCTGCAGA 
2 ATGGCTCGAGCCAGGGTCAGAGATGTTTTCGATGTCGGAGAACAGTTTAACCGCCTTCTGCAGCGCTTCACAAGAA 
SP12 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTTCTTCTGCGTGTTCTGGTTTCTCTACCGCGTCTGGTAAAAAACTGAACGTTTCTACCGAAGCGT 
2 ATGGCTCGAGCCAGGGTCAGAGATGTTTTCGATGTCGGAGAACAGTTTAACCGCCTTCTGACACGCTTCGGTAGAAACGTTC 
SP13 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGTTAACTGTTCTGCGTTCTCTGGTTTCTCTACCGCGTCTGGTAAAAAACTGAACGTTTCTACCGAAG 
2 ATGGCTCGAGCCAGGGTCAGAGATGTTTTCGATGTCGGAGAACAGTTTAACCGCCTTACACAGCGCTTCGGTAGAAACGTTCAGT 
SP14 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGTTAACTGTTCTGCGTTCTCTGGTTTCTCTACCGCGTCTG 
2 ATGGCTCGAGCCAGGGTCAGAAACACACAGTTTTTTACCAGACGCGGTAGAGAAACCA 
SP16 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGCGTGTTCTGGTTTCTCTACCGCGTCTGGTAAAAA 
2 ATGGCTCGAGCCAGGGTCAGAACAAACGTTCAGTTTTTTACCAGACGCGGTAGA 










SP20 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGCGTGCGGTTTCTCTACC 
2 AGAAACGTTCAGTTTTTTACCAGACGCGGTAGAGAAACCGCACGC 

































LiBRC1.1 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGGTTCTGGTAAACCGGTGACCGTTCGTCGTG 
2 ATGGCTCGAGCCAGGGTCCGCCGCCAGGTCACCCAGACGTTCCGCAACTTTCTGCAGGGATTCACGACGAACGGTCACC 
LiBRC1.2 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAGCCGGTTACCGTTCGTCGTGAATCTCTC 
2 ATGGCTCGAGCCAGGGTCTTCCATATCAGGTGCGGCCAGGTCACCCAGACGTTCCGCAACTTTCTGGAGAGATTCACGACGAACGG 
LiBRC1.3 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGCTGCGGCTCCGCCGCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAGCCGGTTACCGTTCG 
2 ATGGCTCGAGCCAGGGTCCGCCGCCAGGTCACCCAGACGTTCCGCAACCTTTTGCAGAGATTCACGACGAACGGTAACCGGCTTAC 
LiBRC1.4 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAACCGGTGACCGTTC 
2 ATGGCTCGAGCCAGGGTCGTCACCCAGACGTTCCGCAACTTTCTGCAGGGATTCACGACGAACGGTCACCGGTTTACC 
LiBRC1.5 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAACCGGTGACCGTTCGTCGTG 
2 ATGGCTCGAGCCAGGGTCAGAACCACCACCCAGACGTTCCGCAACTTTCTGCAGGGATTCACGACGAACGGTCACCG 
LiBRC1.6 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAACCGGTGACCGTTCGTCGTG 
2 ATGGCTCGAGCCAGGGTCAGAGCCACCACCACGTTCCGCAACCTTCTGCAGGGATTCACGACGAACGGTCACCGGTT 
LiBRC1.7 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTGCTGCGGCTCCGCCGCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAGCCGGTTACCGTTCG 
2 ATGGCTCGAGCCAGGGTCCGCCGCCAGGTCACCCAGACGTTCCGCAACCTTTTGCAGAGATTCACGACGAACGGTAACCGGCTTAC 
LiBRC1.8 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAGCCGGTTACCGTTCGT 
2 ATGGCTCGAGCCAGGGTCAGAGCCACCGCCACCCGCAACTTTCTGCAGGGATTCACGACGAACGGTAACCGGCTTACC 
LiBRC1.9 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGCGTCTGGTAAGCCGGTTACCGTTCGT 
2 ATGGCTCGAGCCAGGGTCAGAGCCACCGCCACCAACTTTCTGGAGAGATTCACGACGAACGGTAACCGGCTTACCAG 










LiBRC1.12 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCTGGTTCCGACCCTGTTCTCTACCGCG 
2 ATGGCTCGAGCCAGGGTCACGAACGGTTACCGGTTTACCAGACGCGGTAGAGAACAGGGT 
LiBRC2 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCGTGTTCCGACCCTGTTCGAAACCGGTCGTGGTAAAGCGGTTACCGTTCAGAAACGTTC 
2 ATGGCTCGAGCCAGGGTCCGCTTCCAGAGAGTCCATAGACGCTTCCGCTTTGTCGAGAGAACGTTTCTGAACGGTAACC 
LiBRC2.1 pPEPT1 BsaI 
1 TTCCAGGGATCCGACCCTCGTGTTCCGACCCTGTTCGAAACCGCGCGTGGTAAAGCGGTTACCGTTCAGAAACGTTC 
2 ATGGCTCGAGCCAGGGTCCGCTTCCAGAGAGTCCATAGACGCTTCCGCTTTGTCGAGAGAACGTTTCTGAACGGTAACC 
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LiRad51 (full-
length) pEXP-MBP BsaI/HindII 
1 GAAAACCTGTACTTCCAGTCCGGACAGACCCGTAGCAAAGC 
2 ATAGAATACTCAAGCTTATTAGTCACGTGCGTCACCAAC 
LiRad51ATPase pHAT2 NcoI/HindIII 
1 CCATCACCATCACTCCATGGCAGAAATTATCATGGTTACCACCGGTAG 
2 ACTATAGAATACTCAAGCTTAGTCACGTGCGTC 
LiRad51ATPase,ΔL2 pBAT4 NcoI/HindIII 
1 AAGGAGATATATCCATGGCAGAAATTATCATGGTTACCACCGGTAG 
2 ACTATAGAATACTCAAGCTTAGTCACGTGCGTC 
3 GTTGTTGCCAATGGTGGTCATATTATGGCACATGCCAGC (inner F) 
4 CATAATATGACCACCATTGGCAACAACCTGATTGGTAACAACAAC (inner R) 
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Complex BRC8-2:HumRadA22 SP2:HumRadA22 SP24:HumRadA22
Protein
0.5 mM BRC8-
2:HumRadA22 in 20 mM 
CHES pH 9.5, 100 mM NaCl, 
20 mM ADP/MgCl2 
0.5 mM SP2:HumRadA22 in 
20 mM CHES pH 9.5, 100 
mM NaCl
0.5 mM SP24:HumRadA22 
in 20 mM CHES pH 9.5, 100 
mM NaCl, 20 mM 
ADP/MgCl2 
Condition
0.2 M NH4Cl (Salt)
20 %w/v PEG 3350 
(Precipitant)
8 % w/v PEG 8000 
(precipitant) 0.08 M 
Potassium phosphate pH 
5.6 (buffer)
0.1 M Na3Cit 4.2 pH (Buffer)
20 %w/v PEG 1K 
(Precipitant)
0.2 M Li2SO4 (Salt)
Protein:condition (nl:nl) 200:200 200:200 400:200
PDB 6HQU - -
Data collection processing 
Beamline DLS i03 DLS i03 DLS i04
Wavelength (Å) 0.9762 0.9762Å 0.9795
Space group P 1 21 1 P 41 21 2 P 21 21 2
a, b, c (Å) 114.403 75.473 114.792 112.56 112.56 140.79 140.46 38.64 43.53
α, β, γ (°) 90.00 97.06 90.00 90.00 90.00 90.00 90.00 90.00 90.00
Resolution range (high resolution 
bin) (Å) 85.87 - 1.97 (1.97-1.96) 87.92 - 3.02 (3.02 - 3.07) 70.23 - 1.63 (1.66 - 1.63)
Rmeas 0.091 (2.778) 0.242 (3.751) 0.059 (4.504)
Completeness (%) 99.8 (100.0) 100.0 (100.0) 98.7 (99.2)Number f total / unique 
reflections 522829 / 137994 170095 / 13512 239726 / 30303
Redundancy 3.8 (3.9) 12.8 (13.8) 7.9 (7.8)
<I /σ(I )> 7.4 (0.5) 10.0 (0.9) 12.0 (0.3)
CC1/2 0.998 (0.272) 1.0 (0.3) 1.0 (0.3)
Refinement
R cryst /R free 0.263 / 0.271 0.228 / 0.254 0.260 / 0.270
Resolution range (Å) 85.870 - 1.966 69.29 - 3.02 70.23 - 1.62Number of reflections: work/test 
set 137876/ 6853 17515 / 897 27946 / 1450
Number of atoms 13996 3834 2041
Mean/Wilson B-factor 68.1 / 45.5 95.6 / 79.5 63.3 / 34.4Ramachandran 
favoured/allowed/outliers  (%) 99.00 / 1.00 / 0.00 97.22 / 2.57 / 0.21 99.17 / 0.83 / 0.00
RMSD bonds (Å) 0.011 0.017 0.013
RMSD angles (°) 1.28 1.66 1.69









0.5 mM SP30:HumRadA22 
in 20 mM CHES pH 9.5, 100 
mM NaCl, 20 mM 
ADP/MgCl2 
0.5 mM LiBRC1 
:LiRad51ATPase,ΔL2  in 20 mM 
Tris pH 8.0, 100 mM NaCl, 
100 mM Li2SO4, 20 mM 
ADP/MgCl2 
Condition
14% w/v PEG 4000 
(precipitant), 6% v/v MPD 
(precipitant), 0.1M Na K 
Phos pH 6.2 (buffer)
32% low MW PEG smear 
(precipitant, Molecular 
Dimensions), 0.1M Tris pH 
8.5
Protein:condition (nl:nl) 200:200 200:200
PDB - -
Data collection processing 
Beamline DLS DLS i04-1
Wavelength (Å) 0.9795 0.9159
Space group P 21 21 2 P 4 2 2
a, b, c (Å) 143.13 38.01 43.92 61.00 61.00 119.22
α, β, γ (°)  90.00 90.00 90.00 90.00 90.00 90.00
Resolution range (high 
resolution bin) (Å) 1.25 - 41.99 (1.25 - 1.27) 2.15 - 59.61 (2.15 - 2.18)
Rmeas 0.046 (1.597)  0.119 (8.167)
Completeness (%) 99.6 (95.3)  98.9 (98.9)Number f total / unique 
reflections 513195 / 67481 296871 / 12826
Redundancy 7.6 (4.6)  23.1 (18.1)
<I /σ(I )> 15.8 (0.8) 15.6 (0.4)
CC1/2 1.0 (0.4) 1.0 (0.5)
Refinement
R cryst /R free 0.196 / 0.210 0.211 / 0.267
Resolution range (Å) 36.74 - 1.24 54.31 - 2.15Number of reflections: 
work/test set 64107 / 3361 10597 / 517
Number of atoms 2373 1806
Mean/Wilson B-factor 27.9 / 17.8 67.897 / 50.7Ramachandran 
favoured/allowed/outliers  99.15 / 0.85 / 0.00 98.65 / 1.35 / 0.00
RMSD bonds (Å) 0.014 0.012
RMSD angles (°) 1.61 1.62
